

CITATION REPORT

List of articles citing

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

DOI: 10.1182/blood.v89.11.3909
Blood, 1997, 89, 3909-3918.

Source: <https://exaly.com/paper-pdf/28466024/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2304	Dilantin in the treatment of lightning pains. 1961 , 11, 257-8		8
2303	Review article : Gastrointestinal damage following cardiopulmonary bypass. 1990 , 5, 161-168		11
2302	Gastric mucosa-associated lymphoid tissue lymphomas: more than a fascinating model. 1997 , 89, 1328-30		18
2301	Haematology. The periphery is now central. 1997 , 350 Suppl 3, SIII9		
2300	Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. 1997 , 8, 973-978		86
2299	The changing classification of non-Hodgkin's lymphomas. 1997 , 47, 323-5		16
2298	U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Medical indications. 1997 , 30, 249-263		51
2297	Mantle cell lymphoma: a retrospective study of 121 cases. 1998 , 12, 1281-7		157
2296	Gastric low-grade mucosa-associated lymphoid tissue lymphomas: their histogenesis and high-grade transformation. 1998 , 48, 323-31		26
2295	Differentiation of low-grade non-Hodgkin's lymphomas using paraffin sections by image processing. 1998 , 34, 75-81		1
2294	[Current developments in hematology and internal medicine oncology]. 1998 , 39, 346-54		0
2293	Evaluation and management of the "new" lymphoma entities: mantle cell lymphoma, lymphoma of mucosa-associated lymphoid tissue, anaplastic large-cell lymphoma, and primary mediastinal B-cell lymphoma. 1998 , 22, 283-368		7
2292	B-cell lymphoma of 708 cases in Japan: incidence rates and clinical prognosis according to the REAL classification. 1999 , 135, 73-81		23
2291	[Non-Hodgkin's lymphoma. Aspects of clinical pathology]. 1998 , 19 Suppl 1, 14S-17S		3
2290	Anaplastic large cell lymphoma. 1998 , 5, 165-173		3
2289	Non-Hodgkin's lymphoma. 1998 , 14, 273-83		5
2288	Reply. 1998 , 29, 103-104		2

2287	World Health Organization Classification of lymphomas: a work in progress. 1998 , 9 Suppl 5, S25-30	51
2286	Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification. 1998 , 9, 849-55	227
2285	Reassessment of non-hodgkins's lymphoma with a "nodular" growth variant: a clinicopathologic study of follicular, mantle cell and marginal zone lymphomas prospectively diagnosed with multiparameter analyses. 1998 , 31, 393-403	3
2284	From the R.E.A.L. Classification to the upcoming WHO scheme: a step toward universal categorization of lymphoma entities?. 1998 , 9, 607-12	47
2283	Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. 1998 , 9, 717-20	503
2282	Peripheral T-cell lymphoma: a developing concept. 1998 , 9, 797-801	6
2281	Report of the European Task Force on Lymphomas: workshop on peripheral T-cell lymphomas. 1998 , 9, 835-43	33
2280	Which treatment for mantle-cell lymphoma patients in 1998?. 1998 , 16, 3-5	32
2279	Elderly patients with non-Hodgkin's lymphoma: population-based results in The Netherlands. 1998 , 9, 1219-27	46
2278	Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. 1999 , 10, 1191-7	25
2277	Marginal zone B-cell lymphoma: A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. 1999 , 17, 2486-92	158
2276	Clinicopathological evaluation of the Revised European-American Classification of Lymphoid Neoplasms (REAL) in Japan. 1999 , 34, 143-9	14
2275	Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte. 1999 , 17, 2499-505	72
2274	Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation. 1999 , 17, 1558-67	158
2273	Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. <i>Blood</i> , 1999 , 93, 3913-3921	2.2 434
2272	Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. 1999 , 35, 139-46	12
2271	Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. 1999 , 36, 147-50	11
2270	Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials. 1999 , 35, 537-44	4

2269	Autologous stem cell transplantation for T and null cell CD30-positive anaplastic large cell lymphoma: analysis of 64 adult and paediatric cases reported to the European Group for Blood and Marrow Transplantation (EBMT). 1999 , 23, 437-42	64
2268	The clinical utility of the Revised European-American Lymphoma (R.E.A.L.) Classification: preliminary results of a prospective study in patients with non-Hodgkin's lymphoma from a single centre. 1999 , 10, 1121-4	5
2267	CHOP versus MACOP-B in aggressive lymphoma--a Nordic Lymphoma Group randomised trial. 1999 , 10, 1079-86	39
2266	A case of ALK-positive large T-cell lymphoma expressing epithelial membrane antigen with favorable prognosis. 1999 , 102, 47-50	2
2265	Clinicopathological analysis of 501 non-Hodgkin's lymphomas in Korea according to the revised European-American classification of lymphoid neoplasms. 1999 , 35, 345-54	45
2264	Intermittent 2-hour-infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. 1999 , 35, 129-38	16
2263	De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome. 1999 , 105, 1133-9	51
2262	Immunostaining for cyclin D1 and the diagnosis of mantle cell lymphoma: is there a reliable method?. 1999 , 34, 266-70	40
2261	Distinct chromosome 3 abnormalities in persistent polyclonal B-cell lymphocytosis. 1999 , 26, 221-8	20
2260	Outcome of advanced stage low grade follicular lymphomas in a population-based retrospective cohort. 1999 , 85, 1361-8	5
2259	Aspiration cytopathology of malignant lymphoma. 1999 , 87, 322-324	15
2258	Fine-needle aspiration with flow cytometric immunophenotyping for primary diagnosis of intra-abdominal lymphomas. 1999 , 21, 98-104	25
2257	Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma. 1999 , 13, 889-918	11
2256	Inroads in the Therapy of Indolent Lymphomas: Exploiting Biological Insights. 1999 , 17, 73-86	2
2255	[Radiotherapy of cutaneous lymphomas]. 1999 , 3, 105-11	7
2254	A new, lethal form of follicular lymphoma?. 1999 , 30, 249-50	
2253	Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. 1999 , 30, 263-8	49
2252	Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand. 1999 , 30, 48-53	28

2251	The therapy of primary adult systemic CD30-positive anaplastic large cell lymphoma: results of 40 cases treated in a single center. 1999 , 35, 159-69	18
2250	Intermediate and high grade non Hodgkin's lymphoma in the elderly. 1999 , 33, 243-52	7
2249	Clonality assessment in blood of patients with mantle cell lymphoma. 1999 , 32, 375-9	10
2248	Principles of diagnosis, staging and management. 1999 , 11, 214-229	
2247	Belgian Consensus Recommendations for Flow Cytometric Immunophenotyping. 1999 , 54, 88-98	6
2246	Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification. 1999 , 111, 379-86	17
2245	Cytodiagnosis of lymphoid proliferations by fine needle aspiration biopsy. Adjunctive value of flow cytometry. 1999 , 43, 1070-8	41
2244	Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. 1999 , 10, 115-7	19
2243	Gastric MALT lymphoma: from concept to cure. 1999 , 10, 637-45	170
2242	2'-Chlorodeoxyadenosine Effectively Induces Complete Remission in Hairy Cell Leukaemia. 1999 , 4, 403-14	
2241	A new approach to non-Hodgkin's lymphoma. 2000 , 39, 197-208	7
2240	Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. 2000 , 18, 795-803	281
2239	Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. 2000 , 18, 510-18	120
2238	High-dose chemotherapy and autologous hematopoietic stem cell transplantation: the lymphoma experience and its potential relevance to solid tumors. 2000 , 58, 198-206	10
2237	Primary nodal marginal zone lymphomas of splenic and MALT type. 2000 , 24, 317-9	4
2236	What is a neuroendocrine tumor?. 2000 , 24, 319-20	1
2235	Helicobacter pylori eradication and remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma: a long-term follow-up study. 2000 , 31, 169-71	32
2234	Lennert's lymphoma: a variant of cytotoxic T-cell lymphoma?. 2000 , 24, 1627-33	31

2233	Burkitt's lymphoma: molecular pathogenesis and treatment. 2000 , 18, 574-83	65
2232	Bone marrow staging of patients with non-Hodgkin lymphoma by flow cytometry. 2000 , 88, 894-899	28
2231	Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group. 2000 , 64, 190-6	123
2230	Malignant lymphoma in southern Taiwan according to the revised European-American classification of lymphoid neoplasms. 2000 , 89, 1586-1592	52
2229	Different age limits for elderly patients with indolent and aggressive non-hodgkin lymphoma and the role of relative survival with increasing age. 2000 , 89, 2667-76	36
2228	Marginal zone B-cell lymphomas (MZBL) arising at different sites represent different biological entities. 2000 , 28, 380-6	25
2227	Prognostic models for diffuse large B-cell lymphoma. 2000 , 18, 61-73	17
2226	The current status of lymphoma classification. 2000 , 109, 258-66	19
2225	Autologous stem cell transplantation for anaplastic large-cell lymphomas: results of a prospective trial. 2000 , 109, 736-42	48
2224	Follicular lymphomas--a review of treatment modalities. 2000 , 35, 13-32	6
2223	The management of adult aggressive non-Hodgkin's lymphomas. 2000 , 35, 33-48	14
2222	Frontline transplantation of autologous CD34+ selected blood cells for advanced mantle cell lymphoma: no evidence of long-term cure: a single centre experience. 2000 , 26, 1138-9	5
2221	Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4. 2000 , 14, 292-8	41
2220	Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: prognostic significance of E2F-1 and p16INK4A. 2000 , 14, 898-904	51
2219	Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. 2000 , 14, 1533-59	183
2218	Follicular lymphoma with monocytoid B-cell proliferation: molecular assessment of the clonal relationship between the follicular and monocytoid B-cell components. 2000 , 80, 1593-9	20
2217	Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. 2000 , 403, 503-11	7592
2216	Practical utility of the revised European-American classification of lymphoid neoplasms for Japanese non-Hodgkin's lymphomas. 2000 , 91, 351-60	16

2215	Analysis of the immunoglobulin heavy chain gene of secondary diffuse large B-cell lymphoma that subsequently developed in four cases with B-cell chronic lymphocytic leukemia or lymphoplasmacytoid lymphoma (Richter syndrome). 2000 , 50, 636-43		28
2214	Laparoscopic biopsy of abdominal retroperitoneal lymphadenopathy for the diagnosis of lymphoma. 2000 , 191, 108-13		15
2213	Nasal T/NK cell lymphoma: report of 3 cases involving the palate. 2000 , 58, 1323-7		21
2212	Burkitt's lymphoma in Greek adults. A study of the Hellenic co-operative oncology group. 2000 , 24, 993-8		3
2211	Mantle cell lymphoma. 2000 , 1, 281-5		5
2210	New developments in lymphoma clinical trials. 2000 , 2, 154-6		
2209	Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. 2000 , 17, 225-8		16
2208	Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. <i>Blood</i> , 2000 , 95, 619-626	2.2	182
2207	The gastric marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2000 , 96, 410-419	2.2	195
2206	Mature B-cell lymphoma/leukemia in children and adolescents: intergroup pathologist consensus with the revised European-American Lymphoma Classification. 2000 , 11, 47-51		33
2205	Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. 2000 , 113, 512-8		50
2204	CD-30 positive peripheral T-cell lymphoma of the Waldeyer's ring. 2000 , 38, 199-202		1
2203	Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: results of the Southwest Oncology Group randomized phase III study 8809. 2000 , 18, 2010-6		66
2202	European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. 2000 , 18, 317-24		404
2201	Lymphoproliferative disorders presenting as mediastinal neoplasms. 2000 , 12, 290-300		13
2200	Cutaneous lymphomas: A proposal for a unified approach to classification using the R.E.A.L./WHO Classification. 2000 , 11, S17-S21		18
2199	Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. 2000 , 11, S117-S121		44
2198	De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma. 2000 , 114, 523-33		43

2197	Lymphoma classification [from controversy to consensus: The R.E.A.L. and WHO Classification of lymphoid neoplasms. 2000 , 11, S3-S10	161
2196	Monoclonal antibody therapy in lymphoid malignancies. 2000 , 5, 376-84	49
2195	Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. 2000 , 92, 1240-51	415
2194	[Advantages and deficiencies of the current classification of lymphomas]. 2000 , 200, 239-41	
2193	Untreated aggressive mantle cell lymphoma: results with intensive chemotherapy without stem cell transplant in elderly patients. 2000 , 39, 77-85	56
2192	Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression. 2000 , 38, 317-26	48
2191	Non-Hodgkin's lymphoma subtypes over time in an unselected population of 646 patients: a study of clinico-pathological data and incidence based on a review using the REAL-classification. 2000 , 39, 531-41	11
2190	Diagnosis and management of primary nasal lymphoma of T-cell or NK-cell origin. 2000 , 1, 33-7; discussion 38	46
2189	Primary systemic anaplastic large-cell lymphoma (CD30+): advances in biology and current therapeutic approaches. 2001 , 2, 29-37; discussion 38-9	16
2188	Diffuse large-cell lymphomas: a review of therapy. 2001 , 2, 155-63	3
2187	Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. 2001 , 32, 196-204	31
2186	Coexpression of Bcl-6 and CD10 in diffuse large B-cell lymphomas: significance of Bcl-6 expression patterns in identifying germinal center B-cell lymphoma. 2001 , 32, 954-62	44
2185	Secondary ocular involvement in systemic "memory" B-cell lymphocytic leukemia. 2001 , 108, 1289-95	21
2184	Radiation therapy for malignant lymphoma: enduring importance in the era of systemic therapy. 2001 , 55, 516-8	
2183	Varíl de 33 aBs infectado por el virus de la inmunodeficiencia humana con vñitos y dolor abdominal de 15 dñs de evoluciñ. 2001 , 116, 430-436	
2182	Continuous infusion of vincristine-doxorubicin with bolus of dexamethasone(VAD) alternated with CHEP in the treatment of patients over 60 years old with aggressive non-Hodgkin's lymphoma. 2001 , 40, 529-40	2
2181	Splenic lymphoproliferative disorders in human T lymphotropic virus type-I endemic area of japan: clinicopathological, immunohistochemical and genetic analysis of 27 cases. 2001 , 41, 593-605	5
2180	Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. 2001 , 14, 219-28	154

2179	Cytologic diagnosis of peripheral T-cell lymphoma manifesting as ascites. A case report. 2001 , 45, 385-92	13
2178	MALT Lymphomas. 2001 , 2001, 241-58	123
2177	Rituximab: An innovative therapy for non-Hodgkin's lymphoma. 2001 , 58, 215-229	15
2176	Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features. 2001 , 12, 853-8	24
2175	T-cell lymphoma. 2001 , 215-232	
2174	Primary mediastinal B-cell lymphoma: a review of pathology and management. 2001 , 19, 1855-64	101
2173	High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. 2001 , 19, 2927-36	91
2172	Hodgkin's lymphoma: basing the treatment on the evidence. 2001 , 2001, 178-93	27
2171	Diffuse large B-cell non-Hodgkin's lymphoma presenting as a vaginal mass in a patient with a history of intestinal mucosa-associated lymphoid tissue (MALT) lymphoma. 2001 , 24, 204-8	2
2170	Diffuse large cell lymphoma. 2001 , 13, 325-34	124
2169	T cell and NK cell lymphoproliferative disorders. 2001 , 2001, 259-81	79
2168	Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. 2001 , 12, 457-62	14
2167	Diffuse large B-cell lymphoma with primary retroperitoneal presentation: clinico-pathologic study of nine cases. 2001 , 12, 1445-53	12
2166	Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. <i>Blood</i> , 2001 , 98, 2865-8	2.2 418
2165	The Burkitt-like lymphomas: a Southwest Oncology Group study delineating phenotypic, genotypic, and clinical features. <i>Blood</i> , 2001 , 97, 3713-20	2.2 96
2164	Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. <i>Blood</i> , 2001 , 98, 781-6	2.2 50
2163	Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2001 , 98, 945-51	2.2 251
2162	New approaches to lymphoma diagnosis. 2001 , 2001, 194-220	60

2161	Results of a Controlled Clinical Trial Radiotherapy versus Combined Therapy in the Management of Stage IE Orbital Marginal Zone B-cell Lymphoma. 2001 , 6, 181-5	1
2160	Impact of high-dose chemotherapy on peripheral T-cell lymphomas. 2001 , 19, 3766-70	131
2159	Classification in anatomic pathology. 2001 , 116 Suppl, S5-20	1
2158	Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry. 2001 , 8, 218-39	27
2157	Expression of bcl-6 and CD10 in primary mediastinal large B-cell lymphoma: evidence for derivation from germinal center B cells?. 2001 , 25, 1277-82	66
2156	Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody. 2001 , 74, 70-5	35
2155	The significance of molecular response of follicular lymphoma to central lymphatic irradiation as measured by polymerase chain reaction for t(14;18)(q32;q21). 2001 , 49, 727-32	9
2154	Alk+ CD30+ lymphomas: a distinct molecular genetic subtype of non-Hodgkin's lymphoma. 2001 , 113, 275-95	83
2153	Anaplastic large cell lymphoma: pathological, molecular and clinical features. 2001 , 114, 741-60	106
2152	Peripheral T/NK-cell lymphoma: a report of the IXth Workshop of the European Association for Haematopathology. 2001 , 38, 250-70	69
2151	CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. 2001 , 39, 156-62	78
2150	Extranodal mantle cell lymphoma mimicking marginal zone cell lymphoma. 2001 , 39, 561-5	12
2149	Fine-needle aspiration biopsy of peripheral T-cell lymphomas. A cytologic and immunophenotypic study of 33 cases. 2001 , 93, 151-9	33
2148	The new World Health Organization classification of lymphomas: the past, the present and the future. 2001 , 19, 129-50	92
2147	Analysis of secondary chromosomal alterations in 165 cases of follicular lymphoma with t(14;18). 2001 , 30, 375-82	127
2146	Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin's lymphoma classification project. 2001 , 67, 172-8	40
2145	Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. 2001 , 18, 141-8	17
2144	Peripheral T-cell lymphoma with aberrant expression of CD79a and CD20: a diagnostic pitfall. 2001 , 14, 105-10	110

2143	Autologous stem cell transplantation for clinically aggressive non-Hodgkin's lymphoma: the role of preparative regimens. 2001 , 27, 405-12	59
2142	Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?. 2001 , 28, 813-20	14
2141	Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. 2001 , 8, 378-87	27
2140	Morphological spectrum of cyclin D1-positive mantle cell lymphoma: study of 168 cases. 2001 , 51, 747-61	39
2139	Waldenström macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors. 2001 , 116, 420-8	125
2138	Recommendations for processing and reporting of lymph node specimens submitted for evaluation of metastatic disease. 2001 , 115, 799-801	23
2137	Comparison of lymphoid neoplasm classification. A blinded study between a community and an academic setting. 2001 , 115, 650-5	9
2136	Clinicopathologic analysis of CD10+ and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. 2001 , 116, 183-90	66
2135	Low expression of p27 protein combined with altered p53 and Rb/p16 expression status is associated with increased expression of cyclin A and cyclin B1 in diffuse large B-cell lymphomas. 2001 , 14, 1105-13	39
2134	Peripheral T-cell lymphoma of the colon: double-contrast barium enema examination findings in six patients. 2001 , 218, 751-6	14
2133	Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. 2001 , 115, 266-70	55
2132	An unusual Fc receptor-related protein expressed in human centroblasts. 2002 , 99, 3776-81	39
2131	Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. 2002 , 169, 137-44	81
2130	An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. 2002 , 13, 1264-74	225
2129	Canine T-cell lymphomas: a morphological, immunological, and clinical study of 46 new cases. 2002 , 39, 92-109	132
2128	Lymphoma of the skin. 2002 , 2002, 263-82	15
2127	Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. 2002 , 13, 928-43	101
2126	Blood transfusions and non-Hodgkin's lymphoma. 2002 , 24, 269-79	17

2125	Apoptotic rate in peripheral T-cell lymphomas. A study using a tissue microarray with validation on full tissue sections. 2002 , 118, 328-34	58
2124	CD5- mantle cell lymphoma. 2002 , 118, 216-24	103
2123	Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin's lymphoma?. 2002 , 7, 345-54	
2122	Molecular heterogeneity of diffuse large B-cell lymphoma: implications for disease management and prognosis. 2002 , 7, 239-52	27
2121	Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. 2002 , 43, 97-104	37
2120	Centroblastic and centroblastic/centrocytic lymphoma associated with a prominent epithelioid granulomatous response: a clinicopathologic study of 50 cases. 2002 , 15, 750-8	8
2119	Cytogenetic analysis in mantle cell lymphoma: a review of 214 cases. 2002 , 43, 783-91	46
2118	T-cell non-Hodgkin's lymphoma in adults: clinicopathological characteristics, response to treatment and prognostic factors. 2002 , 43, 805-11	45
2117	Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. 2002 , 29, 473-7	19
2116	Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. 2002 , 13, 1275-84	15
2115	Composite angioimmunoblastic T-cell lymphoma and diffuse large B-cell lymphoma: a case report and review of the literature. 2002 , 118, 848-54	53
2114	Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. 2002 , 13, 523-30	34
2113	Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. 2002 , 13, 140-9	332
2112	Progress and promise in the treatment of indolent lymphomas. 2002 , 7, 217-25	20
2111	Mantle Cell Lymphoma, Blastoid Variant (WHO Classification), Producing Distinctive Morphologic Patterns. 2002 , 7, 88-96	
2110	T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity. 2002 , 20, 1269-77	61
2109	Mantle Cell Lymphoma, Blastoid Variant (WHO Classification), Producing Distinctive Morphologic Patterns. 2002 , 7, 88-96	2
2108	Using unconjugated antibodies as an immunotherapeutic approach to treatment of B-cell neoplasms. 2002 , 25, 266-73	

2107	Angioimmunoblastic Lymphadenopathy With Dysproteinemia and Angioimmunoblastic T-Cell Lymphoma. 2002 , 7, 105-109		
2106	De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. <i>Blood</i> , 2002 , 99, 815-21	2.2	241
2105	In situ localization of follicular lymphoma: description and analysis by laser capture microdissection. <i>Blood</i> , 2002 , 99, 3376-82	2.2	196
2104	Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia. <i>Blood</i> , 2002 , 99, 4379-85	2.2	164
2103	Bedeutung der Helicobacter-pylori-Infektion ff die Pathogenese und Therapie von MALT-Lymphomen des Magens. 2002 , 18, 24-28		
2102	Primary Mediastinal Large B-cell Lymphoma. 2002 , 95, 1005-1007		1
2101	Angioimmunoblastic Lymphadenopathy With Dysproteinemia and Angioimmunoblastic T-Cell Lymphoma. 2002 , 7, 105-109		
2100	Gene expression profiling of lymphoid malignancies. 2002 , 53, 303-18		101
2099	Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. 2002 , 161, 413-20		73
2098	CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. 2002 , 346, 235-42		4169
2097	VIII International Conference on malignant lymphoma. June 12-15, 2002 Lugano, Switzerland. 2002 , 3, 75-81		
2096	Coeliac disease and malignancy. 2002 , 34, 229-37		28
2095	Treatment of lymphoblastic lymphoma in adults. 2002 , 15, 713-28		35
2094	From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. 2002 , 33, 7-20		124
2093	Mantle cell lymphoma: new treatments targeted to the biology. 2002 , 3, 90-6		5
2092	Treatment paradigms in aggressive non-Hodgkin's lymphoma in elderly patients. 2002 , 3 Suppl 1, S12-8		6
2091	Challenges in the management of Burkitt's lymphoma. 2002 , 3 Suppl 1, S19-25		22
2090	The distinction between Burkitt lymphoma and diffuse large B-Cell lymphoma with c-myc rearrangement. 2002 , 15, 771-6		75

2089	Classification of malignant lymphoma. 2002 , 25, 563-70	11
2088	Treatment of aggressive non-Hodgkin's lymphoma with chemotherapy in combination with filgrastim. 2002 , 62 Suppl 1, 33-46	3
2087	Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. 2002 , 43, 1769-75	9
2086	Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. 2002 , 43, 2309-17	44
2085	Focal follicular features in tonsillar diffuse large B-cell lymphomas: follicular lymphoma with diffuse areas or follicular colonization. 2002 , 33, 732-40	8
2084	Recommendations for the reporting of lymphoid neoplasms: a report from the Association of Directors of Anatomic and Surgical Pathology. The Ad Hoc Committee on reporting of lymphoid neoplasms. 2002 , 33, 1064-8	8
2083	CD69 expression correlates with expression of other markers of Th1 T cell differentiation in peripheral T cell lymphomas. 2002 , 33, 330-4	19
2082	Mediastinal (thymic) large B-cell lymphoma: where do we stand?. 2002 , 3, 229-34	100
2081	A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. 2002 , 38, 401-8	73
2080	Current treatment of follicular non-Hodgkin's lymphoma. 2002 , 38, 1167-72	22
2079	Association of expression of CD44v6 with systemic anaplastic large cell lymphoma: comparison with primary cutaneous anaplastic large cell lymphoma. 2002 , 117, 276-82	10
2078	Classificaç� dos linfomas n�-Hodgkin: estudo morfol�gico e imunoistoqu�mico de 145 casos. 2002 , 38, 315-324	3
2077	Rituximab in the treatment of diffuse large B-cell lymphomas. 2002 , 29, 30-35	42
2076	Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. 2002 , 29, 18-22	81
2075	Improving outcomes in transplantation. 2002 , 29, 23-6	7
2074	Cytogenetic characterization of diffuse large cell lymphoma using multi-color fluorescence in situ hybridization. 2002 , 132, 125-32	35
2073	The World Health Organization classification of malignant lymphoma: incidence and clinical prognosis in HTLV-1-endemic area of Fukuoka. 2002 , 52, 1-12	35
2072	Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas. 2002 , 70, 181-5	5

2071	Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection. 2002 , 94, 1500-6	38
2070	International prognostic index-based outcomes for diffuse large B-cell lymphomas. 2002 , 94, 3083-8	42
2069	Primary thyroid lymphoma: can the diagnosis be made solely by fine-needle aspiration?. 2002 , 9, 298-302	75
2068	Follicular lymphoma in Osaka, Japan: histological features and chronological change. 2002 , 76, 333-7	9
2067	Peripheral T-cell lymphoma. 2002 , 4, 434-42	10
2066	Histiocyte-rich, T-cell-rich B-cell lymphoma: a distinct diffuse large B-cell lymphoma subtype showing characteristic morphologic and immunophenotypic features. 2002 , 40, 31-45	53
2065	Marginal zone cell lymphoma--an update on recent advances. 2002 , 40, 117-26	68
2064	Diffuse large B-cell lymphoma: one or more entities? Present controversies and possible tools for its subclassification. 2002 , 41, 482-509	65
2063	Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL?. 2002 , 16, 2134-41	42
2062	Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. 2002 , 8, 68-74	1921
2061	Primary gastric follicular lymphoma with parafollicular monocytoid B-cells and lymphoepithelial lesions, mimicking extranodal marginal zone lymphoma of MALT. 2002 , 441, 614-7	20
2060	Primary mucosa-associated lymphoid tissue (MALT) lymphoma arising from the male urethra. A case report and review of the literature. 2002 , 198, 571-5	11
2059	Recurrent mantle cell lymphoma after allogeneic bone marrow transplantation presenting as isolated rectal mass. 2003 , 48, 1024-6	1
2058	Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. 2003 , 199, 293-302	29
2057	Mantle cell lymphoma: improved diagnostics using a combined approach of immunohistochemistry and identification of t(11;14)(q13;q32) by polymerase chain reaction and fluorescence in situ hybridization. 2003 , 442, 538-47	18
2056	A successful right axillary artery graft to repair a ruptured axillary artery due to the involvement of lymphoma: report of a case. 2003 , 33, 72-4	5
2055	Diffuse large B-cell lymphoma: insights gained from gene expression profiling. 2003 , 77, 321-9	11
2054	[Follicle centre lymphoma: treatment results for stage I and II]. 2003 , 179, 840-6	16

2053	The classification of lymphomas: a new beginning or the end of an era?. 2003 , 30 Suppl 1, S13-8	2
2052	Therapy of non-Hodgkin's lymphoma. 2003 , 30 Suppl 1, S28-36	26
2051	Minimal residual disease (MRD) in follicular lymphoma in the era of immunotherapy with rituximab. 2003 , 13, 223-31	11
2050	The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. 2003 , 3, 185-97	75 ¹
2049	Phenotypic analysis of peripheral T/NK cell lymphoma: study of 408 Japanese cases with special reference to their anatomical sites. 2003 , 53, 333-44	23
2048	Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. 2003 , 30, 21-7	24
2047	First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma. 2003 , 30, 9-15	21
2046	Developing diagnostic criteria in Waldenstrom's macroglobulinemia. 2003 , 30, 196-200	46
2045	Prognosis of localized diffuse large B-cell lymphoma in younger patients. 2003 , 98, 516-21	6
2044	Radiotherapy for extranodal, marginal zone, B-cell lymphoma of mucosa-associated lymphoid tissue originating in the ocular adnexa: a multiinstitutional, retrospective review of 50 patients. 2003 , 98, 865-71	142
2043	Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. 2003 , 98, 2651-6	52
2042	Flow cytometry in the bone marrow staging of mature B-cell neoplasms. 2003 , 54, 10-8	28
2041	Prognostic significance of bcl-2, bax, and p53 expression in diffuse large B-cell lymphoma. 2003 , 73, 101-7	67
2040	Extranodal diffuse follicular center lymphoma mimicking mantle cell lymphoma of the intestine. 2003 , 74, 287-9	8
2039	Lymphoma subtypes in patients with rheumatoid arthritis: increased proportion of diffuse large B cell lymphoma. 2003 , 48, 1543-50	128
2038	Primary low-grade B-cell lymphoma of the mucosa-associated lymphoid tissue of the gallbladder. 2003 , 43, 300-1	16
2037	ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified. 2003 , 43, 462-9	77
2036	Costs of drug delivery for CHOP, COP/CVP, and fludarabine: an international assessment. 2003 , 6, 167-74	11

2035	Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes. 2003 , 120, 424-33	95
2034	Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma: variable outcome according to pathological subtype. 2003 , 120, 978-85	89
2033	Multicolour fluorescence in situ hybridization analysis of t(14;18)-positive follicular lymphoma and correlation with gene expression data and clinical outcome. 2003 , 122, 745-59	30
2032	ALK-negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects--a review. 2003 , 200, 4-15	97
2031	BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation. 2003 , 200, 240-8	62
2030	Development of consensus fluorogenically labeled probes of the immunoglobulin heavy-chain gene for detecting minimal residual disease in B-cell non-Hodgkin lymphomas. 2003 , 94, 877-85	11
2029	Multiple fuzzy neural network system for outcome prediction and classification of 220 lymphoma patients on the basis of molecular profiling. 2003 , 94, 906-13	28
2028	Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. 2003 , 17, 255-9	52
2027	Prognostic value of GST-pi expression in diffuse large B-cell lymphomas. 2003 , 17, 972-7	24
2026	Current trends in large cell lymphoma. 2003 , 17, 1948-60	41
2025	Heterogeneous copy numbers of API2-MALT1 chimeric transcripts in mucosa-associated lymphoid tissue lymphoma. 2003 , 17, 2508-12	6
2024	Catalyzed signal amplification for cyclin D1 detection in mantle cell lymphoma. 2003 , 16, 161-5	10
2023	Rare tumors of the thyroid gland. 2003 , 36, 107-15	17
2022	La clasificaci3n de los linfomas: un anticipo de la taxonom3a del c3ncer en el siglo XXI. 2003 , 203, 386-387	
2021	Nongastric mucosa-associated lymphoid tissue lymphomas. 2003 , 3, 212-24	33
2020	Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma. 2003 , 4, 52-5	12
2019	Cerebral involvement as the initial manifestation of chronic lymphocytic leukaemia. 2003 , 109, 193-5	11
2018	Detection of germinal center B-cell lymphoma in archival specimens: critical evaluation of Bcl-6 protein expression in diffuse large B-cell lymphoma of the tonsil. 2003 , 34, 610-6	12

2017	Non-Hodgkin lymphoma. 2003 , 362, 139-46		109
2016	Classification of cytotoxic T-cell and natural killer cell lymphomas. 2003 , 40, 175-84		89
2015	Towards molecular diagnosis and targeted therapy of lymphoid malignancies. 2003 , 40, 296-307		21
2014	Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. 2003 , 34, 1030-4		85
2013	Splenic involvement by peripheral T-cell and NK-cell neoplasms. 2003 , 20, 105-20		10
2012	Mantle cell lymphoma of the hard palate: a case report and review of the differential diagnosis based on the histomorphology and immunophenotyping pattern. 2003 , 96, 316-20		24
2011	Anaplastic large cell lymphoma. 2003 , 9, 252-258		5
2010	Gene expression profiling of diffuse large B-cell lymphoma. 2003 , 44 Suppl 3, S41-7		78
2009	Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification. 2003 , 44, 241-9		59
2008	Non-Hodgkin's lymphoma in the Netherlands: results from a population-based registry. 2003 , 44, 451-8		17
2007	Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2003 , 101, 78-84	2.2	322
2006	T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. <i>Blood</i> , 2003 , 101, 2335-9	2.2	402
2005	Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP). 2003 , 14, 1758-61		50
2004	High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience. 2003 , 14, 1768-75		95
2003	CXCR4/CD184 immunoreactivity in T-cell non-Hodgkin lymphomas with an overall Th1- Th2+ immunophenotype. 2003 , 119, 424-30		19
2002	Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. 2003 , 21, 5-15		99
2001	Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma. 2003 , 21, 2115-22		106
2000	<i>Helicobacter pylori</i> . 2003 ,		0

1999	18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for assessment of enteropathy-type T cell lymphoma. 2003 , 52, 347-51	61
1998	Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. 2003 , 14, 131-9	147
1997	Differential Expression of T-bet, a T-box Transcription Factor Required for Th1 T-Cell Development, in Peripheral T-Cell Lymphomas. 2003 , 120, 866-873	27
1996	A systematic overview of radiation therapy effects in non-Hodgkin's lymphoma. 2003 , 42, 605-19	54
1995	Peripheral T cell lymphoma: The Sheffield Lymphoma Group experience (1977-2001). 2003 , 22, 1363	
1994	Limited-stage mantle-cell lymphoma. 2003 , 14, 1555-61	84
1993	Flow Cytometry in Hematopathology. 2003 ,	8
1992	Molecular pathogenesis of mucosal-associated lymphoid tissue (MALT) lymphoma. 2003 , 44 Suppl 3, S13-20	13
1991	Ex situ resection of primary cardiac tumors. 2003 , 51, 99-101	16
1990	Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. 2003 , 21, 35-40	235
1989	Recommendations for the reporting of lymphoid neoplasms. 2003 , 119, 185-9	3
1988	Nodal marginal zone lymphoma: a heterogeneous tumor: a comprehensive analysis of a series of 27 cases. 2003 , 27, 762-71	91
1987	Recent developments in the biology and therapy of T-cell and natural killer-cell lymphomas. 2003 , 15, 353-62	12
1986	Importance of esophagogastroduodenoscopy in the evaluation of non-gastrointestinal mucosa-associated lymphoid tissue lymphoma. 2003 , 9, 321-4	16
1985	Total registration of non-Hodgkin's lymphoma and Hodgkin's disease in Scotland: effect of deprivation and caseload on outcome. 2003 , 8, 211-20	5
1984	Primary anaplastic large cell lymphoma of the central nervous system: prognostic effect of ALK-1 expression. 2003 , 27, 487-93	71
1983	Waldenstrom macroglobulinemia involving extramedullary sites: morphologic and immunophenotypic findings in 44 patients. 2003 , 27, 1104-13	60
1982	Marginal zone B-cell lymphoma in children and young adults. 2003 , 27, 522-31	132

1981	Update: gastric MALT lymphoma. 2003 , 15, 347-52		27
1980	Machine learning methods applied to DNA microarray data can improve the diagnosis of cancer. 2003 , 5, 48-55		19
1979	Peripheral T-cell lymphomas expressing CD30 and CD15. 2003 , 27, 1513-22		94
1978	Anaplastic large cell lymphoma presenting as a pleural effusion and mimicking primary effusion lymphoma. A report of 2 cases. 2003 , 47, 809-16		28
1977	Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. <i>Blood</i> , 2003 , 101, 2489-95		424
1976	Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell. <i>Blood</i> , 2003 , 101, 699-702	2.2	39
1975	HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. <i>Blood</i> , 2003 , 101, 433-40	2.2	79
1974	A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. <i>Blood</i> , 2003 , 101, 2363-7	2.2	110
1973	Lymphoid malignancies: immunophenotypic analysis. 2003 , 37, 293-353		0
1972	Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. <i>Blood</i> , 2003 , 102, 2213-9	2.2	181
1971	Female patient with a history of Hashimoto's thyroiditis, diagnosed with MALT lymphoma of both breasts. 2003 , 26, 277-80		3
1970	Invited Commentary. 2003 , 23, 26-28		4
1969	Molecular etiology of mature T-cell non-Hodgkin's lymphomas. 2003 , 8, d156-75		13
1968	Grading follicular lymphoma on fine needle aspiration specimens. Comparison with proliferative index by DNA image analysis and Ki-67 labeling index. 2004 , 48, 119-26		30
1967	Mature T-cell and NK-cell lymphomas in the pediatric age group. 2004 , 122 Suppl, S110-21		3
1966	Role of fine needle aspiration in lymphoma. 2004 , 121, 181-220		1
1965	Bone marrow is involved in less than 10% of patients with nasal-type NK/T cell lymphoma at initial diagnosis. 2004 , 19, 229-33		10
1964	Lymphoma in Asia. 2004 , 02, 151-159		2

1963	T-cell and NK/T-cell lymphomas in southern Taiwan: a study of 72 cases in a single institute. 2004 , 45, 923-8	25
1962	Stem cell transplantation for peripheral T-cell lymphomas. 2004 , 45, 441-6	23
1961	Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma. 2004 , 15, 1413-8	32
1960	Use of the WHO lymphoma classification in a population-based epidemiological study. 2004 , 15, 631-7	19
1959	Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma. 2004 , 15, 1680-3	33
1958	Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. 2004 , 13, 138-43	82
1957	Histologic Patterns of Lung Infiltration of B-Cell, T-Cell, and Hodgkin Lymphomas. 2004 , 121, 718-726	17
1956	CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. 2004 , 10, 5494-500	147
1955	Monoclonal immunoglobulin production is a frequent event in patients with mucosa-associated lymphoid tissue lymphoma. 2004 , 10, 7179-81	63
1954	Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. 2004 , 15, 1467-75	260
1953	Towards understanding the peripheral T-cell lymphomas. 2004 , 15, 1447-9	51
1952	Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma. 2004 , 22, 1469-79	96
1951	Optic neuropathy due to anaplastic large cell lymphoma. 2004 , 19, 81-7	5
1950	Regulation and function of cyclin D2 in B lymphocyte subsets. 2004 , 173, 2901-7	54
1949	Real-time quantitative reverse transcription-PCR for cyclin D1 mRNA in blood, marrow, and tissue specimens for diagnosis of mantle cell lymphoma. 2004 , 50, 80-7	24
1948	Unusual abdominal tumors, case 3. Primary omental T-cell lymphoblastic lymphoma. 2004 , 22, 1522-3	1
1947	A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein. 2004 , 91, 141-9	32
1946	Low-grade lymphoma. 2004 , 2004, 203-20	42

1945	Use of the World Health Organization (WHO) classification of non-Hodgkin's lymphoma in Mumbai, India: a review of 200 consecutive cases by a panel of five expert hematopathologists. 2004 , 45, 1569-77	36
1944	Indolent lymphoma: the pathologist's viewpoint. 2004 , 15, 12-8	16
1943	Antiapoptotic function of apoptosis inhibitor 2-MALT1 fusion protein involved in t(11;18)(q21;q21) mucosa-associated lymphoid tissue lymphoma. 2004 , 64, 3452-7	39
1942	Myeloablative radiochemotherapy followed by autologous peripheral blood stem cell transplantation as first-line therapy in peripheral T-cell lymphomas: first results of a prospective multicenter study. 2004 , 5, 304-11	42
1941	Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. 2004 , 15, 1691-8	92
1940	Molecular heterogeneity of diffuse large B-cell lymphoma. 2004 , 5 Suppl 3, S144-8	1
1939	CD21S antigen expression in tumour cells of diffuse large B-cell lymphomas is an independent prognostic factor indicating better overall survival. 2004 , 125, 180-6	12
1938	Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). 2004 , 45, 268-74	35
1937	Nuclear structure in cancer cells. 2004 , 4, 677-87	703
1936	Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. 2004 , 34, 43-9	36
1935	Stem cell transplantation in follicular lymphoma: progress at last?. 2004 , 34, 929-38	17
1934	Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas. 2004 , 18, 589-96	79
1933	Topoisomerase IIalpha as a prognostic factor in mantle cell lymphoma. 2004 , 18, 1347-9	8
1932	Recommendations for the reporting of lymphoid neoplasms: A report from the Association of Directors of Anatomic and Surgical Pathology. 2004 , 17, 131-135	25
1931	Canine lymphomas: a morphological and immunohistochemical study of 55 cases, with observations on p53 immunoexpression. 2004 , 131, 207-13	42
1930	Integrating Monoclonal Antibodies into the Management of Mantle Cell Lymphoma. 2004 , 31 Suppl 2, 2-6	8
1929	Clearing Minimal Residual Disease with Rituximab Consolidation Therapy. 2004 , 31 Suppl 2, 33-37	10
1928	Primary B-cell lymphoma of the tongue in a patient with systemic sclerosis. 2004 , 40, 103-6	10

1927	Lack of association between DNA base excision repair gene XRCC1 Gln399Arg polymorphism and risk of malignant lymphoma in Japan. 2004 , 149, 77-80	32
1926	Lymphoma: Current concepts and difficult diagnostic disorders. 2004 , 54, S303-S317	
1925	Extranodal lymphoproliferative disorders with emphasis on skin. 2004 , 54, S318-S341	0
1924	T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine. 2004 , 80, 70-4	1
1923	Primary mediastinal large B-cell lymphoma: a single-institution clinical study in Japan. 2004 , 79, 465-71	8
1922	Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. 2004 , 79, 311-21	10
1921	Nuclear factor kappaB activation and antiapoptosis in mucosa-associated lymphoid tissue lymphoma. 2004 , 80, 215-23	9
1920	Molecular signatures of lymphoma. 2004 , 80, 401-9	10
1919	Unusual presentation and diagnosis of extraintestinal follicular lymphoma. 2004 , 49, 1513-7	0
1918	Nodal peripheral T-cell lymphomas and, in particular, their lymphoepithelioid (Lennert's) variant are often derived from CD8(+) cytotoxic T-cells. 2004 , 445, 334-43	65
1917	MALT Lymphoma in Children: Case Report and Review of the Literature. 2004 , 7, 407-13	37
1916	European experiences on aggressive non-Hodgkin's lymphoma in elderly patients. 2004 , 51, 229-40	5
1915	Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases. 2004 , 124, 151-9	156
1914	Molecular basis of mantle cell lymphoma. 2004 , 124, 130-40	80
1913	Prognostic factors influencing survival in patients with B-cell small lymphocytic lymphoma. 2004 , 77, 31-5	10
1912	Identification of cytogenetic subgroups and karyotypic pathways of clonal evolution in follicular lymphomas. 2004 , 39, 195-204	105
1911	Interphase fluorescence in situ hybridization for detection of 8q24/MYC breakpoints on routine histologic sections: validation in Burkitt lymphomas from three geographic regions. 2004 , 40, 10-8	58
1910	Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma. 2004 , 100, 356-65	52

1909	The role of fludarabine in the treatment of follicular and mantle cell lymphoma. 2004 , 101, 883-93		29
1908	Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. 2004 , 101, 1601-8		39
1907	Prevalence and characterization of anaplastic large cell lymphoma and its association with Epstein-Barr virus in Pakistani patients. 2004 , 200, 669-79		10
1906	Somatostatin receptor scintigraphy in MALT lymphoma of the lacrimal gland treated with rituximab. 2004 , 45, 1275-8		9
1905	Survival in young patients (less than 40 years) with follicular lymphoma: a population based study by the Scotland and Newcastle Lymphoma Group. 2004 , 45, 1149-57		6
1904	Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. <i>Blood</i> , 2004 , 103, 275-82	2.2	2955
1903	The spectrum of lymphoma with 8q24 aberrations: a clinical, pathological and cytogenetic study of 87 consecutive cases. 2004 , 45, 519-28		60
1902	Comprehensive whole genome array CGH profiling of mantle cell lymphoma model genomes. 2004 , 13, 1827-37		109
1901	Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. 2004 , 11, 368-76		41
1900	[Lymphoma classification: a collection for specialists or a medical progress?]. 2004 , 24, 125-8		
1899	Intra-oral small lymphocytic lymphoma. 2004 , 40, 73-73		
1898	Lymphomes non hodgkiniens T et NK périphériques. 2004 , 1, 135-149		1
1897	Pathology of primary cutaneous B-cell lymphomas: diagnosis and classification. 2004 , 5, 89-97		9
1896	Radiological features of non-gastric mucosa-associated lymphoid tissue lymphomas. 2004 , 33, 212-25		6
1895	Long-term efficacy of the CHVmP/BV regimen used for aggressive non-Hodgkin's lymphoma in three randomised EORTC trials. 2004 , 40, 474-80		6
1894	Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countries. 2004 , 33, 330-7		33
1893	Intra-oral small lymphocytic lymphoma. 2004 , 40, 73-78		
1892	Building an outcome predictor model for diffuse large B-cell lymphoma. 2004 , 164, 613-22		72

1891	BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. 2004 , 165, 159-66	232
1890	Cytogenetic alterations affecting BCL6 are predominantly found in follicular lymphomas grade 3B with a diffuse large B-cell component. 2004 , 165, 481-90	102
1889	Analysis of 1983 cases of malignant lymphoma in Thailand according to the World Health Organization classification. 2004 , 35, 224-30	47
1888	Extrahepatic disease manifestations of HCV infection: some current issues. 2004 , 40, 341-52	106
1887	Non-Hodgkin lymphoma: an update. 2004 , 5, 341-53	154
1886	A case of GI Burkitt-like lymphoma. 2004 , 60, 152-4	1
1885	Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma. 2004 , 11, 227-38	62
1884	Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. 2004 , 28, 736-47	340
1883	Small Lymphocytic Lymphoma. 2004 , 9, 214-220	
1882	Mantle cell lymphoma. 2004 , 11, 411-8	26
1881	Fine-Needle Aspiration Biopsy of Lymphoma of the Parotid Gland. 2004 , 9, 242-247	
1880	MRI Evaluation of Mucosa-Associated Lymphoid Tissue Lymphoma of the Lacrimal Glands. 2004 , 17, 549-554	
1879	Spontaneous regression of follicular, mantle cell, and diffuse large B-cell non-Hodgkin's lymphomas detected by FDG-PET imaging. 2004 , 29, 685-8	17
1878	Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. 2004 , 28, 464-70	214
1877	T-cell lymphoma in HIV-infected patients. 2004 , 36, 1020-7	35
1876	Rheumatoid arthritis and malignant lymphomas. 2004 , 16, 254-61	85
1875	Emerging prognostic factors in diffuse large B cell lymphoma. 2004 , 16, 436-41	34
1874	Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. <i>Blood</i> , 2004 , 103, 2474-9	2.2 460

1873	Elevated serum-soluble interleukin-2 receptor levels in patients with anaplastic large cell lymphoma. <i>Blood</i> , 2004 , 104, 3355-7	2.2	46
1872	Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions. <i>Blood</i> , 2004 , 104, 795-801	2.2	119
1871	Adult Burkitt leukemia and lymphoma. <i>Blood</i> , 2004 , 104, 3009-20	2.2	406
1870	The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2004 , 104, 3064-71	2.2	500
1869	[Molecular pathophysiology of MALT lymphoma and strategy for therapy]. 2004 , 93, 397-403		
1868	Pediatric follicular lymphomas, marginal zone lymphomas, and marginal zone hyperplasia. 2004 , 122 Suppl, S98-109		20
1867	Primary mediastinal large B-cell lymphoma in an HIV-infected patient. 2005 , 329, 136-8		3
1866	Flow Cytometry in the Biomedical Arena. 2005 , 531-553		
1865	Diagnostic pathology of lymphoproliferative disorders. 2005 , 37, 434-56		8
1864	Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review. 2005 , 29, 935-41		38
1863	Lymphoplasmacytic lymphoma/waldenstrom macroglobulinemia: an evolving concept. 2005 , 12, 246-55		79
1862	Presence of preserved reactive germinal centers in follicular lymphoma is a strong histopathologic indicator of limited disease stage. 2005 , 29, 1661-4		37
1861	Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique. 2005 , 13, 323-32		19
1860	Diagnosis of lymphoma by image-guided needle biopsies: fine needle aspiration biopsy, core biopsy or both?. 2005 , 49, 51-7		58
1859	Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. <i>Blood</i> , 2005 , 105, 301-7	2.2	183
1858	Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. <i>Blood</i> , 2005 , 105, 2916-23	2.2	75
1857	Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization. <i>Blood</i> , 2005 , 105, 1686-93	2.2	62
1856	CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. <i>Blood</i> , 2005 , 105, 1417-23	2.2	812

1855	Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. <i>Blood</i> , 2005 , 106, 1164-74	2.2	166
1854	Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). <i>Blood</i> , 2005 , 106, 2169-74	2.2	386
1853	Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia derives from an extensively hypermutated B cell that lacks ongoing somatic hypermutation. 2005 , 29, 729-34		25
1852	Follicular lymphoma: time for a re-think?. 2005 , 19, 165-78		32
1851	Mantle cell lymphoma presenting with paraproteinemia. 2005 , 22, 319-23		6
1850	CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. 2005 , 81, 58-61		4
1849	Complete and durable remission of refractory mantle cell lymphoma with repeated rituximab monotherapy. 2005 , 81, 319-22		2
1848	Mycosis fungoides associated with intestinal mucosa-associated lymphoid tissue lymphoma. 2005 , 44, 878-80		4
1847	CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses. 2005 , 46, 328-33		28
1846	Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. 2005 , 47, 281-91		24
1845	Follicular lymphoma subgrouping by fluorescence in situ hybridization analysis. 2005 , 96, 77-82		32
1844	The International Prognostic Index determines the outcome of patients with nodal mature T-cell lymphomas. 2005 , 129, 366-72		64
1843	Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. 2005 , 130, 516-26		128
1842	Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkitt-like and lymphoblastic lymphoma. 2005 , 19, 945-52		50
1841	Low-grade follicular lymphoma with t(14;18) presents a homogeneous disease entity otherwise the rest comprises minor groups of heterogeneous disease entities with Bcl2 amplification, Bcl6 translocation or other gene aberrances. 2005 , 19, 1058-63		79
1840	A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. 2005 , 19, 1459-65		51
1839	Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. 2005 , 18, 1377-84		106
1838	Epigenetic immunomodulation of hematopoietic malignancies. 2005 , 32, 503-10		17

1837	Microarray-based classification of diffuse large B-cell lymphoma. 2005 , 74, 453-65	38
1836	Clinicopathological analysis of T-cell lymphoma in Taiwan according to WHO classification: high incidence of enteropathy-type intestinal T-cell lymphoma. 2005 , 75, 221-6	12
1835	Staging non-Hodgkin lymphoma. 2005 , 55, 368-76	175
1834	Expression of survivin and of antigen detected by a novel monoclonal antibody, T332, is associated with outcome of diffuse large B-cell lymphoma and its subtypes. 2005 , 55, 324-30	32
1833	Aggressive Lennert's lymphoma: report of three cases in comparison to non-aggressive Lennert's lymphoma. 2005 , 55, 626-31	8
1832	Amplification of IGH/MYC fusion in clinically aggressive IGH/BCL2-positive germinal center B-cell lymphomas. 2005 , 43, 414-23	33
1831	Liver transplantation for HCV-related cirrhosis in a patient with gastric mucosa-associated lymphoma (MALToma) pretreated with rituximab. 2005 , 11, 839-842	9
1830	Long-term results of dose density therapy in patients with aggressive lymphoma. 2005 , 84, 217-22	5
1829	Molecular epidemiology of follicular lymphoma in Chinese: relationship with bcl-2/IgH translocation and bcl-6 397G/C polymorphism. 2005 , 84, 506-9	3
1828	Analysis of local control in patients with non-Hodgkin's lymphoma according to the WHO classification. 2005 , 181, 385-91	7
1827	Anti-apoptotic action of API2-MALT1 fusion protein involved in t(11;18)(q21;q21) MALT lymphoma. 2005 , 10, 25-34	27
1826	Immunohistochemistry in bone marrow pathology: a useful adjunct for morphologic diagnosis. 2005 , 447, 920-37	45
1825	Follicular lymphoma: management options in the era of targeted therapy. 2005 , 6, 297-308	5
1824	Primary colon lymphoma in Korea: a KASID (Korean Association for the Study of Intestinal Diseases) Study. 2005 , 50, 2243-7	52
1823	Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation. 2005 , 205, 329-35	82
1822	A case of multiple mucosa-associated lymphoid tissue (MALT) lymphoma of the colon identified as simple mucosal discoloration. 2005 , 20, 325-8	17
1821	Cytogenetics of Hematologic Neoplasms. 2005 , 365-420	1
1820	Lymph Nodes. 2005 ,	

1819	Leukemia and Lymphoma of Natural Killer Cells. 2005 , 45, 51-70		19
1818	Prognostic Significance of Biomarkers of Diffuse Large B-cell Lymphomas. 2005 , 40, 15		
1817	Angioimmunoblastic T-cell Lymphoma: Clinical Characteristics and Treatment Outcomes. 2005 , 40, 8		1
1816	Patient-specific vaccine therapy for non-Hodgkin lymphoma. 2005 , 9, 85-90		4
1815	Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. 2005 , 16, 206-14		170
1814	Physical activity, obesity, energy intake, and the risk of non-Hodgkin's lymphoma: a population-based case-control study. 2005 , 162, 1162-73		67
1813	The role of mitoxantrone in the treatment of indolent lymphomas. 2005 , 10, 150-9		45
1812	A 61-year-old man with dyspepsia and weight loss. 2005 , 2, e154		
1811	Case records of the Massachusetts General Hospital. Case 29-2005. A 68-year-old man with periorbital swelling, rash, and weakness. 2005 , 353, 1275-84		5
1810	Body mass index and risk of malignant lymphoma in Scandinavian men and women. 2005 , 97, 210-8		58
1809	In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. 2005 , 16, 1169-76		56
1808	Best Practice No 185. Cytological and molecular diagnosis of lymphoma. 2005 , 58, 561-7		27
1807	Proteomic Profiling of Mature CD10+ B-Cell Lymphomas. 2005 , 124, 920-929		11
1806	Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. 2005 , 23, 2797-804		205
1805	Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. <i>Blood</i> , 2005 , 106, 3725-32	2.2	1084
1804	Use of fine needle aspirates and flow cytometry for the diagnosis, classification, and immunophenotyping of canine lymphomas. 2005 , 17, 323-30		36
1803	Germinal Center and Activated B-Cell Profiles Separate Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma in AIDS and Non-AIDS Cases. 2005 , 124, 790-798		26
1802	Another Piece of the MALT Lymphomas Jigsaw. 2005 , 23, 4832-4		6

1801	Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. 2005 , 23, 3940-7		110
1800	Can patients with early-stage diffuse large B-cell lymphoma be treated without bone marrow biopsy?. 2005 , 16, 215-8		20
1799	Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2005. A 35-year-old woman with difficulty walking, headache, and nausea. 2005 , 352, 185-94		8
1798	Defining the stages of aggressive non-Hodgkin's lymphoma--a work in progress. 2005 , 352, 1250-2		7
1797	Effective treatment of a peripheral T-cell lymphoma/lymphoepitheloid cell variant (Lennert's lymphoma) refractory to chemotherapy with the CD-52 antibody alemtuzumab. 2005 , 46, 771-4		6
1796	[Minimal residual disease in follicular and mantle cell lymphoma. Detection using quantitative molecular monitoring of circulating lymphoma cells]. 2005 , 130, 2130-4		
1795	A review of tositumomab and I(131) tositumomab radioimmunotherapy for the treatment of follicular lymphoma. 2005 , 5, 577-88		13
1794	The Principles of Clinical Cytogenetics. 2005 ,		25
1793	Expression of Polo-Like Kinase (PLK1) in non-Hodgkin's lymphomas. 2005 , 46, 225-31		39
1792	Primary lymphoblastic B-cell lymphoma of the cranial dura mater: a case report and review of the literature. 2005 , 46, 1651-7		13
1791	Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. <i>Blood</i> , 2005 , 106, 668-72	2.2	89
1790	Improved survival of follicular lymphoma patients in the United States. 2005 , 23, 5019-26		230
1789	WHO non-Hodgkin's lymphoma classification by criterion-based report review followed by targeted pathology review: an effective strategy for epidemiology studies. 2005 , 14, 2213-9		18
1788	Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 cases. 2005 , 113, 97-103		27
1787	Follicular colonization of nodal marginal-zone B-cell lymphoma resembling follicular lymphoma: report of 6 cases. 2005 , 13, 73-8		9
1786	Proteomic analysis of apoptotic pathways reveals prognostic factors in follicular lymphoma. 2005 , 11, 5847-55		99
1785	Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. 2005 , 23, 6370-8		137
1784	Mantle cell lymphoma: at last, some hope for successful innovative treatment strategies. 2005 , 23, 657-8		21

1783	Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. 2005 , 97, 1345-53	153
1782	Dietary factors and risk of non-hodgkin lymphoma in men and women. 2005 , 14, 512-20	82
1781	Natural killer T-cell lymphoma of the tongue. 2005 , 114, 55-7	6
1780	Treatment strategies in follicular lymphomas: current status and future perspectives. 2005 , 23, 6394-9	72
1779	Inhibition of caspase 9 and not caspase 8 mediated apoptosis may determine clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. 2005 , 4, 526-8	8
1778	Effective treatment of indolent non-hodgkin's lymphomas with mitoxantrone, chlorambucil and prednisone. 2005 , 28, 73-8	4
1777	Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma. 2005 , 69, 499-502	9
1776	Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). 2005 , 14, 925-33	156
1775	Aggressive peripheral T-cell lymphomas (specified and unspecified types). 2005 , 2005, 267-77	40
1774	Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas. 2005 , 2005, 299-306	3
1773	Analysis of the Bcl-2 and p53 protein expression in the lymphoproliferative lesions in the upper Egypt. 2005 , 4, 324-8	12
1772	High proportion of T-cell systemic non-Hodgkin lymphoma in HIV-infected patients in Lima, Peru. 2005 , 40, 558-64	9
1771	Alcohol consumption and risk of non-Hodgkin lymphoma: a pooled analysis. 2005 , 6, 469-76	120
1770	Staging and classification of lymphoma. 2005 , 35, 160-4	44
1769	Medical Biomethods Handbook. 2005 ,	2
1768	Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. <i>Blood</i> , 2005 , 106, 3183-90	2.2 304
1767	Synchronous mucosa-associated lymphoid tissue (MALT) lymphomas involving bilateral orbits and breasts: a rare clinical entity. 2005 , 46, 1247-50	3
1766	Monoclonal antibody therapy of leukaemias and lymphomas. 2005 , 5, 1225-43	8

1765	Routine application of the proton-pump inhibitor pantoprazole in patients with gastric lymphoma undergoing chemotherapy. 2005 , 40, 1222-5	5
1764	High-dose therapy and autologous stem cell transplantation in Korean patients with aggressive T/NK-cell lymphoma. 2005 , 46, 1599-1604	13
1763	Accumulation of miR-155 and BIC RNA in human B cell lymphomas. 2005 , 102, 3627-32	1180
1762	Characteristics of 40 primary extranodal non-Hodgkin lymphomas of the oral cavity in perspective of the new WHO classification and the International Prognostic Index. 2005 , 34, 391-5	89
1761	A "floral" variant of nodal marginal zone lymphoma. 2005 , 36, 202-6	13
1760	CD10 and BCL6 expression in the diagnosis of angioimmunoblastic T-cell lymphoma: utility of detecting CD10+ T cells by flow cytometry. 2005 , 36, 784-91	59
1759	Long-term follow-up after autologous hematopoietic stem cell transplantation for low-grade non-Hodgkin lymphoma. 2005 , 11, 129-35	21
1758	Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. 2005 , 11, 739-54	18
1757	API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation. 2005 , 334, 51-60	22
1756	Mantle cell lymphoma in the ocular adnexal region. 2005 , 112, 114-9	72
1755	Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: are they distinct or the same entity?. 2005 , 5, 220-4	42
1754	Adult Burkitt's lymphoma. 2005 , 6, 11-20	14
1753	Prognosis of follicular lymphomas. 2005 , 6, 21-5	3
1752	Late non-neoplastic events in patients with aggressive non-Hodgkin's lymphoma in four randomized European Organisation for Research and Treatment of Cancer trials. 2005 , 6, 122-30	44
1751	Modern histological classification of low grade B-cell lymphomas. 2005 , 18, 11-26	9
1750	Pathology and genetics of primary central nervous system and intraocular lymphoma. 2005 , 19, 705-17, vii	32
1749	State-of-the-art therapeutics: marginal-zone lymphoma. 2005 , 23, 6415-20	92
1748	Histopathology Reporting. 2006 ,	

1747	A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling. 2006 , 354, 2419-30	776
1746	Burkitt's lymphoma--the message from microarrays. 2006 , 354, 2495-8	41
1745	Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis. 2006 , 47, 1885-93	44
1744	The role of anthracyclines in follicular lymphomas. 2006 , 47, 2267-8	
1743	Standardization in immunohistochemistry: the role of antigen retrieval in molecular morphology. 2006 , 81, 3-12	47
1742	Purine analogue combinations for indolent lymphomas. 2006 , 43, S11-21	5
1741	Purine analogues in advanced T-cell lymphoid malignancies. 2006 , 43, S27-34	12
1740	Precursor T-Cell Lymphoblastic Lymphoma. 2006 , 456-463	
1739	Burkitt's lymphoma presenting as a rapidly growing thyroid mass. 2006 , 16, 1053-7	16
1738	Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. 2006 , 79, 179-84	27
1737	A 65-year-old woman with intractable nasal congestion. 2006 , 96, 281-5	1
1736	Canine indolent nodular lymphoma. 2006 , 43, 241-56	164
1735	A clinicopathologic and molecular study of follicular lymphoma in Taiwan. 2006 , 6, 314-8	6
1734	The role of high-dose therapy in peripheral T-cell lymphomas. 2006 , 6, 373-9	5
1733	Therapeutic lymphoma vaccines: importance of T-cell immunity. 2006 , 5, 381-94	16
1732	[A 61-year-old woman with rapid increase of volume in upper right limb, pain and functional limitation]. 2006 , 206, 109-10	
1731	Pathology of B-cell non-Hodgkin's lymphomas and multiple myeloma. 2006 , 131, 1-48	1
1730	"In situ-like" mantle cell lymphoma: a report of two cases. 2006 , 59, 995-6	47

1729	Primary CNS lymphoma. 2006 , 24, 1281-8		273
1728	Primary skeletal muscle marginal zone lymphoma with persistent tissue tropism and PET-avidity. 2006 , 47, 117-20		14
1727	Self-reported hepatitis and non-Hodgkin lymphoma: an analysis according to the time since hepatitis diagnosis. 2006 , 16, 400-5		3
1726	Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. 2006 , 21, 397-405		27
1725	Primary systemic anaplastic large cell lymphoma in a single Korean institution: clinical characteristics and treatment outcome. 2006 , 21, 633-8		5
1724	Marginal Zone B-Cell Lymphomas. 2006 , 381-396		2
1723	Classification and Histopathology of the Lymphomas. 2006 , 2-38		4
1722	Molecular Monitoring of Lymphoma. 2006 , 83-109		
1721	T-cell non-Hodgkin lymphoma. <i>Blood</i> , 2006 , 107, 1255-64	2.2	178
1720	Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. <i>Blood</i> , 2006 , 108, 1668-76	2.2	221
1719	Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. <i>Blood</i> , 2006 , 108, 4178-86	2.2	214
1718	Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: A Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. <i>Blood</i> , 2006 , 108, 4163-9	2.2	103
1717	Molecular cytogenetic evidence of t(14;18)(IGH;BCL2) in a substantial proportion of primary cutaneous follicle center lymphomas. 2006 , 30, 529-36		70
1716	Lymphomes non hodgkiniens T et NK périphériques. 2006 , 1, 1-9		
1715	Contribution of immunohistochemistry to small B-cell lymphoma classification. 2006 , 14, 1-6		10
1714	Mature B-cell lymphoma in children and adolescents: International group pathologist consensus correlates with histology technical quality. 2006 , 28, 568-74		13
1713	Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. 2006 , 30, 1274-80		102
1712	Lymphoma of the female genital tract: current status. 2006 , 25, 1-21		97

1711	Marginal zone lymphoma. 2006 , 4, 311-8	22
1710	Malignancies of the Immune System: Use of Immunologic and Molecular Tumor Markers in Classification and Diagnostics. 2006 , 1152-1170	
1709	Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. 2006 , 208, 714-23	184
1708	Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. 2006 , 132, 303-16	152
1707	Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. 2006 , 133, 43-9	22
1706	Transformed diffuse large B-cell lymphomas with gains of the discontinuous 12q12-14 amplicon display concurrent deregulation of CDK2, CDK4 and GADD153 genes. 2006 , 133, 612-21	14
1705	Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma. 2006 , 134, 202-7	97
1704	Diagnosis of Burkitt lymphoma in due time: a practical approach. 2006 , 134, 294-301	34
1703	Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma. 2006 , 97, 499-504	33
1702	Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL). 2006 , 45, 766-9	37
1701	Quantification of immunohistochemistry--issues concerning methods, utility and semiquantitative assessment II. 2006 , 49, 411-24	383
1700	Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. 2006 , 19, 891-8	17
1699	Clinicopathologic implications of tissue inhibitor of metalloproteinase-1-positive diffuse large B-cell lymphoma. 2006 , 19, 963-73	8
1698	High throughput tissue microarray analysis of FHIT expression in diffuse large cell B-cell lymphoma from Saudi Arabia. 2006 , 19, 1124-9	5
1697	Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. 2006 , 25, 1560-70	116
1696	Treatment of mantle cell lymphoma: current approach and future directions. 2006 , 58, 257-65	22
1695	Current controversies in follicular lymphoma. 2006 , 20, 179-200	11
1694	Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. 2006 , 64, 928-34	109

1693	Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. 2006 , 83, 450-3	4
1692	Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. 2006 , 84, 248-55	19
1691	Predictive value of prognostic indices in patients with follicular lymphomas. 2006 , 23, 533-42	1
1690	Marginal zone lymphoma of both spleen and kidney displaying transformation into large B-cell lymphoma. 2006 , 38, 431-7	1
1689	Extranodal marginal zone B-cell lymphoma mimicking meningioma in lateral ventricle: a case report and possible pathogenesis. 2006 , 80, 63-7	21
1688	Helicobacter pylori-negative / API2-MALT1 translocation-negative low-grade MALT lymphoma. 2006 , 9, 229-34	3
1687	Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. 2006 , 85, 723-9	23
1686	Nodal marginal zone B-cell lymphoma: Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. 2006 , 85, 781-6	37
1685	Treatment of Burkitt lymphoma in children and adults: Lessons from Africa. 2006 , 1, 230-40	8
1684	Lymphoblastic lymphoma in adults. 2006 , 1, 241-7	5
1683	Gene arrays in lymphoma: Where will they fit in?. 2006 , 1, 129-36	3
1682	Clinical and molecular prognostic factors in follicular lymphoma. 2006 , 8, 359-67	2
1681	Findings of fluorine-18-FDG PET in extranodal origin lymphoma--in three cases of diffuse large B cell type lymphoma. 2006 , 20, 689-93	12
1680	The therapeutic use of rituximab in non-Hodgkin's lymphoma. 2006 , 78, 5-14	3
1679	Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. 2006 , 76, 42-50	74
1678	Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. 2006 , 76, 58-63	33
1677	Association of Epstein-Barr virus with human immunodeficiency virus-negative peripheral T-cell lymphomas in Japan. 2006 , 76, 109-18	17
1676	Mantle cell lymphoma in Taiwan: clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. 2006 , 56, 440-8	19

1675	Grading follicular lymphoma on fine-needle aspiration specimens--a practical approach. 2006 , 108, 1-9	25
1674	Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. 2006 , 107, 175-83	174
1673	Update on the molecular biology of mantle cell lymphoma. 2006 , 24, 22-7	77
1672	Prognosis of follicular lymphomas. 2006 , 24, 64-72	14
1671	Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B-cell lymphoma. 2006 , 24, 97-104	18
1670	Mantle cell lymphomas acquire increased expression of CCL4, CCL5 and 4-1BB-L implicated in cell survival. 2006 , 118, 2092-7	31
1669	Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. 2006 , 119, 971-9	46
1668	A case of primary intestinal Burkitt-like lymphoma: usefulness of sonographic diagnosis. 2006 , 34, 138-42	2
1667	Clinicopathological analysis of 598 malignant lymphomas in Taiwan: seven-year experience in a single institution. 2006 , 81, 568-75	38
1666	Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska Lymphoma Study Group Experience. 2006 , 17, 920-7	53
1665	Treatment of gastric mucosa-associated lymphoid tissue lymphoma: Helicobacter pylori eradication and beyond. 2006 , 6, 361-71	22
1664	Addition of a short course of chemotherapy did not improve outcome in patients with localized marginal B-cell lymphoma of the orbit. 2006 , 70, 173-6	21
1663	[Peripheral T-cell lymphoma: diagnosis and treatment]. 2006 , 131, 685-90	3
1662	Lymphomatous proptosis as a novel feature of mantle cell lymphoma. 2006 , 47, 71-5	10
1661	18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) visualizes follicular lymphoma irrespective of grading. 2006 , 17, 780-4	97
1660	Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. 2006 , 15, 630-8	74
1659	Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. 2006 , 24, 5350-7	192
1658	Striking male predominance of mantle cell lymphoma in Taiwan. 2006 , 59, 780	4

1657	Non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue. 2006 , 11, 1100-17	64
1656	Follicular lymphoma: today's treatments and tomorrow's targets. 2006 , 7, 1273-90	6
1655	Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. 2006 , 17, 1418-23	88
1654	Current treatment strategies in follicular lymphomas. 2006 , 17 Suppl 10, x155-9	2
1653	BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. 2006 , 24, 961-8	238
1652	Diagnosis of Deep-Seated Lymphoma and Leukemia by Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsy. 2006 , 125, 703-709	27
1651	Cigarette smoking and alcohol consumption as determinants of survival in non-Hodgkin's lymphoma: a population-based study. 2006 , 17, 1283-9	27
1650	Chronic paraneoplastic cutaneous syndrome preceding an indolent variant of mantle cell lymphoma: favorable response to rituximab. 2006 , 115, 113-6	3
1649	Hybrid cytogenetics of chronic lymphocytic leukemia and follicular cell lymphoma in a case of non-Hodgkin's lymphoma. 2006 , 116, 150-2	
1648	Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. 2006 , 24, 4867-74	600
1647	Prognostic biomarkers in diffuse large B-cell lymphoma. 2006 , 24, 995-1007	209
1646	Primary gastrointestinal tract lymphoma: diagnosis and management of common neoplasms. 2006 , 6, 1609-28	15
1645	99mTechnetium-SESTAMIBI uptake in malignant lymphomas. Correlation with chemotherapy response. 2006 , 4, 23-8	6
1644	Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. <i>Blood</i> , 2006 , 107, 265-76.2	1153
1643	Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. 2006 , 24, 3880-6	134
1642	Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. 2006 , 11, 285-91	51
1641	Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. 2007 , 60, 361-72	109
1640	Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. 2007 , 25, 1986-92	415

1639	Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. 2007 , 25, 390-8		193
1638	Nodal aggressive B-cell lymphomas: a diagnostic approach. 2007 , 60, 1076-85		5
1637	Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). <i>Blood</i> , 2007 , 110, 695-708	2.2	313
1636	BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma. 2007 , 28, 1740-4		40
1635	Distribution and clinicopathologic characteristics of non-Hodgkin's lymphoma in India: a study of 935 cases using WHO classification of lymphoid neoplasms (2000). 2007 , 48, 122-33		19
1634	Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 2007 , 48, 564-9		12
1633	F-18-fluoro-deoxy-glucose positron emission tomography in the assessment of peripheral T-cell lymphomas. 2007 , 48, 1531-8		39
1632	Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. 2007 , 25, 1216-22		148
1631	TREATMENT OF FOLLICULAR LYMPHOMA A REVIEW. 2007 , 62, 408-418		
1630	Chlorambucil - rituximab as first line combination therapy in follicular non-Hodgkin's lymphoma: a clinical and biological analysis. 2007 , 48, 437-8		2
1629	Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. 2007 , 48, 1482-95		10
1628	Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma. 2007 , 48, 1630-2		26
1627	Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. 2007 , 18, 535-40		50
1626	Hematopoietic stem cell transplantation in peripheral T-cell lymphomas. 2007 , 48, 1496-501		12
1625	Prevalence of HCV infection in nongastric marginal zone B-cell lymphoma of MALT. 2007 , 18, 346-50		95
1624	Dietary and weight changes after treatments for lymphoma. 2007 , 57, 168-76		2
1623	Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma. 2007 , 48, 1548-55		45
1622	Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell-like diffuse large B cell lymphoma. 2007 , 204, 633-43		160

1621	Anaplastic Large Cell Lymphoma. 2007 , 127, 707-22	155
1620	Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. 2007 , 18, 2020-4	23
1619	Peripheral blood natural killer cell count is associated with clinical outcome in patients with aalPI 2-3 diffuse large B-cell lymphoma. 2007 , 18, 1209-15	69
1618	Tumor sclerosis but not cell proliferation or malignancy grade is a prognostic marker in advanced-stage follicular lymphoma: the German Low Grade Lymphoma Study Group. 2007 , 25, 3330-6	47
1617	Influence of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone on serologic parameters and clinical course in lymphoma patients with autoimmune diseases. 2007 , 18, 647-51	14
1616	Blastic transformation of low-grade follicular lymphoma. 2007 , 25, 2326-8	6
1615	A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. 2007 , 18, 116-121	136
1614	T-cell non-Hodgkin's lymphoma: treatment outcomes and survival in 3 large UK centres. 2007 , 118, 123-5	1
1613	The cost-effectiveness of rituximab in non-Hodgkin's lymphoma. 2007 , 7, 319-26	4
1612	Classification systems for low back pain: a review of the methodology for development and validation. 2007 , 12, 33-42	36
1611	Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. 2007 , 13, 5124-32	347
1610	Primary cerebral ALK-1-positive anaplastic large cell lymphoma in a child. Case report and literature review. 2007 , 43, 516-21	36
1609	Indicators of lumbar zygapophyseal joint pain: survey of an expert panel with the Delphi technique. 2007 , 87, 1348-61	44
1608	Role of radiation therapy in the treatment of stage I/II mucosa-associated lymphoid tissue lymphoma. 2007 , 18, 672-8	30
1607	Rituximab maintenance therapy: a step forward in follicular lymphoma. 2007 , 92, 826-33	26
1606	The prognostic significance of the intra-follicular tumor cell proliferative rate in follicular lymphoma. 2007 , 92, 184-90	48
1605	Lymphoproliférations pulmonaires. 2007 , 2, 1-8	
1604	Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. 2007 , 14, 160-6	40

1603	T-Cell and NK-Cell Neoplasms. 275-365		11
1602	Hematologic manifestations of celiac disease. <i>Blood</i> , 2007 , 109, 412-21	2.2	230
1601	Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways. <i>Blood</i> , 2007 , 109, 5455-62	2.2	37
1600	Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. <i>Blood</i> , 2007 , 109, 331-8	2.2	117
1599	How I treat indolent lymphoma. <i>Blood</i> , 2007 , 109, 4617-26	2.2	78
1598	The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. <i>Blood</i> , 2007 , 109, 4952-63	2.2	445
1597	How I treat patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 29-36	2.2	112
1596	High-grade B-cell lymphoma/leukemia associated with t(14;18) and 8q24/MYC rearrangement: a neoplasm of germinal center immunophenotype with poor prognosis. 2007 , 92, 1297-301		77
1595	The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms. 2007 , 14, 151-9		5
1594	Oral-cutaneous CD4-positive T-cell lymphoma: a study of two patients. 2007 , 29, 62-7		12
1593	The critical role of histology in an era of genomics and proteomics: a commentary and reflection. 2007 , 14, 375-400		15
1592	Cutaneous involvement with Burkitt-like lymphoma. 2007 , 29, 184-6		5
1591	Natural history of follicular grade 3 non-Hodgkin's lymphoma. 2007 , 19, 433-7		17
1590	Primary follicular lymphoma of the testis and epididymis in adults. 2007 , 31, 1050-8		48
1589	Endobronchial Involvement of Mantle Cell Lymphoma. 2007 , 14, 196-197		
1588	New treatment concepts in diffuse large B-cell lymphomas (DLBL): chemotherapy and biological therapy. 2007 , 2, 149-62		4
1587	Inhibition of cyclin-dependent kinase-2 induces apoptosis in human diffuse large B-cell lymphomas. 2007 , 6, 2982-9		30
1586	The curability of follicular lymphoma. 2007 , 37, 31-5		7

1585	[A cytological, immunophenotypical and cytogenetical study of 136 consecutive cases of B-cell chronic lymphoid hemopathies]. 2007 , 55, 59-72		2
1584	[Genitourinary lymphomas]. 2007 , 41, 1-5		1
1583	T-cell/NK-cell lymphomas: a review. 2007 , 253, 1-13		11
1582	Historical Perspective on the Treatment Challenges of Low-Grade Non-Hodgkin's Lymphoma. 2007 , 44, S2-S6		1
1581	Microarray analysis of gene expression of cancer to guide the use of chemotherapeutics. 2007 , 46, 222-9		11
1580	A 68-year-old man with multiple colonic polyps discovered upon routine colonoscopy. 2007 , 4, 671-673		
1579	Primary mediastinal large B-cell lymphoma: a retrospective analysis of rituximab and CHOP chemotherapy. 2007 , 4, 673-677		1
1578	Flow Cytometry in Hematopathology. 2007 ,		1
1577	The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. <i>Blood</i> , 2007 , 110, 972-8	2.2	245
1576	Linfomas del aparato urogenital. 2007 , 39, 1-4		
1575	[Malt lung lymphoma]. 2007 , 63, 177-82		1
1574	Ileal polyposis caused by follicular lymphoma. 2007 , 5, e30		2
1573	Enfermedades linfoproliferativas pulmonares. 2007 , 11, 1-8		
1572	Fludarabine: a review of its use in non-Hodgkin's lymphoma. 2007 , 67, 1633-55		26
1571	Gene expression profiling in diffuse large B-cell lymphoma. 2007 , 48, 669-82		6
1570	Hodgkin's Disease and Lymphomas. 2007 , 322-346		
1569	MALT lymphoma : recent advances in aetiology and molecular genetics. 2007 , 47, 31-42		109
1568	Primary duodenal mucosa-associated lymphoid tissue (MALT) lymphoma--a rare presentation of gastric outlet obstruction. 2007 , 21, 393-5		7

1567	Primary hepatic follicular lymphoma : a case report and discussion of chemotherapy and favorable outcomes. 2007 , 47, 73-7	25
1566	Synchronous adenocarcinoma and mantle cell lymphoma of the stomach. 2007 , 48, 1061-5	2
1565	Classification and treatment of rare and aggressive types of peripheral T-cell/natural killer-cell lymphomas of the skin. 2007 , 14, 112-23	15
1564	. 2007 ,	36
1563	Unusual lymphomas in the elderly. 311-341	
1562	Lymph Nodes. 2007 ,	
1561	Non-Hodgkin lymphoma. 290-310	
1560	Primary mediastinal B-cell lymphoma. 2007 , 25, 157-63	36
1559	Temporal trends in the incidence rate of childhood cancer in Germany 1987-2004. 2008 , 122, 1859-67	55
1558	"Virtual flow cytometry" of immunostained lymphocytes on microscopic tissue slides: IHCFlow tissue cytometry. 2007 , 72, 63-76	10
1557	Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. 2007 , 109, 2077-82	46
1556	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. 2007 , 110, 121-8	39
1555	Cytomorphologic examination of anaplastic large cell lymphoma by fine-needle aspiration cytology. 2007 , 111, 499-507	35
1554	Peripheral T-cell lymphomas. 2007 , 21, 201-16	72
1553	The transcription factor nuclear factor-kappa B and cancer. 2007 , 19, 154-61	169
1552	Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I(131) tositumomab. 2007 , 26, 3614-28	74
1551	Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. 2007 , 40, 239-43	46
1550	The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study. 2007 , 40, 443-50	82

1549	Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. 2007 , 40, 973-8	20
1548	Powerful strategy for polymerase chain reaction-based clonality assessment in T-cell malignancies Report of the BIOMED-2 Concerted Action BHM4 CT98-3936. 2007 , 21, 215-21	195
1547	MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. 2007 , 21, 1812-8	71
1546	Cytogenetic abnormalities in MALT lymphomas and their precursor lesions from different organs. A fluorescence in situ hybridization (FISH) study. 2007 , 50, 217-24	17
1545	Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. 2007 , 51, 70-9	33
1544	Current management of follicular lymphomas. 2007 , 136, 191-202	23
1543	Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. 2007 , 137, 117-24	41
1542	Clinical outcome of low-grade NHL patients with bone marrow involvement. 2007 , 37, 305-9	8
1541	Clinical implications of nodal marginal zone B-cell lymphoma among Japanese: study of 65 cases. 2007 , 98, 44-9	32
1540	Diagnostic and prognostic significance of gene expression profiling in lymphomas. 2007 , 115, 1135-46	21
1539	Mucosa-associated lymphoid tissue lymphoma: molecular pathogenesis and clinicopathological significance. 2007 , 57, 474-84	53
1538	A novel t(3;8)(q27;q24.1) simultaneously involving both the BCL6 and MYC genes in a diffuse large B-cell lymphoma. 2007 , 172, 45-53	17
1537	The therapeutic use of rituximab in non-Hodgkin's lymphoma. 2007 , 77, 5-14	68
1536	Comparative analysis of extra-nodal NK/T-cell lymphoma and peripheral T-cell lymphoma: significant differences in clinical characteristics and prognosis. 2008 , 80, 55-60	49
1535	Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. 2008 , 80, 133-42	92
1534	Retrospective study of 82 cases of canine lymphoma in Austria based on the Working Formulation and immunophenotyping. 2007 , 136, 186-92	30
1533	The role of bortezomib in the treatment of lymphoma. 2007 , 25, 766-75	27
1532	Absence of chlamydial infection in Japanese patients with ocular adnexal lymphoma of mucosa-associated lymphoid tissue. 2007 , 85, 223-30	32

1531	Clinicopathologic significance of loss of CD19 expression in diffuse large B-cell lymphoma. 2007 , 85, 41-8	8
1530	Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. 2007 , 85, 212-8	13
1529	High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival. 2007 , 86, 435-42	40
1528	Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. 2007 , 86, 557-64	21
1527	Genetic polymorphisms of methylenetetrahydrofolate reductase and promoter methylation of MGMT and FHIT genes in diffuse large B cell lymphoma risk in Middle East. 2007 , 86, 887-95	19
1526	[Follicular and mantle cell lymphoma. Extranodal involvement of primarily nodal indolent B-cell lymphomas]. 2007 , 28, 21-8	4
1525	[Mediastinal large B-cell lymphoma]. 2007 , 28, 36-40	1
1524	[Burkitt's and Burkitt-like lymphoma. Molecular definition and value of the World Health Organisation's diagnostic criteria]. 2007 , 28, 41-5	5
1523	[Extranodal marginal zone B-cell lymphoma of MALT-type]. 2007 , 28, 6-14	1
1522	Follicular lymphoma with extensive gastrointestinal tract involvement: follow-up by capsule endoscopy. 2007 , 52, 1031-5	7
1521	Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. 2007 , 15, 877-84	25
1520	Crystal-storing histiocytosis associated with MALT lymphoma of the ocular adnexa: a case report with review of literature. 2007 , 450, 103-8	25
1519	Presentation of two cases of nasal type NK/T-cell lymphoma. 2007 , 264, 39-43	7
1518	Usefulness of FDG PET for diagnosis and radiotherapy of the patient with malignant lymphoma involving bone marrow. 2007 , 25, 130-4	1
1517	Helicobacter pylori infection and gastric cancer. 2007 , 21, 281-97	76
1516	Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. 2008 , 19, 841-58	76
1515	Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1). 2008 , 57, 1225-39	19
1514	[Malignant lymphoma of the prostate--diagnosis on the second biopsy]. 2008 , 103, 245-8	1

1513	Genomic deletion and promoter methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. 2008 , 1, 85-95	4
1512	Clinicopathologic conference: case 2. 2008 , 2, 279-82	2
1511	Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?. 2008 , 22, 23-30	17
1510	Primary mantle-cell non-Hodgkin's lymphoma of the tongue. 2008 , 88, 206-208	16
1509	Unexpected finding of laparoscopic appendectomy: appendix MALT lymphoma in children. 2008 , 24, 471-3	7
1508	Unique morphological spectrum of lymphomas in Nijmegen breakage syndrome (NBS) patients with high frequency of consecutive lymphoma formation. 2008 , 216, 337-44	36
1507	S-phase kinase protein 2 is an attractive therapeutic target in a subset of diffuse large B-cell lymphoma. 2008 , 216, 483-94	19
1506	Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. 2008 , 113, 367-75	17
1505	Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. 2008 , 113, 508-14	193
1504	Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. 2008 , 113, 791-8	193
1503	Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. 2008 , 113, 2714-23	95
1502	Peripheral T-cell lymphomas, unspecified (or not otherwise specified): a review. 2008 , 26, 8-20	53
1501	Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas. 2008 , 26, 152-8	29
1500	Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. 2008 , 122, 144-54	140
1499	The role of viral and bacterial pathogens in gastrointestinal cancer. 2008 , 216, 378-88	32
1498	The correlation between cellular size and protein expression levels--normalization for global protein profiling. 2008 , 71, 448-60	16
1497	TARC and IL-5 expression correlates with tissue eosinophilia in peripheral T-cell lymphomas. 2008 , 32, 1431-8	27
1496	CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report. 2008 , 204, 779-83	9

1495	MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma. 2008 , 72, 1154-60	34
1494	Extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue of the gallbladder. 2008 , 12, 137-141	0
1493	Hematopoietic SCT for peripheral T-cell lymphoma. 2008 , 42, 773-81	20
1492	Time of relapse after initial therapy significantly adds to the prognostic value of the IPI-R in patients with relapsed DLBCL undergoing autologous stem cell transplantation. 2008 , 41, 715-20	20
1491	NOD/SCID mouse model of canine T-cell lymphoma with humoral hypercalcaemia of malignancy: cytokine gene expression profiling and in vivo bioluminescent imaging. 2008 , 6, 39-54	13
1490	Diffuse large B-cell lymphoma after transformation from low-grade follicular lymphoma: morphological, immunohistochemical, and FISH analyses. 2008 , 99, 1760-8	35
1489	Recent advances in the understanding and management of diffuse large B-cell lymphoma in children. 2008 , 142, 329-47	69
1488	Cytogenetic abnormalities and clinical correlations in peripheral T-cell lymphoma. 2008 , 141, 461-9	87
1487	Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. 2008 , 142, 538-50	37
1486	Germinal center B (GCB) and non-GCB cell-like diffuse large B cell lymphomas have similar outcomes following autologous haematopoietic stem cell transplantation. 2008 , 142, 404-12	25
1485	MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. 2008 , 142, 732-44	146
1484	Integrated genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. 2008 , 143, 210-21	24
1483	Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma. 2008 , 143, 268-73	19
1482	Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. 2008 , 143, 395-403	87
1481	Nodal marginal zone B-cell lymphoma with prominent follicular colonization - difficulties in diagnosis: a study of 15 cases. 2008 , 52, 331-9	47
1480	Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas. 2008 , 52, 578-84	4
1479	MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type. 2008 , 53, 205-17	97
1478	Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001-2006. 2008 , 58, 174-82	108

1477	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the extracranial head and neck region: a high rate of dissemination and disease recurrence. 2008 , 44, 949-55	25
1476	[Mesenteric panniculitis, first clinical manifestation of a disseminated B cell lymphoma]. 2008 , 208, 109-10	2
1475	Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. 2008 , 7, 40	50
1474	Recent prognostic factors in diffuse large B-cell lymphoma indicate NF-kappaB pathway as a target for new therapeutic strategies. 2008 , 49, 2048-58	23
1473	Mucosa-associated lymphoid tissue lymphoma in Sjögren's syndrome: risks, management, and prognosis. 2008 , 34, 921-33, viii	58
1472	Highly aggressive lymphomas in adults. 2008 , 22, 965-78, ix	12
1471	Clinicopathologic significance of immunophenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. 2008 , 39, 875-84	19
1470	Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. 2008 , 39, 885-94	17
1469	Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?. 2008 , 39, 1331-40	11
1468	Oral non-Hodgkin's lymphoma: review of the literature and World Health Organization classification with reference to 40 cases. 2008 , 105, 194-201	123
1467	Modern techniques for the diagnostic evaluation of the trephine bone marrow biopsy: methodological aspects and applications. 2008 , 42, 203-52	30
1466	Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. 2008 , 44, 579-87	29
1465	Diffuse large B cell lymphoma: from gene expression profiling to prediction of outcome. 2008 , 14, 108-11	10
1464	Mantle cell lymphoma: an overview of diagnostic and therapeutic advances. 2008 , 5, 465-472	1
1463	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. 2008 , 319, 1676-9	660
1462	Classification of non-Hodgkin's lymphoma. 2008 , 22, 781-805, vii	12
1461	Indolent lymphomas other than follicular and marginal zone lymphomas. 2008 , 22, 903-40, viii	5
1460	Marginal zone lymphomas. 2008 , 22, 883-901, viii	40

1459	Peripheral T-cell non-Hodgkin's lymphoma. 2008 , 22, 997-1005, x		40
1458	Overview of lymphoma diagnosis and management. 2008 , 46, 175-98, vii		69
1457	Follicular lymphoma: clinical features and treatment. 2008 , 22, 863-82, viii		32
1456	Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. 2008 , 105, 13520-5		746
1455	Texture classification using nonlinear color quantization: Application to histopathological image analysis. 2008 ,		20
1454	A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). <i>Blood</i> , 2008 , 112, 2248-60	2.2	165
1453	Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. <i>Blood</i> , 2008 , 112, 4384-99	2.2	283
1452	Oncologic, endocrine & metabolic emerging drugs in B-cell non-Hodgkin's lymphoma. 2008 , 13, 323-43		1
1451	Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States. 2008 , 49, 2099-107		120
1450	Treatment of follicular lymphoma: current status. 2008 , 49 Suppl 1, 7-17		11
1449	Non-gastric extra-nodal marginal zone lymphomas--a single centre experience on 76 patients. 2008 , 49, 2308-15		26
1448	What is the real risk of central nervous system involvement in mantle cell lymphoma?. 2008 , 49, 2237-9		7
1447	Clonal evolution in t(14;18)-positive follicular lymphoma, evidence for multiple common pathways, and frequent parallel clonal evolution. 2008 , 14, 7180-7		43
1446	T-cell lymphoma: one name with a dozen faces. 2008 , 49, 2033-4		
1445	Burkitt lymphoma versus diffuse large B-cell lymphoma. 2008 , 19 Suppl 4, iv67-9		22
1444	Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population. 2008 , 49, 122-9		32
1443	Correlation of cyclin D1 transcript levels, transcript type and protein expression with proliferation and histology among mantle cell lymphoma. 2008 , 61, 920-7		20
1442	CD40 ligand protects from TRAIL-induced apoptosis in follicular lymphomas through NF-kappaB activation and up-regulation of c-FLIP and Bcl-xL. 2008 , 181, 1001-11		67

1441 Correction. **2008**, 61, 880-880

1440 Low-grade mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of 97 patients by the Hellenic Cooperative Oncology Group (HeCOG). **2008**, 19, 780-6 28

1439 Follicular lymphoma of the duodenum: a clinicopathologic analysis of 26 cases. **2008**, 38, 547-52 23

1438 Predicting outcome in follicular lymphoma by using interactive gene pairs. **2008**, 14, 478-87 5

1437 Computerized microscopic image analysis of follicular lymphoma. **2008**, 12

1436 Extranodal lymphoma: a comparative study. **2008**, 13, 163-9 19

1435 The outcome of haemopoietic stem cell transplantation in the treatment of lymphoplasmacytic lymphoma in the UK: a British Society Bone Marrow Transplantation study. **2008**, 13, 119-27 21

1434 Distinct gene expression profiles: nodal versus extranodal diffuse large B-cell lymphoma. **2008**, 75, 71-80 17

1433 Receptor-directed therapy of T-cell leukemias and lymphomas. **2008**, 5, 235-48 17

1432 Primary mediastinal B-cell lymphoma. **2008**, 349-58 57

1431 A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. **2008**, 59, 237-50 149

1430 Marginal zone lymphomas: management of nodal, splenic, and MALT NHL. **2008**, 359-64 34

1429 International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. **2008**, 26, 4124-30 1396

1428 A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. **2008**, 14, 2154-60 24

1427 Update on T-cell lymphoma. **2008**, 19 Suppl 4, iv74-6 10

1426 Cancer waiting times: what is the value of a lymphoma waiting time?. **2008**, 53, 5-7 1

1425 A unique case of adolescent CD56-negative extranodal NK/T-cell lymphoma, nasal type. **2008**, 11, 50-4 11

1424 Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. **2008**, 26, 211-7 172

1423	Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. 2008 , 19, 958-63		160
1422	Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem-cell transplantation. 2008 , 19, 1935-40		61
1421	[Malignant lymphoma in adults]. 2008 , 133, 2109-14		0
1420	Therapeutic options in mantle cell lymphoma. 2008 , 49, 398-409		22
1419	Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. 2008 , 49, 81-7		61
1418	A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. 2008 , 19, 247-53		84
1417	Cervical lymphadenopathy resulting in a diagnosis of lymphoma. 2008 , 53, 13-6		10
1416	Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas. 2008 , 93, 1033-8		59
1415	A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. <i>Blood</i> , 2008 , 111, 558-65	2.2	676
1414	Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. 2008 , 26, 5107-12		66
1413	Lymphomes de l'appareil urogénital. 2008 , 1, 1-4		
1412	Prognostic factors in follicular lymphoma: a single institution study. 2008 , 20, 185-93		3
1411	Leukemia and Lymphoma Immunophenotyping and Cytogenetics. 2008 , 221-256		
1410	Functionally associated targets in mantle cell lymphoma as defined by DNA microarrays and RNA interference. <i>Blood</i> , 2008 , 111, 1617-24	2.2	37
1409	Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. <i>Blood</i> , 2008 , 111, 369-75	2.2	34
1408	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008 , 111, 4463-70	2.2	237
1407	Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. <i>Blood</i> , 2008 , 112, 3088-98	2.2	138
1406	15. Treatment of Malignant Lymphoma. 2008 , 97, 2315-2320		

1405	A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study BR.21. 2008 , 3, 590-8	44
1404	Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma. 2008 , 93, 688-96	32
1403	T- Lymphoblastic lymphoma in adults. 2008 , 30,	
1402	Role of peroxisome proliferator-activated receptor gamma and its ligands in the treatment of hematological malignancies. 2008 , 2008, 834612	19
1401	Lymphoid Malignancies of Non-precursor Cells: General Considerations. 2008 , 287-296	
1400	A Case of a Synchronous Peripheral T-cell Lymphoma in a Patient with Systemic Lupus Erythematosus. 2009 , 44, 273	
1399	A Case Report of Helicobacter Pylori Negative Gastric MALT Lymphoma with Monoclonal Gammopathy. 2009 , 44, 261	1
1398	[Prognostic factors in Hodgkin and non-Hodgkin lymphomas]. 2009 , 96, 461-73	1
1397	Novel ORC4L gene mutation in B-cell lymphoproliferative disorders. 2009 , 338, 527-9	14
1396	Lack of prognostic value of MMP-9 expression and immunohistochemically defined germinal center phenotype in patients with diffuse large B-cell lymphoma treated with modern chemotherapy with or without CD20 antibody. 2009 , 50, 1301-7	8
1395	Risk of non-Hodgkin lymphoma associated with germline variation in genes that regulate the cell cycle, apoptosis, and lymphocyte development. 2009 , 18, 1259-70	52
1394	Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. 2009 , 27, 5039-48	73
1393	Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. 2009 , 27, 3044-51	30
1392	EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies. 2009 , 15, 2514-22	48
1391	Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. 2009 , 27, 5404-9	232
1390	Lymphoma immunotherapy: vaccines, adoptive cell transfer and immunotransplant. 2009 , 1, 809-24	9
1389	Frontline autologous stem cell transplantation for peripheral T-cell lymphoma. 2009 , 2, 255-60	
1388	Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. 2009 , 27, 5023-30	83

1387	Quantitative PCR analysis for Bcl-2/IgH in a phase III study of Yttrium-90 Ibritumomab Tiuxetan as consolidation of first remission in patients with follicular lymphoma. 2009 , 27, 6094-100	37
1386	Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma. 2009 , 1, 31-40	29
1385	Immunophenotyping of diffuse large B-cell lymphoma (DLBCL) defines multiple sub-groups of germinal centre-like tumours displaying different survival characteristics. 2009 , 35, 961-71	11
1384	Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma. 2009 , 14, 84-9	19
1383	S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German society for digestive and metabolic diseases (DGVS) in cooperation with the German society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e. V., German society for rheumatology, AWMF-registration-no. 021 / 001. 2009 , 47, 1230-63	48
1382	[S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease"]. 2009 , 47, 68-102	56
1381	Optimal application of antibodies in the treatment of follicular lymphoma: current standards and future strategies. 2009 , 1, 1015-24	1
1380	B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP. 2009 , 40, 79-86	
1379	Characterization of follicular lymphoma in the small intestine using double-balloon endoscopy. 2009 , 2009, 835258	12
1378	Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence. 2009 , 14 Suppl 2, 17-29	32
1377	Genetic polymorphisms in nitric oxide synthase genes modify the relationship between vegetable and fruit intake and risk of non-Hodgkin lymphoma. 2009 , 18, 1429-38	10
1376	Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. 2009 , 27, 4365-70	107
1375	Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment. 2009 , 20, 1080-5	103
1374	Antibody-based therapy of leukaemia. 2009 , 11, e29	29
1373	Aggressive non-Hodgkin's lymphoma. 2009 , 37, 202-207	1
1372	Iterative Bayesian Model Averaging: a method for the application of survival analysis to high-dimensional microarray data. 2009 , 10, 72	35
1371	Prognostic implications of cytogenetic aberrations in diffuse large B-cell lymphomas. 1999 , 62, 184-90	19
1370	Nodal marginal zone lymphoma: current knowledge and future directions of an heterogeneous disease. 2009 , 83, 165-74	36

1369	Lymphoma in adolescents and young adults. 2009 , 36, 381-418	57
1368	Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival. 2010 , 85, 51-6	19
1367	Clinical and molecular features of mucosa-associated lymphoid tissue (MALT) lymphomas of salivary glands. 2009 , 31, 1181-7	13
1366	Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. 2009 , 115, 3728-37	29
1365	Diffuse large B-cell lymphoma: clinical characterization and prognosis of Waldeyer ring versus lymph node presentation. 2009 , 115, 4980-9	20
1364	Fine needle aspiration cytology of ALK1(-), CD30+ anaplastic large cell lymphoma post renal transplantation: a case report and literature review. 2010 , 38, 213-6	6
1363	Diffuse large B-cell lymphoma with a high number of epithelioid histiocytes (lymphoepithelioid B-cell lymphoma): a study of Osaka Lymphoma Study Group. 2009 , 455, 285-93	8
1362	Histopathological Image Analysis Using Model-Based Intermediate Representations and Color Texture: Follicular Lymphoma Grading. 2009 , 55, 169-183	137
1361	Correlating metabolic activity with cellular proliferation in follicular lymphomas. 2009 , 11, 296-302	26
1360	Pralatrexate, a new hope for aggressive T-cell lymphomas?. 2009 , 11, 215-20	7
1359	The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis. 2009 , 89, 326-331	7
1358	Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China. 2009 , 90, 303-310	14
1357	Prognostic factors in low-grade non-Hodgkin lymphomas. 2009 , 4, 202-10	11
1356	Frontline therapy in mantle cell lymphoma: the role of high-dose therapy and integration of new agents. 2009 , 4, 213-7	4
1355	Mantle cell lymphoma: are current therapies changing the course of disease?. 2009 , 11, 371-7	1
1354	Prognostic impact of C-REL expression in diffuse large B-cell lymphoma. 2009 , 2, 20-6	18
1353	Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report. 2009 , 88, 379-81	6
1352	Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. 2009 , 88, 351-8	22

1351	Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. 2009 , 145, 173-9	78
1350	Advances in the management and monitoring of extranodal NK/T-cell lymphoma, nasal type. 2009 , 147, 13-21	65
1349	Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of today's knowledge. 2009 , 23, 225-34	165
1348	Array-based DNA methylation profiling in follicular lymphoma. 2009 , 23, 1858-66	61
1347	t(11;18)(q21;q21) in extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in stomach: a study of 48 cases. 2009 , 22, 79-86	10
1346	Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma. 2009 , 44, 287-93	5
1345	Primary ALK-1-negative anaplastic large cell lymphoma of the brain: case report and review of the literature. 2009 , 29, 166-71	21
1344	Recent developments in the treatment of aggressive non-Hodgkin lymphoma. 2009 , 23, 11-23	22
1343	Gene expression profiling in lymphoma diagnosis and management. 2009 , 22, 191-210	27
1342	[Monoclonal gammopathy and primary colonic mantle cell lymphoma]. 2009 , 30, 279-81	2
1341	Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. 2009 , 27, 106-13	299
1340	An NMR Study of the Bortezomib Degradation under Clinical Use Conditions. 2009 , 2009, 704928	12
1339	Denileukin diftitox: a novel immunotoxin. 2009 , 9, 1445-51	76
1338	Peripheral T-cell lymphoma presenting as an ischemic stroke in a 23-year-old woman: a case report and review of the literature. 2009 , 3, 83	4
1337	Prognostic tools in follicular lymphomas. 2009 , 2, 549-62	10
1336	Clinical features and treatment outcomes of adult B- and T-lymphoblastic lymphoma: results of multicentre analysis in Korea. 2009 , 50, 1119-25	17
1335	Mantle cell lymphoma - does primary intensive immunochemotherapy improve overall survival for younger patients?. 2009 , 50, 1249-56	4
1334	Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide. 2009 , 50, 1283-9	5

1333	Favorable outcomes of radiotherapy for early-stage mucosa-associated lymphoid tissue lymphoma. 2009 , 90, 231-5			36
1332	Biology and treatment of follicular lymphoma. 2009 , 2, 533-47			10
1331	Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. 2009 , 27, 3822-9			538
1330	Bone marrow involvement by hodgkin and non-hodgkin lymphomas. 2009 , 23, 873-902			33
1329	Indolent lymphomas of mature B lymphocytes. 2009 , 23, 769-90			21
1328	The spectrum of peripheral T-cell lymphomas. 2009 , 16, 292-8			14
1327	Primary and secondary T-cell lymphomas of the breast: clinico-pathologic features of 11 cases. 2009 , 17, 301-6			49
1326	FDG positron emission tomography/computed tomography scan may identify mantle cell lymphoma patients with unusually favorable outcome. 2009 , 30, 770-8			40
1325	Lymphomes pulmonaires primitifs. 2009 , 6, 1-10			
1324	Gene expression profiling of pulmonary mucosa-associated lymphoid tissue lymphoma identifies new biologic insights with potential diagnostic and therapeutic applications. <i>Blood</i> , 2009 , 113, 635-45	2.2		43
1323	Prognostic subgroup distribution in diffuse large B-cell lymphoma of the upper aerodigestive tract. 2009 , 41, 133-9			6
1322	Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project. <i>Blood</i> , 2009 , 113, 3931-7	2.2		544
1321	Tumors of the Pharynx, Tongue, and Mouth. 2009 , 589-618			
1320	Primary cutaneous blastoid mantle cell lymphoma-case report. 2009 , 31, 398-400			28
1319	Exceptionally low metabolic activity in aggressive peripheral T-cell lymphoma. 2009 , 30, 838-40			2
1318	Upper back pain: an unusual presentation of non-Hodgkin's lymphoma. 2010 , 89, 863-4			
1317	Cyclin D3 is dispensable for human diffuse large B-cell lymphoma survival and growth: evidence for redundancy with cyclin E. 2010 , 9, 820-8			10
1316	Diffuse FDG renal uptake in lymphoma. 2010 , 35, 813-5			9

1315	Anthracyclines-containing regimens for treatment of follicular lymphoma in adults. 2010 ,		1
1314	The Classification of Lymphoma: Updating the WHO Classification. 2010 , 614-638		
1313	NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. 2010 , 8, 288-334		185
1312	The Mantle Cell Lymphoma International Prognostic Index: Does it work in routine practice?. 2010 , 1, 187-188		6
1311	A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. 2010 , 37, 367-76		19
1310	Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice. 2010 , 8 Suppl 6, S1-14; quiz S15		10
1309	The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation. <i>Blood</i> , 2010 , 115, 289-95	2.2	145
1308	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). <i>Blood</i> , 2010 , 115, 1530-3	2.2	143
1307	Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. <i>Blood</i> , 2010 , 116, 1795-802	2.2	60
1306	The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. <i>Blood</i> , 2010 , 116, 4430-5	2.2	43
1305	The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan. 2010 , 89, 553-62		37
1304	A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. 2010 , 89, 1107-13		26
1303	[Gastric MALT-type lymphoma. Pathology, pathogenesis, diagnostics and therapy]. 2010 , 31, 188-94		2
1302	Nodal follicular lymphoma: the role of radiotherapy for stages I and II. 2010 , 186, 191-6		13
1301	Gastrointestinal follicular lymphoma: review of the literature. 2010 , 45, 370-88		82
1300	Epstein-Barr virus and Hodgkin's lymphoma in Cairo, Egypt. 2010 , 3, 11-8		12
1299	Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. 2010 , 27, 55-8		5
1298	SEOM clinical guidelines for the treatment of follicular non-Hodgkin's lymphoma. 2010 , 12, 760-4		1

1297	F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma. 2010 , 24, 115-9	2
1296	Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients. 2010 , 91, 456-63	18
1295	Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. 2010 , 92, 732-43	33
1294	Alcohol consumption and non-Hodgkin lymphoma survival. 2010 , 4, 101-9	15
1293	Rare pediatric non-hodgkin lymphoma. 2010 , 5, 163-8	13
1292	Prognostic markers in peripheral T-cell lymphoma. 2010 , 5, 222-8	25
1291	Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?. 2010 , 12, 374-82	8
1290	Risk of non-Hodgkin lymphoma and nitrate and nitrite from the diet in Connecticut women. 2010 , 21, 889-96	16
1289	Improved survival for non-Hodgkin lymphoma patients in New South Wales, Australia. 2010 , 10, 231	11
1288	Burkitt's lymphoma in a patient presenting with inferior alveolar nerve hypoesthesia in the absence of a regional tumor: A case report and review of the literature. 2010 , 22, 180-184	1
1287	Enteropathy-associated T-cell lymphoma: a review on clinical presentation, diagnosis, therapeutic strategies and perspectives. 2010 , 34, 590-605	31
1286	Clinical outcome of patients with follicular lymphoma and bulky disease after rituximab-CHOP immunochemotherapy with and without consolidating radiotherapy. 2010 , 85, 11-9	4
1285	Assessment of bone marrow involvement in non-Hodgkin's lymphomas: comparison between histology and flow cytometry. 2010 , 85, 405-15	25
1284	Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. 2010 , 116, 3797-806	74
1283	Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. 2010 , 116, 3843-51	95
1282	Marginal zone B-cell lymphoma of the infratemporal fossa: a rare case and review. 2010 , 120, 2430-3	1
1281	Marginal zone B-cell lymphoma of the head and neck: a rare case and review. 2010 , 120 Suppl 4, S165	1
1280	VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience. 2010 , 51, 209-15	6

1279	Diffuse large B-cell lymphoma in the spinal epidural space: A study of the Osaka Lymphoma Study Group. 2010 , 206, 439-44	8
1278	2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma. 2010 , 34, 184-9	26
1277	Primary mantle cell lymphoma of the thyroid. 2010 , 34, 548-50	8
1276	Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis. 2010 , 34, 379-86	23
1275	Enteropathy associated T-cell lymphoma and its precursor lesions. 2010 , 24, 43-56	76
1274	Primary cutaneous marginal zone lymphoma. 2010 , 74, 156-62	22
1273	Molecular targeted therapies for diffuse large B-cell lymphoma based on apoptosis profiles. 2010 , 220, 509-20	20
1272	Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling. 2010 , 222, 180-90	42
1271	Ongoing remission after intensive ALL-type chemotherapy in pediatric intestinal T-cell lymphoma. 2010 , 54, 610-2	
1270	CD56-negative extranodal nasal type NK/T-cell lymphoma. 2010 , 55, 186-9	6
1269	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas. 2010 , 150, 170-8	36
1268	Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. 2010 , 151, 159-66	110
1267	A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma. 2010 , 102, 19-22	12
1266	Inhibition of c-MET is a potential therapeutic strategy for treatment of diffuse large B-cell lymphoma. 2010 , 90, 1346-56	26
1265	Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. 2010 , 45, 311-6	44
1264	Usefulness of double balloon enteroscopy and video capsule endoscopy for the diagnosis and management of primary follicular lymphoma of the gastrointestinal tract in its early stages. 2010 , 22, 33-8	23
1263	Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness. 2010 , 2, 37-45	3
1262	Extranodal natural-killer/t-cell lymphoma, nasal type. 2010 , 2010, 627401	50

1261	Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas. 2010 , 2010, 320624	28
1260	Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma. 2010 , 3, 167-78	6
1259	Surveillance investigations after high-dose therapy with stem cell rescue for recurrent follicular lymphoma have no impact on management. 2010 , 95, 1130-5	8
1258	[Helicobacter pylori eradication for stage I(E)]gastric mucosa-associated lymphoid tissue lymphoma: predictive factors of complete remission]. 2010 , 55, 94-9	6
1257	Constitutive activity of nuclear transcription factor kappaB is observed in follicular lymphoma. 2010 , 50, 45-50	5
1256	Lymphomas diagnosed in Uganda during the HIV/AIDS pandemic. 2009 , 86, 226-32	3
1255	Mechanisms of Oncogenesis. 2010 ,	3
1254	Precursor T cell acute lymphoblastic lymphoma presenting as bilateral facial nerve palsy. 2010 , 56, 258-60	6
1253	The significance of bone marrow involvement in aggressive lymphomas: A retrospective comparison of clinical outcomes between peripheral T cell lymphoma and diffuse large B cell lymphoma in China. 2010 , 124, 239-44	3
1252	Diffuse large B-cell lymphoma in Chinese patients: immunophenotypic and cytogenetic analyses of 124 cases. 2010 , 133, 305-13	28
1251	Primary cutaneous anaplastic large cell lymphoma. 2010 , 27, 558-63	4
1250	Vegetable and fruit intake and non-Hodgkin lymphoma survival in Connecticut women. 2010 , 51, 1047-54	31
1249	Immunophenotyping of mature T/NK cell neoplasm presenting as leukemia. 2010 , 47, 189-93	4
1248	Cytotoxic T cells in H. pylori-related gastric autoimmunity and gastric lymphoma. 2010 , 2010, 104918	32
1247	The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. 2010 , 87, 627-32	23
1246	[Current aspects of the pathology and differentiation of extranodal marginal zone B-cell lymphoma, MALT-Type, and gastrointestinal diffuse large B-cell lymphoma]. 2010 , 48, 833-8	4
1245	Incidence and survival of lymphohematopoietic neoplasms according to the World Health Organization classification: a population-based study from the Victorian Cancer Registry in Australia. 2010 , 51, 456-68	11
1244	[Molecular abnormalities in lymphomas]. 2010 , 97, 1347-64	3

1243	Characterization of T-cell lymphomas by FDG PET/CT. 2010 , 195, 333-40	81
1242	[Primary mediastinal B-cell lymphoma]. 2010 , 66, 32-5	1
1241	I-kappa-kinase-2 (IKK-2) inhibition potentiates vincristine cytotoxicity in non-Hodgkin's lymphoma. 2010 , 9, 228	14
1240	Prognostic significance of BAD and AIF apoptotic pathways in diffuse large B-cell lymphoma. 2010 , 10, 118-24	11
1239	A decade of progress in lymphoma: advances and continuing challenges. 2010 , 10, 414-23	38
1238	RETRAIT: Lymphomes T intestinaux associ�� une ent��opathie (maladie c��liaque et sprue r��fractaire): pr��sentation, diagnostic, prise en charge th��rapeutique, pronostic et perspectives. 2010 ,	
1237	Follicular non-Hodgkin's lymphoma. 2010 , 65, 408-20	12
1236	Lymphoma--emerging realities in sub-Saharan Africa. 2010 , 42, 141-50	12
1235	Unifocal and multifocal reactive lymphoid hyperplasia vs follicular lymphoma of the ocular adnexa. 2010 , 150, 412-426.e1	49
1234	Angioimmunoblastic T-cell lymphoma presenting as extensive psoriasis: a case report and discussion. 2010 , 7, 90-92	
1233	Rituximab in indolent lymphomas. 2010 , 47, 133-42	27
1232	Status of ongoing collaborative efforts. 2010 , 47 Suppl 1, S18-20	
1231	Common misdiagnoses in lymphomas and avoidance strategies. 2010 , 11, 579-88	33
1230	Prognostic factors in follicular lymphoma. 2010 , 28, 2902-13	117
1229	Masses of the Anterior Mediastinum. 2010 , 365-384	
1228	Genomics in the Management of Lymphomas. 2010 , 407-420	
1227	F-18 fluorodeoxyglucose positron emission tomography and/or computed tomography findings of an unusual breast lymphoma case and concurrent cervical cancer: a case report. 2010 , 4, 282	2
1226	Non-Hodgkin's lymphoma in the elderly. 2010 , 27, 211-38	7

1225	Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. 2010 , 51, 1225-32	31
1224	Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. 2010 , 51, 2208-14	10
1223	Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma. 2010 , 51, 1305-14	43
1222	I-131 tositumomab. 2010 , 10, 1271-8	13
1221	Pretreatment total serum protein is a significant prognostic factor for the outcome of patients with peripheral T/natural killer-cell lymphomas. 2010 , 51, 813-21	23
1220	Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma. 2011 , 52, 620-8	21
1219	Intratumoral plasmacytoid dendritic cells associate with increased survival in patients with follicular lymphoma. 2011 , 52, 1230-8	11
1218	Economic impact of disease progression in follicular non-Hodgkin lymphoma. 2011 , 52, 2117-23	13
1217	Evaluation of the pharmacokinetics, preclinical and clinical efficacy of pralatrexate for the treatment of T-cell lymphoma. 2011 , 7, 1141-52	11
1216	Prognostication of diffuse large B-cell lymphoma in the rituximab era. 2011 , 52, 360-73	23
1215	Classification of canine malignant lymphomas according to the World Health Organization criteria. 2011 , 48, 198-211	264
1214	Clinical features of gastrointestinal follicular lymphoma: comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma. 2011 , 83, 191-7	17
1213	Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. 2011 , 29, 3389-95	91
1212	Lymphoma cytogenetics. 2011 , 31, 725-61, x-xi	10
1211	Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. 2011 , 52, 2097-104	8
1210	High-dose therapy/autologous hematopoietic stem cell transplantation in relapsed or refractory marginal zone non-Hodgkin lymphoma. 2011 , 11, 253-6	13
1209	Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma. 2011 , 11, 467-74	14
1208	A prospective phase II study of RICE re-induction, then high-dose fludarabine and busulfan, followed by autologous or allogeneic blood stem cell transplantation for indolent b-cell lymphoma. 2011 , 11, 475-82	2

1207	Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. 2011 , 11, 498-506		52
1206	Mantle cell lymphoma of the maxillary sinus invading the orbit. 2011 , 82, 22-31		1
1205	Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases. 2011 , 64, 319-24		32
1204	The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. <i>Blood</i> , 2011 , 117, 5019-32	2.2	1356
1203	Immunohistology of Non-Hodgkin Lymphoma. 2011 , 156-188		3
1202	Ophthalmic Oncology. 2011 ,		21
1201	Differential expression of cell-cycle regulatory proteins defines distinct classes of follicular lymphoma. 2011 , 42, 972-82		7
1200	Consolidation par 90Y-epratuzumab en fractionnement dans le lymphome B diffus à grandes cellules : résultats préliminaires d'une étude de phase II. 2011 , 35, 478-486		
1199	Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study. 2011 , 23, 17-24		11
1198	Improving therapy for patients with aggressive lymphoma. 2011 , 44, 179-82		
1197	Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. 2011 , 12, 361-8		135
1196	Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. 2011 , 12, 773-84		84
1195	Molecular pathogenesis of diffuse large B-cell lymphoma. 2011 , 28, 167-77		63
1194	Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type. 2011 , 32, 913-20		7
1193	A case of monoclonal gammopathy in extranodal marginal zone B-cell lymphoma of the small intestine. 2011 , 31, 18-21		3
1192	Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma. 2011 , 7, 401-8		1
1191	Hepatocellular Adenoma in Men: A Rare Cause for Liver Resection. 2011 , 77, 373-376		4
1190	Successful Endoscopic Management of an Esophagojejunostomy Leak Using Fibrin Glue Injection after a Total Gastrectomy. 2011 , 77, 376-378		2

1189 Neonatal Graves Disease and Recurrent Goiter. **2011**, 77, 380-382

1188 A Novel Use of a Gastrojejunostomy Tube for Duodenal Diversion after Traumatic Duodenal Injury. **2011**, 77, 361-362

1187 Colonic Obstruction Resulting from Fecalith in Patients with Scleroderma. **2011**, 77, 364-366

1

1186 Gastric Antral Stenosis: Late Complication of Acid Ingestion. **2011**, 77, 369-370

1185 Radium Implant Treatment of a Birthmark at Infancy and Its Association with Malignancy. **2011**, 77, 372-373

1184 Recurrent Abdominal Pain in Chilaiditi's Syndrome Could Represent an Indication for Elective Surgery?. **2011**, 77, 386-387

1183 Primary Gallbladder Lymphoma. **2011**, 77, 360-361

3

1182 Total Gastrectomy and Pancreaticoduodenectomy for Gastric Polyposis and Duodenal Ampullary Adenoma in a Patient with Attenuated Familial Adenomatous Polyposis. **2011**, 77, 378-380

2

1181 Treatment of Achalasia with Extreme Megaesophagus: Heller Myotomy or Esophagectomy?. **2011**, 77, 362-364

1

1180 Vanishing Surgeons: Cultural, Economical, and Social Limitations for Pakistani Medical Students and Trainees. **2011**, 77, 368-368

1179 Performance in War Game Simulations between Medical Students and Interns. **2011**, 77, 370-372

1

1178 Clinical and Pathological Characteristics of Breast Cancer Patients with History of Appendectomy. **2011**, 77, 382-383

1177 Comparison of long-term clinical outcomes of CHOP chemotherapy between Japanese patients with nodal peripheral T-cell lymphomas and those with diffuse large B-cell lymphoma in the study group of the Tohoku Hematology Forum. **2011**, 51, 29-35

7

1176 Flow cytometric immunophenotyping of hematological malignancies: the way forward in Nigeria. **2011**, 17

1

1175 Marginal zone B-cell lymphoma. **2011**,

1174 Clinico-hematologic Findings of Leukemic Bone Marrow Involvement in Korean Patients with Non-Hodgkin Lymphoma. **2011**, 1, 81

0

1173 Primary cutaneous B-cell lymphoblastic lymphoma in an elderly man. **2011**, 46, 283-6

3

1172 An update on the management of peripheral T-cell lymphoma and emerging treatment options. **2011**, 2, 119-29

5

1171	Sudden False Oxygen Desaturation and Factitious Methemoglobinemia after Subcutaneous Injection of Isosulfan Blue (Lymphazurin). 2011 , 77, 383-385			
1170	Management of Persistent Sciatic Artery Embolization to the Lower Extremity Using Covered Stent through a Transgluteal Approach. 2011 , 77, 366-368			9
1169	Prognostic value of immunohistochemical biomarkers at different cut-off values in patients with diffuse large B-cell lymphoma treated with CHOP chemotherapy. 2011 , 26, 1556-62			5
1168	Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens. 2011 , 6, e23916			10
1167	Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. 2011 , 6, e24703			59
1166	Current and Emerging Therapies in Peripheral T-cell Lymphoma: Focus on Pralatrexate. 2011 , 3, CMT.S3778			1
1165	Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Involving the Parotid Gland. 2011 , 16, 161-166			
1164	Molecular predictors of response in aggressive T-cell lymphomas. 2011 , 17, 142-8			0
1163	Changing pattern of lymphoma subgroups at a tertiary academic complex in a high-prevalence HIV setting: a South African perspective. 2011 , 56, 460-6			38
1162	A patient death attributable to implant-related primary anaplastic large cell lymphoma of the breast. 2011 , 128, 112e-118e			70
1161	Lymphome du manteau: un modèle biologique et clinique. 2011 , 6, 1-10			
1160	Nfe2l3 (Nrf3) deficiency predisposes mice to T-cell lymphoblastic lymphoma. <i>Blood</i> , 2011 , 117, 2005-8	2.2		32
1159	Peripheral T-cell lymphoma. <i>Blood</i> , 2011 , 117, 6756-67	2.2		228
1158	Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. <i>Blood</i> , 2011 , 118, 2976-84	2.2		113
1157	Primary anaplastic large cell lymphoma of trachea with subcutaneous emphysema and progressive dyspnea. 2011 , 4, 188-91			7
1156	Significance of aldehyde dehydrogenase 1 expression in stromal cells of diffuse large B-cell lymphoma. 2011 , 2, 591-594			5
1155	Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. 2011 , 96, 1121-7			159
1154	Primary gastric diffuse large B-cell lymphoma with orbital involvement: diagnostic usefulness of 18F-fluorodeoxyglucose positron emission tomography. 2011 , 50, 1953-6			4

1153	Non-Hodgkin's lymphomas. 2011 , 9, 484-560	47
1152	Optimization of postremission therapy in follicular lymphoma: efficacy of rituximab maintenance. 2011 , 9, 563-71	
1151	VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study. 2011 , 155, 190-7	40
1150	Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54). 2011 , 86, 111-6	7
1149	Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. 2011 , 21, 293-8	66
1148	Primary uterine localization of malt lymphoma: a case report and literature review. 2011 , 35, e185-7	3
1147	Partitioning histopathological images: an integrated framework for supervised color-texture segmentation and cell splitting. 2011 , 30, 1661-77	133
1146	Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution. 2011 , 6, 77	145
1145	Synchronous perforation of non-Hodgkin's lymphoma of the small intestine and colon: a case report. 2011 , 5, 57	3
1144	Nodal follicular lymphoma without complete follicular dendritic cell networks is related to localized clinical stage. 2011 , 61, 737-41	11
1143	Life-threatening complications related to minocycline pleurodesis. 2011 , 92, 1122-4	4
1142	Role of surgery after chemotherapy in B-cell lymphoma of thymus causing airway compression and right ventricle outflow tract obstruction. 2011 , 92, 1120-2	5
1141	Pathogenesis of non-Hodgkin's lymphoma. 2011 , 29, 1803-11	159
1140	Autoimmune phenomena in untreated and treated marginal zone lymphoma. 2011 , 12, 2369-79	6
1139	2008-WHO-Klassifikation der malignen Lymphome im Jahr 2011. 2011 , 17, 769-788	0
1138	Pathologie primärpulmonaler Lymphome. 2011 , 8, 328-332	
1137	Cell cycle and apoptosis regulatory protein (CARP)-1 is a novel, adriamycin-inducible, diffuse large B-cell lymphoma (DLBL) growth suppressor. 2011 , 67, 1401-13	4
1136	[Reflections of a Virchow medal laureate]. 2011 , 32 Suppl 2, 167-73	

1135	Prognostic evaluation of immunohistochemical profiles in diffuse large B-cell lymphoma: a Chinese study. 2011 , 28, 241-8	6
1134	Hepatosplenic T-cell lymphoma. 2011 , 27, 39-42	5
1133	The Outcome of HyperCVAD Combined with Alemtuzumab for the Treatment of Aggressive T-Cell and NK-Cell Neoplasms. 2011 , 27, 136-45	1
1132	Non-Hodgkin lymphoma in childhood and adolescence: frequency and distribution of immunomorphological types from a tertiary care center in South India. 2011 , 7, 318-25	13
1131	Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?. 2011 , 6, 58-66	17
1130	Primary mediastinal DLBCL: evolving biologic understanding and therapeutic strategies. 2011 , 13, 407-15	12
1129	Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations. 2011 , 2, 8	33
1128	Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma. 2011 , 86, 515-8	1
1127	Follicular lymphoma: 2011 update on diagnosis and management. 2011 , 86, 768-75	32
1126	Clinicopathological aspects of mucosa-associated lymphoid tissue (MALT) lymphoma of the parotid gland: a retrospective single-center analysis of 28 cases. 2011 , 33, 763-7	19
1125	Establishment of a novel MALT lymphoma cell line, ma-1, from a patient with t(14;18)(q32;q21)-positive Helicobacter pylori-independent gastric MALT lymphoma. 2011 , 50, 908-21	7
1124	Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. 2011 , 117, 2530-40	96
1123	Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma. 2011 , 117, 2461-6	6
1122	Lymphoblastic lymphoma. 2011 , 79, 330-43	114
1121	Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. 2011 , 35, 380-6	53
1120	CD10 and ICOS expression by multiparametric flow cytometry in angioimmunoblastic T-cell lymphoma. 2011 , 24, 993-1003	27
1119	Aktuelle molekular-zytogenetische Aspekte zur Pathologie und Differenzierung von extranodalen Marginalzonen B-Zell-Lymphomen vom MALT-Typ und gastrointestinalen diffusen großzelligen B-Zell-Lymphomen. 2011 , 32, 48-53	
1118	Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03). 2011 , 52, 409-16	8

1117	Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network. 2011 , 52, 1675-80	36
1116	Acquired immune-mediated thrombophilia in lymphoproliferative disorders. 2011 , 52, 1836-43	19
1115	Lack of survival improvement in patients with peripheral T-cell lymphoma: a Surveillance, Epidemiology, and End Results analysis. 2011 , 52, 194-204	9
1114	The ALK gene, an attractive target for inhibitor development. 2011 , 11, 1406-19	10
1113	Prognostic impact of MUM1 expression by immunohistochemistry on primary mediastinal large B-cell lymphoma. 2011 , 52, 1495-503	17
1112	Follicular non-Hodgkin lymphoma grades 3A and 3B have a similar outcome and appear incurable with anthracycline-based therapy. 2011 , 22, 1164-1169	46
1111	Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. 2011 , 29, 1445-51	148
1110	Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. 2011 , 29, 2787-94	193
1109	Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. 2011 , 136, 195-210	59
1108	Revisiting the Marrow Metabolic Changes after Chemotherapy in Lymphoma: A Step towards Personalized Care. 2011 , 2011, 942063	3
1107	Extranodal MALT Lymphoma of the Right Triceps Muscle following Influenza Vaccine Injection: A Rare Case with an Interesting Presentation. 2011 , 2011, 617293	9
1106	Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. 2011 , 29, 1182-9	442
1105	Diffuse large B-cell lymphoma with germinal center B-cell phenotype mimicking primary effusion lymphoma. 2011 , 29, e271-3	3
1104	Marginal zone lymphomas with plasmacytic differentiation and related disorders. 2011 , 136, 211-25	63
1103	Hibernation: Poikilotherms. 2011 ,	4
1102	Transferrin receptor expression in canine lymphoma. 2011 , 48, 466-74	1
1101	Classification of non-Hodgkin lymphomas in Guatemala according to the World Health Organization system. 2011 , 52, 1681-8	15
1100	Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. <i>Blood</i> , 2011 , 117, 3402-8	2.2 290

1099	Stem cell transplantation as a biological therapy for peripheral T-cell lymphomas. 2011 , 11, 31-40	3
1098	Gene expression profiling in follicular lymphoma and its implication for clinical practice. 2011 , 52, 59-68	11
1097	Malignant lymphoma in northern Iraq: a retrospective analysis of 270 cases according to the World Health Organization classification. 2011 , 48, 446-51	20
1096	Centralized review offers promise for the clinician, the pathologist, and the patient with newly diagnosed lymphoma. 2011 , 29, 1398-9	2
1095	Pathology review of outside material: when does it help and when can it hurt?. 2011 , 29, 2724-7	8
1094	Diffuse large B-cell lymphoma: update on therapy and prognosis. 2011 , 1, 989-997	
1093	A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma. 2012 , 23, 2687-2695	23
1092	Expert second-opinion pathology review of lymphoma in the era of the World Health Organization classification. 2012 , 23, 159-166	35
1091	Gastric Cancer and Helicobacter pylori. 2012 , 25-60	
1090	European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. 2012 , 97, 360-5	66
1089	Pain in the butt: marginal zone lymphoma of the gluteus muscle. 2012 , 30, e86-7	1
1088	Clinicopathological Features and Outcomes of T- and NK-Cell Lymphomas in European Russia. 2012 , 5, CMBD.S7804	
1087	Indolent B-cell lymphomas associated with HCV infection: clinical and virological features and role of antiviral therapy. 2012 , 2012, 638185	47
1086	Automated analysis of multidimensional flow cytometry data improves diagnostic accuracy between mantle cell lymphoma and small lymphocytic lymphoma. 2012 , 137, 75-85	32
1085	Follicular lymphoma: to treat or not to treat is no longer the question. 2012 , 104, 3-5	1
1084	Early stage follicular lymphoma, current management and controversies. 2012 , 24, 475-9	10
1083	Waldenström macroglobulinemia: a review of the entity and its differential diagnosis. 2012 , 19, 11-27	20
1082	Cost-utility analysis of primary prophylaxis versus secondary prophylaxis with granulocyte colony-stimulating factor in elderly patients with diffuse aggressive lymphoma receiving curative-intent chemotherapy. 2012 , 30, 1064-71	25

1081	Follicular lymphoma grading using cell-graphs and multi-scale feature analysis. 2012 ,	12
1080	Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features. 2012 , 25, 1149-59	53
1079	Clinical evidence for the role of pixantrone in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. 2012 , 2, 49-58	5
1078	P53 deletion is independently associated with increased age and decreased survival in a cohort of Chinese patients with diffuse large B-cell lymphoma. 2012 , 53, 2182-5	3
1077	The miR-17-92 microRNA cluster: a novel diagnostic tool in large B-cell malignancies. 2012 , 92, 1574-82	62
1076	Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies. 2012 , 2, e65	18
1075	Potent antitumor effects of bevacizumab in a microenvironment-dependent human lymphoma mouse model. 2012 , 2, e67	10
1074	How to predict the outcome in mature T and NK cell lymphoma by currently used prognostic models?. 2012 , 2, e93	11
1073	Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGA. 2012 , 17, 663-72	36
1072	Cytokine BAFF gene variation is associated with survival of patients with T-cell lymphomas. 2012 , 18, 2250-6	11
1071	A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. 2012 , 53, 254-8	24
1070	Endoscopic ultrasound and endobronchial ultrasound-guided fine-needle aspiration of deep-seated lymphadenopathy: Analysis of 1338 cases. 2012 , 9, 14	23
1069	Novel therapies for aggressive B-cell lymphoma. 2012 , 2012, 302570	15
1068	Lenalidomide in diffuse large B-cell lymphomas. 2012 , 2012, 498342	10
1067	Exploring risk factors for follicular lymphoma. 2012 , 2012, 626035	22
1066	Lenalidomide in diffuse large B-cell lymphoma. 2012 , 2012, 861060	14
1065	Advances in the diagnosis and management of lymphoma. 2012 , 29	1
1064	Adult lymphoblastic lymphoma. 2012 , 18, 432-8	46

1063	Mechanisms of AIDS-related lymphoma pathogenesis. 2012 , 7, 229-238		3
1062	Radiological Findings of a 57-Year-Old Male with Follicular Lymphoma of the Mandible. 2012 , 21, 88-90		
1061	High expression and nuclear localization of β -catenin in diffuse large B-cell lymphoma. 2012 , 5, 1433-7		20
1060	Rare T Cell Lymphomas. 2012 , 659-666		
1059	Immunohistochemical detection of CD3 in T-cell lymphomas: superior sensitivity of rabbit monoclonal 2GV6 antibody compared to mouse monoclonal F72B8 antibody. 2012 , 35, 175-179		1
1058	Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. <i>Blood</i> , 2012 , 120, 812-21	2.2	34
1057	Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases. <i>Blood</i> , 2012 , 120, 4795-801	2.2	90
1056	Extranodal natural killer/T-cell lymphoma, nasal type: clinical and computed tomography findings in the head and neck region. 2012 , 122, 2632-9		16
1055	¹⁸ F-FDG-PET/CT in lymphoma: two decades of experience. 2012 , 31, 340-9		4
1054	A general framework for the segmentation of follicular lymphoma virtual slides. 2012 , 36, 442-51		26
1053	Diagnosis and management of rare gastrointestinal lymphomas. 2012 , 53, 2341-50		20
1052	Diffuse large B-cell lymphoma of the orbit: clinicopathologic, immunohistochemical, and prognostic features of 20 cases. 2012 , 154, 87-98.e1		31
1051	Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. 2012 , 18, S82-91		17
1050	The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines. 2012 , 48, 68-75		21
1049	Galectin-3 binds to CD45 on diffuse large B-cell lymphoma cells to regulate susceptibility to cell death. <i>Blood</i> , 2012 , 120, 4635-44	2.2	67
1048	Follicular lymphoma: 2012 update on diagnosis and management. 2012 , 87, 988-95		34
1047	Characteristics and outcomes of diffuse large B-cell lymphoma presenting in leukaemic phase. 2012 , 158, 608-14		23
1046	Rituximab: current status as therapy for malignant and benign hematologic disorders. 2012 , 26, 71-82		14

1045 Gastrointestinal Lymphoma. **2012**, 239-267

1044 The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. **2012**, 43, 2274-81 29

1043 Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma: antigen-driven origin and IGHV4-34 as a particular subgroup of the non-GCB subtype. **2012**, 181, 1879-88 24

1042 Autologous transplantation and management of younger patients with mantle cell lymphoma. **2012**, 25, 211-20 4

1041 A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. **2012**, 12, 393-9 10

1040 Considerations in the initial management of follicular lymphoma. **2012**, 9, S53-S60 6

1039 An Efficient Computational Framework for the Analysis of Whole Slide Images: Application to Follicular Lymphoma Immunohistochemistry. **2012**, 3, 269-279 27

1038 Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: a clinicopathological study. **2012**, 36, 1403-9 10

1037 Dietary nitrate and nitrite intake and non-Hodgkin lymphoma survival. **2012**, 64, 488-92 6

1036 Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients. **2012**, 29, 2176-82 18

1035 Angioimmunoblastic T-cell lymphoma: the effect of initial treatment and microvascular density in 31 patients. **2012**, 29, 2311-6 5

1034 Expression of Spy1 protein in human non-Hodgkin's lymphomas is correlated with phosphorylation of p27 Kip1 on Thr187 and cell proliferation. **2012**, 29, 3504-14 22

1033 18F-FDG-PET/CT in lymphoma: Two decades of experience. **2012**, 31, 340-349

1032 Prognostic relevance of pretreatment quality of life in diffuse large B-cell lymphoma patients treated with rituximab-CHOP: results from a prospective cohort study. **2012**, 91, 1747-56 12

1031 The impact of age, Charlson comorbidity index, and performance status on treatment of elderly patients with diffuse large B cell lymphoma. **2012**, 91, 1383-91 32

1030 Hematologic Malignancy: The Lymphomas. **2012**, 531-553 1

1029 Gastrointestinal Mantle Cell Lymphoma-A Tale of Two Endoscopies. **2012**, 43 Suppl 1, S20-4 2

1028 Non-Hodgkin lymphoma in Chile: a review of 207 consecutive adult cases by a panel of five expert hematopathologists. **2012**, 53, 1311-7 11

1027	Bacteria and Cancer. 2012 ,	4
1026	Lymphoma and Leukemia of the Nervous System. 2012 ,	3
1025	Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type. 2012 , 53, 1032-45	14
1024	Mantle cell lymphoma of the larynx: Primary case report. 2012 , 6, 201	4
1023	Germinal center B-cell-like versus non-germinal center B-cell-like as important prognostic factor for localized nodal DLBCL. 2012 , 52, 91-9	7
1022	The many faces of marginal zone lymphoma. 2012 , 2012, 426-432	52
1021	Tonsillar follicular lymphoma in a child. 2012 , 2012,	2
1020	Outcome of R-CHOP or CHOP regimen for germinal center and nongerminal center subtypes of diffuse large B-cell lymphoma of Chinese patients. 2012 , 2012, 897178	9
1019	Non-Hodgkin's Lymphomas, version 3.2012. 2012 , 10, 1487-98	28
1018	Linfoma MALT de par�tida, presentaci�n de un caso cl�nico y revisi�n del tema. 2012 , 72, 79-86	1
1017	Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. 2012 ,	
1016	ALK+ anaplastic large cell lymphoma exhibits phosphatidylinositol-3 kinase/Akt activity with retained but inactivated PTEN--a report from the Children's Oncology Group. 2012 , 59, 440-7	6
1015	Molecular genetic characterization of lymphoma: application to cytology diagnosis. 2012 , 40, 542-55	20
1014	Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks. 2012 , 30, 175-9	15
1013	EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. 2012 , 26, 1908-75	557
1012	The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. 2012 , 87, 511-9	61
1011	Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. 2012 , 87, 604-9	79
1010	Comparison of outcomes after allogeneic hematopoietic stem cell transplantation in patients with follicular lymphoma, diffuse large B-cell lymphoma associated with follicular lymphoma, or de novo diffuse large B-cell lymphoma. 2012 , 87, 770-5	11

1009	Increasing incidence of enteropathy-associated T-cell lymphoma in the United States, 1973-2008. 2012 , 118, 3786-92	36
1008	Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. 2012 , 13, 82-101	2
1007	Uncommon late relapse of angioimmunoblastic T-cell lymphoma after 16-year remission period. 2012 , 18, 737-41	
1006	Clinical significance of the WHO grades of follicular lymphoma in a population-based cohort of 505 patients with long follow-up times. 2012 , 156, 225-33	90
1005	Guidelines on the investigation and management of follicular lymphoma. 2012 , 156, 446-67	49
1004	Racial patterns of extranodal natural killer/T-cell lymphoma, nasal type, in California: a population-based study. 2012 , 156, 626-32	30
1003	Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis. 2012 , 36, 749-55	7
1002	Topo II β gene alterations correlated with survival in patients with diffuse large B-cell lymphoma. 2012 , 42, 310-20	8
1001	Polymorphisms in immune function genes and non-Hodgkin lymphoma survival. 2012 , 6, 102-14	14
1000	Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity. 2012 , 30, 368-75	16
999	Diffuse swelling of the buccal mucosa and palate as first and only manifestation of an extranodal non-Hodgkin 'double-hit' lymphoma: report of a case. 2012 , 16, 69-74	8
998	Absolute monocytosis at diagnosis correlates with survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-derived suppressor cells. 2013 , 31, 65-71	47
997	Diffuse large B-cell lymphoma of the ocular adnexal region: a nation-based study. 2013 , 91, 163-9	20
996	Ibrutinib: a strong candidate for the future of mantle cell lymphoma treatment. 2013 , 9, 495-7	1
995	Lymphoma. 2013 ,	1
994	Bendamustine salvage therapy for T cell neoplasms. 2013 , 92, 1249-54	25
993	Patients with activated B-cell like diffuse large B-cell lymphoma in high and low infectious disease areas have different inflammatory gene signatures. 2013 , 54, 996-1003	6
992	Diagnostic prediction of complex diseases using phase-only correlation based on virtual sample template. 2013 , 14 Suppl 8, S11	3

991	Non-Hodgkin Lymphoma. 2013,	1
990	T-Cell Lymphomas. 2013,	1
989	Burkitt's Lymphoma. 2013,	1
988	Treatment of adolescents with aggressive B-cell malignancies: the pediatric experience. 2013, 8, 226-35	6
987	Prognostic value of Waldeyer's ring involvement of diffuse large B-cell lymphoma treated with R-CHOP. 2013, 97, 397-402	9
986	Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups. 2013, 97, 98-102	3
985	Lenalidomide induced response in a patient with follicular lymphoma of the skin and an anti-rituximab-antibody. 2013, 6, 123-126	1
984	A case report of concurrent gastric and pulmonary mucosa-associated lymphoid tissue lymphomas and review of the literature on clonality analysis. 2013, 92, 1707-9	2
983	Simple but powerful prognostic scoring model for MALT lymphoma: a retrospective study. 2013, 92, 421-3	1
982	[Nodular lymphocyte-predominant Hodgkin's lymphoma and differential diagnoses]. 2013, 34, 233-43	1
981	60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. 2013,	7
980	Clinically important variants of diffuse large B-cell lymphoma. 2013, 49, 27-30	1
979	Treatment strategies for peripheral T-cell lymphomas. 2013, 26, 43-56	6
978	International analysis of the frequency and outcomes of NK/T-cell lymphomas. 2013, 26, 23-32	44
977	Overexpression of LC3A autophagy protein in follicular and diffuse large B-cell lymphomas. 2013, 6, 20-5	12
976	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. 2013, 369, 507-16	1139
975	Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma. 2013, 37, 1156-61	16
974	Canine lymphomas: association of classification type, disease stage, tumor subtype, mitotic rate, and treatment with survival. 2013, 50, 738-48	147

973	Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management. 2013 , 88, 1082-8	64
972	Clinicopathological features of neuropathy associated with lymphoma. 2013 , 136, 2563-78	113
971	High expression of cyclic nucleotide phosphodiesterase 7B mRNA predicts poor prognosis in mantle cell lymphoma. 2013 , 37, 536-40	5
970	Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas. 2013 , 37, 619-23	21
969	A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. 2013 , 13, 664-70	27
968	The aggressive peripheral T-cell lymphomas: 2013. 2013 , 88, 910-8	21
967	Anthracycline-containing regimens for treatment of follicular lymphoma in adults. 2013 , CD008909	3
966	Clinical significance of cytogenetic aberrations in bone marrow of patients with diffuse large B-cell lymphoma: prognostic significance and relevance to histologic involvement. 2013 , 6, 76	13
965	MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas. 2013 , 8, 37	9
964	Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. 2013 , 6, 69	17
963	ADC measurements in diffuse large B-cell lymphoma and follicular lymphoma: a DWI and cellularity study. 2013 , 82, e158-64	49
962	Peripheral T-cell lymphomas: in "real life" experience are we really improving?. 2013 , 54, 2337-8	
961	Using primary site as a predictor of survival in mantle cell lymphoma. 2013 , 119, 1570-7	31
960	EBV counteracts IL-21-induced apoptosis in an EBV-positive diffuse large B-cell lymphoma cell line. 2013 , 133, 766-70	8
959	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study. 2013 , 119, 4129-36	13
958	Racial differences in chronic lymphocytic leukemia. Digging deeper. 2013 , 119, 3593-5	9
957	Managing newly diagnosed follicular lymphoma: state of the art and future perspectives. 2013 , 13, 313-25	2
956	Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in non-Hodgkin lymphoma and significant correlations with lactic acid dehydrogenase and β -microglobulin. 2013 , 91, 214-20	7

955	Dissecting lymphoma incidence to inform epidemiologic and clinical research. 2013 , 54, 1575-6	4
954	Brentuximab vedotin: treatment role for relapsed refractory systemic anaplastic large-cell lymphoma. 2013 , 6, 361-73	6
953	ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. 2013 , 24, 857-77	225
952	Tissue flow cytometry immunophenotyping in the diagnosis and classification of non-Hodgkin's lymphomas: a retrospective evaluation of 1,792 cases. 2013 , 84, 82-95	29
951	Class-imbalanced classifiers for high-dimensional data. 2013 , 14, 13-26	169
950	Diffuse large B-cell lymphoma. 2013 , 87, 146-71	240
949	Expression of DBC1 and Androgen Receptor Predict Poor Prognosis in Diffuse Large B Cell Lymphoma. 2013 , 6, 370-81	22
948	Molecular pathogenesis in non-Hodgkin lymphoma: implications for therapy. 2013 , 49, 155-6	2
947	Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy. 2013 , 4, 134-40	5
946	Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy. 2013 , 44, 2529-35	21
945	Efficacy and toxicity of two schedules of bortezomib in patients with recurrent or refractory follicular lymphoma: a randomised phase II trial from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). 2013 , 49, 904-10	16
944	Clinical significance of serum-soluble interleukin-2 receptor in patients with follicular lymphoma. 2013 , 13, 410-6	18
943	Allogeneic stem cell transplantation for diffuse large B cell lymphoma: defining the role of allografts. 2013 , 49, 63-71	1
942	Clinical applications of BAC array-CGH to the study of diffuse large B-cell lymphomas. 2013 , 973, 121-45	1
941	MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma. 2013 , 54, 1188-93	14
940	Historical Landmarks in the Understanding of the Lymphomas. 2013 , 789-833	1
939	Pathology of Non-Hodgkin's and Hodgkin's Lymphomas. 2013 , 867-918	
938	Immunology of the Lymphomas. 2013 , 919-943	

937 Diagnosis and Treatment of Non-Hodgkin's Lymphoma of Adults. **2013**, 1027-1047

936 Diffuse Large B-Cell Lymphoma. **2013**, 151-173

1

935 Inhibition of miR-21 induces biological and behavioral alterations in diffuse large B-cell lymphoma. **2013**, 130, 87-94

29

934 Natural Killer Cell Immunoglobulin-like Receptor (KIR) genotypes in Follicular Lymphoma patients: results of a pilot study. **2013**, 525, 136-40

5

933 Current and emerging therapies in mantle cell lymphoma. **2013**, 14, 198-211

14

932 Diagnosing and classifying malignant lymphomas is improved by referring cases to a panel of expert pathologists. **2013**, 6, 179-185

1

931 Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. **2013**, 31, 3351-9

48

930 Differences in the cytogenetic alteration profiles of diffuse large B-cell lymphoma among Chinese and American patients. **2013**, 206, 183-90

5

929 Low-dose involved-field radiation in the treatment of non-hodgkin lymphoma: predictors of response and treatment failure. **2013**, 86, 121-7

36

928 Clinical, histopathological and immunohistochemical characterization of canine indolent lymphoma. **2013**, 11, 272-86

78

927 Tensor-based computation and modeling in multi-resolution digital pathology imaging: application to follicular lymphoma grading. **2013**,

926 Nodal and leukemic small B-cell neoplasms. **2013**, 26 Suppl 1, S15-28

9

925 Examining racial differences in diffuse large B-cell lymphoma presentation and survival. **2013**, 54, 268-76

33

924 The predictive value of interim and final [18F] fluorodeoxyglucose positron emission tomography after rituximab-chemotherapy in the treatment of non-Hodgkin's lymphoma: a meta-analysis. **2013**, 2013, 275805

14

923 Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma. **2013**, 4, 425

20

922 Biostable ssDNA aptamers specific for Hodgkin lymphoma. **2013**, 13, 14543-57

4

921 Primary effusion lymphoma. **2013**, 137, 1152-4

29

920 Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. **2013**, 9, e1003137

91

919	Recent advances in the management of mantle cell lymphoma. 2013 , 25, 716-21	6
918	Transformation of follicular lymphoma to Epstein-Barr virus-related Hodgkin-like lymphoma. 2013 , 31, e53-6	12
917	Mantle cell lymphoma of blastoid variant with skin lesion and rapid progression: a case report and literature review. 2013 , 35, 851-5	5
916	Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab. 2013 , 19, 2551-61	14
915	Novel agents in indolent lymphomas. 2013 , 4, 133-48	12
914	In vitro and in vivo therapeutic efficacy of carfilzomib in mantle cell lymphoma: targeting the immunoproteasome. 2013 , 12, 2494-504	21
913	Inter-reader variability in follicular lymphoma grading: Conventional and digital reading. 2013 , 4, 30	16
912	Follicular lymphoma in situ presenting as dermatopathic lymphadenopathy. 2013 , 2013, 481937	1
911	Stage IAE Follicular Lymphoma of the Breast: Case Report and Review of the Literature. 2013 , 2013, 597527	1
910	Cross talk between follicular Th cells and tumor cells in human follicular lymphoma promotes immune evasion in the tumor microenvironment. 2013 , 190, 6681-93	61
909	A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. 2013 , 163, 334-42	33
908	Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. 2013 , 31, 2103-9	126
907	MIB-1 labeling index as a prognostic factor for patients with follicular lymphoma treated with rituximab plus CHOP therapy. 2013 , 104, 1670-4	11
906	Splenic marginal zone lymphoma: a population-based study on the 2001-2008 incidence and survival in the United States. 2013 , 54, 1380-6	35
905	Clinicopathological prognostic indicators in 107 patients with diffuse large B-cell lymphoma transformed from follicular lymphoma. 2013 , 104, 952-7	7
904	Body mass index, weight change, and survival in non-Hodgkin lymphoma patients in Connecticut women. 2013 , 65, 43-50	14
903	Smurf2 suppresses B-cell proliferation and lymphomagenesis by mediating ubiquitination and degradation of YY1. 2013 , 4, 2598	40
902	Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. 2013 , 54, 1004-11	30

901	Lymphoma classification: past, present and future. 2013 , 6-30		
900	Patterns of use of 18-fluoro-2-deoxy-D-glucose positron emission tomography for initial staging of grade 1-2 follicular lymphoma and its impact on initial treatment strategy in the National Comprehensive Cancer Network Non-Hodgkin Lymphoma Outcomes database. 2013 , 54, 2155-62		9
899	Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. 2013 , 31, 3688-95		269
898	Prognostic impact of concordant and discordant cytomorphology of bone marrow involvement in patients with diffuse, large, B-cell lymphoma treated with R-CHOP. 2013 , 66, 420-5		19
897	Treatment response and overall outcome of patients with relapsed and refractory peripheral T-cell lymphoma compared to diffuse large B-cell lymphoma. 2013 , 54, 507-13		10
896	Regression of follicular lymphoma of the duodenum following eradication of <i>H. pylori</i> infection. 2013 , 52, 2611-4		8
895	HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma. <i>Blood</i> , 2013 , 122, 1448-54	2.2	18
894	Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. <i>Blood</i> , 2013 , 122, 981-7	2.2	173
893	Non-Hodgkin's lymphomas, version 1.2013. 2013 , 11, 257-72; quiz 273		43
892	Treatment of early-stage follicular lymphoma: do as I say, not as I do. 2013 , 2, 1-3		
891	[A case of angioimmunoblastic T-cell lymphoma arising in the cervical region]. 2013 , 116, 1114-9		
890	[Leptomeningeal infiltration of primary CNS B-cell lymphoma diagnosed by the biopsy of cauda equina: a case report]. 2013 , 53, 803-8		4
889	Management of mantle cell lymphoma in the elderly patient. 2013 , 8, 1229-36		9
888	Waldenstrom's macroglobulinemia presenting with lytic bone lesions: a rare presentation. 2013 , 48, 230-3		3
887	Implant-associated anaplastic large cell lymphoma of the breast: Insight into a poorly understood disease. 2013 , 21, 95-8		19
886	Improving but inferior survival in patients with chronic lymphocytic leukemia in taiwan: a population-based study, 1990-2004. 2013 , 8, e62930		15
885	Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone. 2013 , 8, e65156		13
884	Molecular pathology of lymphoma. 738-750		

883 T-cell non-Hodgkin lymphoma. 226-253

882 Influence of NK cell count on the survival of patients with diffuse large B-cell lymphoma treated with R-CHOP. **2014**, 49, 162-9 11

881 Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial Effect in Overcoming Stroma-Mediated Chemotherapy Resistance in Mantle Cell Lymphoma Cells. **2014**, 14, 296-306 10

880 Case series of precursor B-cell lymphoblastic lymphoma. **2014**, 49, 270-4 1

879 Pidilizumab in the treatment of diffuse large B-cell lymphoma. **2014**, 14, 1361-8 19

878 Mantle Cell Lymphoma. **2014**, 1687-1700

877 Emerging drugs for T-cell lymphoma. **2014**, 19, 201-13 3

876 The prognostic value of mid- and post-treatment [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma. **2014**, 28, 805-11 14

875 Value of multidetector computed tomography in the diagnosis of mucosa-associated lymphoid tissue-lymphomas in the parotid gland: A case report and review of the literature. **2014**, 7, 781-786 2

874 MicroRNA and gene networks in human diffuse large B-cell lymphoma. **2014**, 8, 2225-2232 10

873 Prognostic value of bone marrow involvement by clonal immunoglobulin gene rearrangements in follicular lymphoma. **2014**, 67, 1072-7 12

872 A rare case of non-invasive ductal carcinoma of the breast coexisting with follicular lymphoma: A case report with a review of the literature. **2014**, 7, 1001-1006 7

871 Evaluation of a panel of expert pathologists: review of the diagnosis and histological classification of Hodgkin and non-Hodgkin lymphomas in a population-based cancer registry. **2014**, 55, 1018-22 10

870 Impact of karyotype organization on interlocus recombination between T cell receptor genes in Equidae. **2014**, 144, 306-14 1

869 Clinical features of de novo CD25-positive follicular lymphoma. **2014**, 55, 307-13 10

868 Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors. **2014**, 55, 715-7 4

867 Central review of lymphoma diagnosis: still a prerequisite for best patient care in 2014?. **2014**, 55, 973-4

866 Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma. **2014**, 55, 2932-4 9

865	Treatment options for patients with relapsing and refractory peripheral T-cell lymphoma. 2014 , 3, 343-352	
864	The three CARMA sisters: so different, so similar: a portrait of the three CARMA proteins and their involvement in human disorders. 2014 , 229, 990-7	31
863	Prevalence of <i>Achromobacter xylosoxidans</i> in pulmonary mucosa-associated lymphoid tissue lymphoma in different regions of Europe. 2014 , 164, 804-10	40
862	The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. 2014 , 120, 1830-7	26
861	[Pulmonary malt lymphoma]. 2014 , 101, 195-202	1
860	Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis. 2014 , 14, 153	84
859	Therapeutic approaches in patients with newly diagnosed follicular lymphoma. 2014 , 10, 1967-80	3
858	Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. 2014 , 66, 225-33	34
857	TNF- α Receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. 2014 , 38, 1138-46	6
856	TNF- α Expression in tumor cells as a novel prognostic marker for diffuse large B-cell lymphoma, not otherwise specified. 2014 , 38, 228-34	19
855	Clinical significance of MYC expression and/or "high-grade" morphology in non-Burkitt, diffuse aggressive B-cell lymphomas: a SWOG S9704 correlative study. 2014 , 38, 494-501	38
854	Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma. 2014 , 20, 1814-22	32
853	Extranodal natural killer/T-cell lymphoma nasal type: detection by computed tomography features. 2014 , 124, 2670-5	3
852	Rare Lymphomas. 2014 ,	
851	Long-term survey of survival time, histological transformation, and secondary malignancies in Japanese patients with advanced-stage follicular lymphoma in the rituximab era: Hokkaido Hematology Study Group. 2014 , 100, 281-9	8
850	Epigenetic function of activation-induced cytidine deaminase and its link to lymphomagenesis. 2014 , 5, 642	18
849	Primary mediastinal large B-cell lymphoma: Clinical features, prognostic factors and survival with RCHOP in Arab patients in the PET scan era. 2014 , 31, 228-31	3
848	A rare presentation of in situ mantle cell lymphoma and follicular lymphoma: a case report and review of the literature. 2014 , 2014, 145129	5

847	Coexisting mantle cell lymphoma and prostate adenocarcinoma. 2014 , 2014, 247286	6
846	Disruption of chromosomal locus 1p36 differentially modulates TAp73 and Bp73 expression in follicular lymphoma. 2014 , 55, 2924-31	3
845	Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. 2014 , 24, 33-42	57
844	Expression of microRNA-1234 related signal transducer and activator of transcription 3 in patients with diffuse large B-cell lymphoma of activated B-cell like type from high and low infectious disease areas. 2014 , 55, 1158-65	6
843	Arsenic trioxide suppressed mantle cell lymphoma by downregulation of cyclin D1. 2014 , 93, 255-65	11
842	FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis. 2014 , 41, 565-74	109
841	Ibrutinib in B-cell Lymphomas. 2014 , 15, 226-37	13
840	Atlas of Fine Needle Aspiration Cytology. 2014 ,	7
839	Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome. 2014 , 20, 1676-86	34
838	Follicular lymphoma: 2014 update on diagnosis and management. 2014 , 89, 429-36	51
837	Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. <i>Blood</i> , 2014 , 123, 3553-62	2.2 58
836	Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicopathologic and survival outcome analysis of 45 cases according to the primary tumor site. 2014 , 70, 1002-9	33
835	Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. 2014 , 89, 248-61	21
834	Hematopoietic stem cell transplantation for non-Hodgkin lymphoma. 2014 , 28, 1073-95	16
833	Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. 2014 , 120, 1993-9	26
832	Follicular lymphoma grade 3: review and updates. 2014 , 14, 431-5	8
831	Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life. 2014 , 93, 1985-92	6
830	Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. 2014 , 15, 1311-8	199

829	Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells. 2014 , 155, 160-75	113
828	Long-term outcomes of modified Berlin-Frankfurt-Münster-90 regimen in adults with T-lymphoblastic lymphoma: a single-center experience. 2014 , 55, 1800-5	10
827	Clinical aspects of malt lymphomas. 2014 , 9, 262-72	10
826	Rituximab (Rituxan®). 2014 , 1909-2022	
825	Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. 2014 , 4, e220	27
824	Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naïve patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. 2014 , 15, 1019-26	215
823	Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. 2014 , 135, 2834-46	26
822	Interferon alpha with or without rituximab achieves a high response rate and durable responses in relapsed FL: 17 years' experience in a single centre. 2014 , 93, 147-156	4
821	Accelerated therapeutic progress in diffuse large B cell lymphoma. 2014 , 93, 541-56	21
820	The tumour microenvironment in B cell lymphomas. 2014 , 14, 517-34	308
819	Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock. 2014 , 8, 254-8	
818	Quercetin potentiates the antitumor activity of rituximab in diffuse large B-cell lymphoma by inhibiting STAT3 pathway. 2014 , 70, 1357-62	10
817	MALT lymphoma of the small bowel with protein-losing enteropathy. 2014 , 99, 198-201	5
816	Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma. 2014 , 99, 737-42	23
815	Primary B-lymphoblastic lymphoma of gallbladder involving mandibular bone. 2014 , 99, 790-3	6
814	Ocular adnexal lymphomas: report of 2 cases of mantle cell lymphomas and short review of literature. 2014 , 30, 163-8	4
813	Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease. 2014 , 48, 187-95	32
812	Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project. 2014 , 2014, 76-86	27

811	Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma. 2014 , 166, 920-8		11
810	Small intestinal CD4+ T-cell lymphoma is a heterogenous entity with common pathology features. 2014 , 12, 599-608.e1		45
809	Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications. 2014 , 159, 192-201		79
808	Pathology consultation on intermediate-to-large B-cell lymphomas. 2014 , 141, 305-17		6
807	[Malignant lymphoma in a perineural spreading along trigeminal nerve, which developed as trigeminal neuralgia]. 2014 , 54, 660-3		2
806	Non-Hodgkin's lymphomas, version 2.2014. 2014 , 12, 916-46		31
805	Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. 2014 , 99, 125-30		64
804	Simultaneous occurrence of early gastric carcinoma and mucosa-associated lymphoid tissue lymphoma of the omentum. 2014 , 8, 101-6		3
803	Role of radiotherapy in the treatment of primary mediastinal large B-cell lymphoma. 2015 , 10, 2925-2930		5
802	Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. 2015 , 90, 739-45		71
801	The aggressive peripheral T-cell lymphomas: 2015. 2015 , 90, 665-73		16
800	Use of transplantation in lymphoma. 2015 , 23-29		
799	Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma. <i>Blood</i> , 2015 , 125, 82-9	2.2	37
798	Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy. <i>Blood</i> , 2015 , 126, 1407-14	2.2	20
797	Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. 2015 , 13, 326-62		37
796	Ulcerative Colitis Diagnosed in a Patient after Primary Rectal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Treated. 2015 , 24, 123-129		
795	Small Bowel Obstruction Due to MALT Lymphoma: Sonographic Appearance and CT Correlation. 2015 , 31, 173-175		
794	Classification of follicular lymphoma: the effect of computer aid on pathologists grading. 2015 , 15, 115		22

793	Precursor T-lymphoblastic lymphoma: Speedy diagnosis in FNA and effusion cytology by morphology, immunochemistry, and flow cytometry. 2015 , 123, 557-65	17
792	Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial. 2015 , 170, 496-503	30
791	Classification of non-Hodgkin lymphoma in South-eastern Europe: review of 632 cases from the international non-Hodgkin lymphoma classification project. 2015 , 171, 366-72	6
790	Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and Bcl-2 kinase downregulation. 2015 , 26, 974-83	3
789	Role of radiation therapy in primary mediastinal large B-cell lymphoma in rituximab era: A US population-based analysis. 2015 , 90, 1052-4	15
788	Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. 2015 , 90, 790-5	160
787	Computerized image analysis of the Ki-67 proliferation index in mantle cell lymphoma. 2015 , 67, 62-9	11
786	Rituximab maintenance therapy in diffuse large B-cell lymphoma: is XY the most important variable?. 2015 , 100, 853-5	3
785	Diffuse large B cell lymphoma presenting with acute liver failure: a case report. 2015 , 2,	1
784	Current trends in the treatment of primary mediastinal large B-cell lymphoma - an overview. 2015 , 19, 428-35	4
783	Atypical Presentation of Transformed Follicular Lymphoma.. 2015 , 05,	
782	Comparison of Ocular Adnexal Mantle Cell Lymphoma and MALT Lymphoma. 2015 , 56, 815	
781	Molecular Pathogenesis of MALT Lymphoma. 2015 , 2015, 102656	32
780	Radiotherapy Compared to Other Strategies in the Treatment of Stage I/II Follicular Lymphoma: A Study of 404 Patients with a Median Follow-Up of 15 Years. 2015 , 10, e0131158	18
779	Nodal Marginal Zone Large B-Cell Lymphoma with Burkitt Translocation and Complex Chromosomal Changes Associated with Overexpression of BCL2, MYC, and BCL6. 2015 , 55, 175-80	0
778	Evaluation of the role of Epstein-Barr virus in cases of nodal or extranodal T- and NK-cell lymphoma using eber in situ hybridization. 2015 , 66, 161-9	10
777	A primary systemic ALCL present initially as cutaneous localized skin lesions: report of an unusual case. 2015 , 37, e12-4	3
776	Persistent complete remission of acute leukemic-phase CCR4-positive gamma-delta peripheral T-cell lymphoma by autologous stem cell transplantation with mogamulizumab. 2015 , 102, 498-505	5

775	Tumor-associated and immunochemotherapy-dependent long-term alterations of the peripheral blood NK cell compartment in DLBCL patients. 2015 , 4, e990773	20
774	Primary mediastinal large B-cell lymphoma. 2015 , 41, 476-85	30
773	R-CHOP therapy alone for limited-stage follicular lymphoma. 2015 , 39, 582-5	3
772	High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. <i>Blood</i> , 2015 , 126, 604-11	2.2 104
771	Prognostic impact of concordant and discordant bone marrow involvement and cell-of-origin in Korean patients with diffuse large B-cell lymphoma treated with R-CHOP. 2015 , 68, 733-8	12
770	Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study. 2015 , 33, 2492-9	291
769	Discordant mycosis fungoides and cutaneous B-cell lymphoma: A case report and review of the literature. 2015 , 1, 219-21	1
768	Disseminated extranodal marginal zone lymphoma involving the gastrocnemius muscle with sural neurolymphomatosis. 2015 , 94, 1939-40	2
767	Update in large cell lymphoma: understanding the pathology report. 2015 , 2015, 605-17	3
766	LMP1 promotes nasal NK/T-cell lymphoma cell function by eIF4E via NF- κ B pathway. 2015 , 34, 3264-71	14
765	[Extranodal NK/T-cell lymphoma, nasal-type, revealed by cutaneous breast involvement]. 2015 , 142, 104-11	6
764	Topotecan combined with Ifosfamide, Etoposide, and L-asparaginase (TIEL) regimen improves outcomes in aggressive T-cell lymphoma. 2015 , 32, 402	3
763	Clustering of CARMA1 through SH3-GUK domain interactions is required for its activation of NF- κ B signalling. 2015 , 6, 5555	18
762	High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. 2015 , 56, 2379-87	13
761	Classification of non-Hodgkin lymphoma in Algeria according to the World Health Organization classification. 2015 , 56, 965-70	8
760	CD43 expression in diffuse large B-cell lymphoma, not otherwise specified: CD43 is a marker of adverse prognosis. 2015 , 46, 593-9	24
759	Diffuse thyroid 18F-FDG uptake after R-CHOP therapy predicts favorable outcome in patients with DLBCL. 2015 , 94, 995-1001	2
758	CD5-positive follicular lymphoma: clinicopathologic correlations and outcome in 88 cases. 2015 , 28, 787-98	20

757	Prognostic impact of κ microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma. 2015 , 56, 688-93	13
756	Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. 2015 , 2, e326-33	38
755	Advances in the diagnosis and treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma. 2015 , 4, S1-S11	0
754	Surgical Pathology of Liver Tumors. 2015 ,	4
753	Serbian lymphoma study group: demographic characteristics of 257 patients with follicular lymphoma. 2015 , 72, 483-8	1
752	Reticuloendothelial malignancy of head and neck: A comprehensive review. 2015 , 7, S145-57	1
751	Additional survival benefit of involved-lesion radiation therapy after R-CHOP chemotherapy in limited stage diffuse large B-cell lymphoma. 2015 , 92, 91-8	16
750	Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. 2015 , 29, 417-25	45
749	The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. 2015 , 29, 958-67	27
748	MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16. 2015 , 21, 4881-91	42
747	Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma. 2015 , 18, 189-97	24
746	Non-anaplastic peripheral T-cell lymphoma in children and adolescents--a retrospective analysis of the NHL-BFM study group. 2015 , 168, 835-44	31
745	TET1 is a tumor suppressor of hematopoietic malignancy. 2015 , 16, 653-62	139
744	Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. 2015 , 94, 803-12	43
743	Serum profiling by mass spectrometry combined with bioinformatics for the biomarkers discovery in diffuse large B-cell lymphoma. 2015 , 36, 2193-9	7
742	A rare case of anasarca caused by infiltration of the pituitary gland by diffuse large B-cell lymphoma. 2015 , 15, 10	2
741	Inhibition of human diffuse large B-cell lymphoma growth by JC polyomavirus-like particles delivering a suicide gene. 2015 , 13, 29	11
740	Current therapeutic strategies and new treatment paradigms for follicular lymphoma. 2015 , 165, 197-226	9

739	Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation. 2015 , 16, 29	2
738	Novel targeted therapies in diffuse large B-cell lymphoma. 2015 , 52, 126-37	23
737	Molecular Pathogenesis of B Cell Lymphomas. 2015 , 399-416	
736	Clinicopathologic features and management of blastoid variant of mantle cell lymphoma. 2015 , 56, 2759-67	17
735	The biology and management of systemic anaplastic large cell lymphoma. <i>Blood</i> , 2015 , 126, 17-25	2.2 121
734	Patients Older Than 65 Years With Non-Hodgkin Lymphoma Are Suitable for Treatment With (90)Yttrium-Ibritumumab Tiuxetan: A Single-Institution Experience. 2015 , 15, 464-71	7
733	Diffusion-weighted MRI for lymphoma staging--letter. 2015 , 21, 221	1
732	Radical surgery may be not an optimal treatment approach for pulmonary MALT lymphoma. 2015 , 36, 6409-16	10
731	Disease characteristics, treatment patterns, and outcomes of follicular lymphoma in patients 40 years of age and younger: an analysis from the National Lymphocare Study□ 2015 , 26, 2311-7	18
730	Disparities in receipt of radiotherapy and survival by age, sex and ethnicity among patients with stage I diffuse large B-cell lymphoma. 2015 , 56, 983-6	6
729	ALK-positive (2p23 rearranged) anaplastic large cell lymphoma with localization to the skin in a pediatric patient. 2015 , 42, 182-187	20
728	Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings. 2015 , 94, 2025-32	23
727	Chemotherapy and treatment algorithms for follicular lymphoma: a look at all options. 2015 , 15, 1337-49	3
726	Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes. 2015 , 8, 581-93	15
725	Hematologic Malignancies Identified in Patients with Hypereosinophilia and Hypereosinophilic Syndromes. 2015 , 3, 920-5	26
724	Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. 2015 , 50, 1299-305	7
723	Coming of Age: Breast Implant-Associated Anaplastic Large Cell Lymphoma After 18 Years of Investigation. 2015 , 42, 605-13	69
722	Multicenter analysis of treatment outcomes in adult patients with lymphoblastic lymphoma who received hyper-CVAD induction followed by hematopoietic stem cell transplantation. 2015 , 94, 617-25	9

721	Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. 2015 , 33, 113-24	43
720	The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients. 2015 , 33, 145-50	24
719	Allogeneic stem-cell transplantation for peripheral T-cell lymphoma: a systemic review and meta-analysis. 2015 , 133, 136-44	11
718	Tumor suppressors in follicular lymphoma. 2015 , 56, 1981-8	5
717	A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board. 2015 , 15, 59-74	12
716	Bone marrow biopsy in diffuse large B-cell lymphoma: useful or redundant test?. 2015 , 54, 67-72	17
715	Salvage therapy with single agent L-asparaginase followed by local irradiation in an elderly patient with CD56-positive primary isolated extramedullary T-cell lymphoblastic lymphoma of the sinus. 2015 , 94, 173-5	1
714	Precursor B cell lymphoblastic lymphoma presenting as periorbital swelling. 2016 , 2016,	2
713	Early, Isolated Duodenal Mucosa-Associated Lymphoid Tissue Lymphoma Presenting without Symptoms or Grossly Apparent Endoscopic Lesions and Diagnosed by Random Duodenal Biopsies. 2016 , 10, 323-31	1
712	Patologia sistemica da virus dell'epatite C: la crioglobulinemia mista e altre manifestazioni extraepatiche. 2016 , 4, 1	
711	Clinical Outcomes after Allogeneic Stem Cell Transplantation for Adult Lymphoblastic Lymphoma. 2016 , 56, 28-33	4
710	The DDGP (cisplatin, dexamethasone, gemcitabine, and pegaspargase) regimen for treatment of extranodal natural killer (NK)/T-cell lymphoma, nasal type. 2016 , 7, 58396-58404	12
709	Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients. 2016 , 31, 1160-3	6
708	EBV-Related Malignancies, Outcomes and Novel Prevention Strategies. 2016 , 16, 4-21	14
707	The Comparative Diagnostic Features of Canine and Human Lymphoma. 2016 , 3,	36
706	Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China. 2016 , 5, 185-91	98
705	Highly Diverse Efficacy of Salvage Treatment Regimens for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review. 2016 , 11, e0161811	7
704	Idiotypic vaccination for Non-Hodgkin lymphoma. 2016 ,	

703	Comparative histopathologic analysis of cutaneous extranodal natural killer/T-cell lymphomas according to their clinical morphology. 2016 , 43, 324-33	6
702	Grading of follicular lymphoma in cytological samples. 2016 , 27, 390-397	1
701	Clinical approach to diffuse large B cell lymphoma. 2016 , 30, 477-491	19
700	A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy. 2016 , 174, 571-81	33
699	Rare Posterior Pharyngeal Mass: Atypical Marginal Zone Hyperplasia. 2016 , 38, 152-4	1
698	CT, MRI, and 18F-FDG PET/CT Findings in Untreated Pulmonary and Hepatic B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Over a Five-Year Period: A Case Report. 2016 , 95, e3197	7
697	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. 2016 , 173, 274-82	11
696	ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma. 2016 , 12, 1553-63	66
695	NK Cell Activation in the Antitumor Response Induced by IFN- γ -Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients. 2016 , 197, 795-806	18
694	Relative frequency of non-Hodgkin lymphoma subtypes in selected centres in North Africa, the middle east and India: a review of 971 cases. 2016 , 172, 699-708	6
693	Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era. 2016 , 172, 724-34	27
692	NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016. 2016 , 14, 1067-79	80
691	Clinical and histopathological evaluation of 16 dogs with T-zone lymphoma. 2016 , 78, 1237-44	25
690	Multifocal Gastric Ulcers Caused by Diffuse Large B Cell Lymphoma in a Patient With Significant Weight Loss. 2016 , 4, 2324709616683721	
689	A Case Series of diffuse large B-cell lymphoma and burkitt lymphoma presenting with peritoneal lymphomatosis. 2016 , 28, 262-265	7
688	T-cell Lymphoma Epidemiology: the Known and Unknown. 2016 , 11, 492-503	25
687	Prognostic factors in follicular lymphoma: new tools to personalize risk. 2016 , 2016, 269-276	4
686	Therapeutic Potential of Resveratrol in Lymphoid Malignancies. 2016 , 68, 365-73	12

685	Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease. 2016 , 101, e207-10			1
684	Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. 2016 , 22, 1440-1448			36
683	The Expanding Spectrum of Follicular Lymphoma. 2016 , 9, 29-40			1
682	FDG-PET imaging in hematological malignancies. 2016 , 30, 317-31			27
681	Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas. 2016 , 21, 536-41			9
680	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets. 2016 , 57, 1991-2013			17
679	Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04). 2016 , 103, 676-85			3
678	Idelalisib for treatment of B-cell malignancies. 2016 , 73, 547-55			14
677	Elevated RNA expression of long non-coding HOTAIR promotes cell proliferation and predicts a poor prognosis in patients with diffuse large B cell lymphoma. 2016 , 13, 5125-31			51
676	Is watch and wait still acceptable for patients with low-grade follicular lymphoma?. <i>Blood</i> , 2016 , 127, 2804-8	2.2		22
675	The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. <i>Blood</i> , 2016 , 127, 2082-92	2.2		150
674	Radiotherapy for Non-Hodgkin's lymphoma: still standard practice and not an outdated treatment option. 2016 , 11, 110			17
673	Inflammatory myopathies and lymphoma. 2016 , 369, 377-389			9
672	Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. 2016 , 101, 1244-1250			87
671	The burden of non-Hodgkin lymphoma in Central and South America. 2016 , 44 Suppl 1, S168-S177			13
670	Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. 2016 , 57, 2874-2889			1
669	Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (B Cell). 2016 , 692-705			
668	Hematopoietic Cell Transplantation for Non'Hodgkin Lymphoma (T Cell). 2016 , 703-716			

667	90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years. 2016 , 5, 1093-7	14
666	Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. 2016 , 7, 567-576	60
665	Cutaneous peripheral T-cell lymphoma, not otherwise specified: A single-center prognostic analysis. 2016 , 75, 992-999	16
664	Cutaneous mantle cell lymphoma: a clinicopathologic review of 10 cases. 2016 , 43, 1112-1120	8
663	Detection of the value of consecutive serum total light chain (sTLC) in patients diagnosed with diffuse large B cell lymphoma. 2016 , 95, 1999-2007	0
662	Gastrointestinal follicular lymphoma: using primary site as a predictor of survival. 2016 , 5, 2669-2677	13
661	Composite lymphoma with diffuse large B-cell lymphoma and classical Hodgkin lymphoma components: A case report and review of the literature. 2016 , 212, 1179-1190	7
660	Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. 2016 , 12, 2782-2788	5
659	Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases. 2016 , 11, 514-527	94
658	Collision tumor consisting of primary follicular lymphoma and adenocarcinoma in the cecum: A case report and literature review. 2016 , 11, 2801-2805	11
657	CD10 down expression in follicular lymphoma correlates with gastrointestinal lesion involving the stomach and large intestine. 2016 , 107, 1687-1695	10
656	An unusual presentation of gastric mucosa-associated lymphoid tissue (MALT)-type lymphoma. 2016 , 6, 31707	2
655	Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. 2016 , 12, 1759-68	14
654	Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project. 2016 , 172, 716-23	12
653	Long-term complication in follicular lymphoma: assessing the risk of secondary neoplasm in 242 patients treated or not with 90-yttrium-ibritumomab-tiuxetan. 2016 , 97, 576-582	7
652	Clinical management of HIV-associated hematologic malignancies. 2016 , 9, 361-76	7
651	Pulmonary mucosa-associated lymphoid tissue lymphoma revisited. 2016 , 47, 1244-60	37
650	Subtype distribution of lymphomas in South of Iran, analysis of 1085 cases based on World Health Organization classification. 2016 , 95, 613-8	8

649	Genetic polymorphisms in the DNA repair gene, XRCC1 associate with non-Hodgkin lymphoma susceptibility: A systematic review and meta-analysis. 2016 , 59, 91-103	7
648	Autologous and allogeneic hematopoietic stem cell transplantation in follicular lymphoma. 2016 , 16, 57-66	8
647	Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project. 2016 , 95, 245-51	25
646	How to select the frontline treatment for a patient with peripheral T-cell lymphoma. 2016 , 57, 783-8	4
645	Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India. 2016 , 32, 182-5	
644	Differentiation of Diffuse Large B-cell Lymphoma From Follicular Lymphoma Using Texture Analysis on Conventional MR Images at 3.0 Tesla. 2016 , 23, 696-703	19
643	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. 2016 , 17, 319-331	103
642	Molecular subtyping of diffuse large B-cell lymphoma: update on biology, diagnosis and emerging platforms for practising pathologists. 2016 , 48, 5-16	7
641	Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma. 2016 , 16, 175-81	23
640	Allogeneic hematopoietic cell transplantation as curative therapy for non-transformed follicular lymphomas. 2016 , 51, 654-62	8
639	Mantle cell lymphoma with multiple lymphomatous polyposis and intussusception: A case report. 2016 , 11, 654-656	3
638	High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. 2016 , 42, 1-6	34
637	Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy. 2016 , 9, 471-7	10
636	Activation of the Constitutive Androstane Receptor Increases the Therapeutic Index of CHOP in Lymphoma Treatment. 2016 , 15, 392-401	12
635	HIV-associated Hematological Malignancies. 2016 ,	4
634	The Impact of DNA Methylation in Hematopoietic Malignancies. 2016 , 2, 70-83	48
633	B-cell Non-Hodgkin Lymphomas with Plasmacytic Differentiation. 2016 , 9, 11-28	9
632	Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. 2016 , 30, 1062-70	73

631	Refractory celiac disease. 2016 , 10, 537-46	20
630	Elucidation and Pharmacological Targeting of Novel Molecular Drivers of Follicular Lymphoma Progression. 2016 , 76, 664-74	35
629	Clinicopathologic features, management and outcomes of blastoid variant of mantle cell lymphoma: a Nebraska Lymphoma Study Group Experience. 2016 , 57, 1327-34	13
628	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. 2016 , 22, 380-385	28
627	Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?. 2016 , 30, 89-100	40
626	A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. 2016 , 57, 604-8	11
625	Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report. 2017 , 23, 235-239	4
624	Stem cell transplantation outcomes in lymphoblastic lymphoma. 2017 , 58, 366-371	8
623	Non-Hodgkin lymphoma in Romania: a single-centre experience. 2017 , 35, 198-205	5
622	Cutaneous Extranodal Natural Killer/T-Cell Lymphomas Histopathologically Mimicking Benign Inflammatory Disease. 2017 , 39, 171-176	5
621	Estrogen receptor β in diffuse large B-cell lymphoma growth and as a prognostic biomarker. 2017 , 58, 418-427	11
620	Characteristics and outcomes of lymphoblastic lymphoma - the University of Miami experience. 2017 , 58, 195-198	
619	Epidemiology and environmental aspects of marginal zone lymphomas. 2017 , 30, 84-91	20
618	Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. 2017 , 10, 239-249	60
617	Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma. 2017 , 31, 239-253	27
616	Clinical aspects and therapy of gastrointestinal MALT lymphoma. 2017 , 30, 109-117	31
615	Diagnosis and treatment of CD20 negative B cell lymphomas. 2017 , 5, 5	9
614	Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma. 2017 , 92, 448-453	20

613	Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. <i>Blood</i> , 2017 , 130, 310-322	2.2	66
612	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. <i>Blood</i> , 2017 , 129, 2224-2232	2.2	184
611	18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation. 2017 , 58, 2328-2334		28
610	Expression of programmed death-1 in cutaneous extranodal natural killer/T-cell lymphoma and its effect on clinical findings and biological behaviour. 2017 , 31, 821-827		6
609	Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. 2017 , 10, 99-115		12
608	Unmet needs in the first-line treatment of follicular lymphoma. 2017 , 28, 2094-2106		26
607	Prognostic Value of the Pretreatment Advanced Lung Cancer Inflammation Index (ALI) in Diffuse Large B Cell Lymphoma Patients Treated with R-CHOP Chemotherapy. 2017 , 137, 76-85		28
606	Can histologic transformation of follicular lymphoma be predicted and prevented?. <i>Blood</i> , 2017 , 130, 258-266	2.2	32
605	Co-delivery of vincristine and quercetin by nanocarriers for lymphoma combination chemotherapy. 2017 , 91, 287-294		43
604	The Lymphomas. 2017 , 775-804		
603	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features. 2017 , 41, 1322-1332		18
602	Follicular lymphomas and their transformation: Past and current research. 2017 , 10, 515-524		8
601	Lymphoma of the eyelid. 2017 , 62, 312-331		20
600	A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. 2017 , 123, 1174-1183		33
599	The aggressive peripheral T-cell lymphomas: 2017. 2017 , 92, 706-715		47
598	Mechanisms of Molecular Carcinogenesis □Volume 2. 2017 ,		1
597	LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. 2017 , 41, 877-886		13
596	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 1.2017. 2017 , 15, 293-311		49

595	Lymphoproliferative Disorders of the Lung. 2017 , 94, 157-175		32
594	Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?. 2017 , 52, 1487-1494		12
593	Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy. <i>Blood</i> , 2017 , 129, 3037-3039	2.2	57
592	Autologous and Allogeneic Hematopoietic Cell Transplantation in Peripheral T/NK-cell Lymphomas: A Histology-Specific Review. 2017 , 31, 335-357		8
591	Rare T Cell Lymphomas. 2017 , 830-839		
590	3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro. 2017 , 17, 407-414		46
589	Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone. 2017 , 96, 253-259		15
588	Constitutive activation of alternative nuclear factor kappa B pathway in canine diffuse large B-cell lymphoma contributes to tumor cell survival and is a target of new adjuvant therapies. 2017 , 58, 1702-1710		5
587	T-Cell Lymphoma: Recent Advances in Characterization and New Opportunities for Treatment. 2017 , 109,		21
586	Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. 2017 , 96, 405-410		11
585	RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. 2017 , 176, 759-769		26
584	Maintenance therapy following induction chemoimmunotherapy in patients with diffuse large B-cell lymphoma: current perspective. 2017 , 28, 2680-2690		10
583	A novel overlapped nuclei splitting algorithm for histopathological images. 2017 , 151, 57-70		4
582	Radiation Therapy in Mantle Cell Lymphoma. 2017 , 1-14		
581	The inhibitory effect of MEG3/miR-214/AIFM2 axis on the growth of T-cell lymphoblastic lymphoma. 2017 , 51, 316-326		26
580	Epstein-Barr virus (EBV) provides survival factors to EBV diffuse large B-cell lymphoma (DLBCL) lines and modulates cytokine induced specific chemotaxis in EBV DLBCL. 2017 , 152, 562-573		11
579	Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy. 2017 , 17, 488-497.e2		7
578	Breast implant-associated anaplastic large cell lymphoma: A review and assessment of cutaneous manifestations. 2017 , 3, 140-144		11

577	Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management. 2017 , 92, 806-813	111
576	Perioperative Considerations for Chylothorax. 2017 , 31, 2277-2281	
575	The Search for Surrogate Endpoints in Trials in Diffuse Large B-Cell Lymphoma: The Surrogate Endpoints for Aggressive Lymphoma Project. 2017 , 22, 1415-1418	5
574	Targeting the T cell receptor β chain constant region for immunotherapy of T cell malignancies. 2017 , 23, 1416-1423	112
573	Speaker Presentations. 2017 , 61, S1-S14	
572	Prognostic value of lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte ratio in follicular lymphoma: a retrospective cohort study. 2017 , 7, e017904	17
571	Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma. 2017 , 102, 2104-2112	34
570	Risk of Second Primary Malignancies in Patients With Follicular Lymphoma: A United States Population-based Study. 2017 , 17, 569-574	17
569	Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). 2017 , 28, 2185-2190	22
568	A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China. 2017 , 35, 619-629	15
567	Transformation of marginal zone lymphoma (and association with other lymphomas). 2017 , 30, 131-138	17
566	Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). 2017 , 70, 585-621	32
565	Marginal zone lymphoma in elderly and geriatric patients. 2017 , 30, 158-165	7
564	Primary pituitary diffuse large B-cell lymphoma with somatotroph hyperplasia and acromegaly: case report. 2017 , 126, 1725-1730	11
563	Long-term outcome for patients with early stage marginal zone lymphoma and mantle cell lymphoma. 2017 , 58, 623-632	5
562	Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement. 2017 , 58, 996-998	10
561	Waldenström Macroglobulinemia. 2017 ,	
560	Waldenström Macroglobulinaemia: Pathological Features and Diagnostic Assessment. 2017 , 3-19	

559	Epidemiology of Hematologic Malignancies. 2017 , 543-569	7
558	Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma. 2017 , 12, 63-82	10
557	18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. 2017 , 44, 589-597	38
556	Different predictive values of interim F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma. 2017 , 31, 1-11	7
555	Primary Mediastinal Large B-cell Lymphoma Presenting as a Bulky Anterior Mediastinal Tumor: A Case Report. 2017 , 66, 86-90	
554	Interim F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma. 2017 , 14, 6715-6723	6
553	Hematopoietic Cell Transplants for Hodgkin Lymphoma. 361-371	
552	Hematopoietic Cell Transplants for Mantle Cell Lymphoma. 402-416	
551	High-Grade B-Cell Neoplasm with Surface Light Chain Restriction and Tdt Coexpression Evolved in a -Rearranged Diffuse Large B-Cell Lymphoma: A Dilemma in Classification. 2017 , 2017, 6891957	7
550	Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients. 2017 , 2017, 7960907	2
549	T-Cell Non-Hodgkin Lymphomas: Spectrum of Disease and the Role of Imaging in the Management of Common Subtypes. 2017 , 18, 71-83	10
548	An essential EBV latent antigen 3C binds Bcl6 for targeted degradation and cell proliferation. 2017 , 13, e1006500	20
547	The role of B cell antigen receptors in mantle cell lymphoma. 2017 , 10, 164	12
546	Lymphoblastic lymphoma of the palate. 2017 , 30, 445-446	
545	Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. 2017 , 6, 169-184	66
544	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. 2017 , 35, 2008-2017	98
543	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. 2017 , 35, 2473-2481	106
542	Prognostic value of pretreatment plasma D-dimer levels in patients with diffuse large B cell lymphoma (DLBCL). 2018 , 482, 191-198	11

541	Malignant lymphoma in the HIV-positive patient. 2018 , 101, 119-126	15
540	Transient antagonism of anti-CD20 monoclonal antibodies and PI3K inhibitor idelalisib in DLBCL cell lines. 2018 , 101, 143	1
539	Retrospective analysis of frontline treatment efficacy in elderly patients with diffuse large B-cell lymphoma. 2018 , 101, 28-37	4
538	Pathology of Non-Hodgkin and Hodgkin Lymphomas. 2018 , 773-826	
537	Non-Hodgkin Lymphoma in Adults. 2018 , 444-462	
536	Watch-and-wait policy versus rituximab-combined chemotherapy in Japanese patients with intestinal follicular lymphoma. 2018 , 33, 1461-1468	16
535	Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study. 2018 , 23, 454-460	13
534	Association of Soluble Interleukin-2 Receptor and C-Reactive Protein with the Efficacy of Bendamustine Salvage Treatment for Indolent Lymphomas and Mantle Cell Lymphoma. 2018 , 139, 12-18	4
533	Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes. 2018 , 36, 533	4
532	Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors. 2018 , 26, 3321-3344	11
531	Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2. 2018 , 103, 1182-1190	15
530	Hepatic Lymphoma Diagnosis. 2018 , 11, 389-402	11
529	Immunology of the Lymphomas. 2018 , 827-852	
528	Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. 2018 , 20, 33	10
527	Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study. 2018 , 36, 159-165	6
526	Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. 2018 , 36, 28-36	17
525	Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. 2018 , 181, 561-564	4
524	Risk stratification of diffuse large B-cell lymphoma with interim PET-CT based on different cutoff Deauville scores. 2018 , 59, 340-347	15

523	Extranodal Marginal Zone Lymphoma of the Central Nervous System. 2018 , 18, 34-37.e8	22
522	ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population. 2018 , 97, 149-159	1
521	Management of untreated advanced stage follicular lymphoma: Role of patient discernment. 2018 , 31, 23-30	1
520	PET/CT for Lymphoma Post-therapy Response Assessment in Other Lymphomas, Response Assessment for Autologous Stem Cell Transplant, and Lymphoma Follow-up. 2018 , 48, 37-49	18
519	Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. 2018 , 18, e103-e108	2
518	FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy. <i>Blood</i> , 2018 , 131, 226-235	2.2 19
517	Small Bowel Obstruction Secondary to Ileal Mucosa-Associated Lymphoid Tissue Lymphoma. 2018 , 49, 207-210	2
516	Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma. 2018 , 59, 670-678	3
515	Comparison of protein-based cell-of-origin classification to the Lymph2Cx RNA assay in a cohort of diffuse large B-cell lymphomas in Malaysia. 2018 , 71, 215-220	9
514	Prognostic impact of germinal center B-cell-like and non-germinal center B-cell-like subtypes of bone marrow involvement in patients with diffuse large B-cell lymphoma treated with R-CHOP. 2018 , 97, e13046	10
513	Hematopoietic Neoplasia. 2018 , 363-395	
512	Secondary skin involvement in gastric diffuse large B-cell lymphoma treated with chidamide: A case report. 2018 , 97, e13093	3
511	Review of Hematopathology Consult Cases: A Two-Year Experience in a Tertiary Referral Center in Lebanon. 2018 , 2018, 3028625	1
510	Rituximab Maintenance Therapy and Bendamustine Containing Treatments may improve the Survival of Mantle Cell Lymphoma: Retrospective Analysis in Single Institute. 2018 , 08,	
509	Diffuse Aggressive B-Cell Lymphomas. 2018 , 271-305.e5	
508	Metabolic Reprogramming of Non-Hodgkin's B-Cell Lymphomas and Potential Therapeutic Strategies. 2018 , 8, 556	25
507	An evaluation of pixantrone for the treatment of non-Hodgkin's lymphoma. 2018 , 19, 1829-1834	2
506	Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification. 2018 , 7, 5843-5858	26

505	Novel Immunotherapies for T Cell Lymphoma and Leukemia. 2018 , 13, 494-506	16
504	Leptin and its receptor in glucose metabolism of T-cell lymphoma. 2018 , 16, 5838-5846	5
503	KRAS mutation in secondary malignant histiocytosis arising from low grade follicular lymphoma. 2018 , 13, 78	12
502	A Preliminary Study on Metadherin as a Potential Marker for Progression of Diffuse Large B Cell Lymphoma. 2018 , 22, 481-486	2
501	Follicular Lymphoma Diagnostic Caveats and Updates. 2018 , 142, 1330-1340	21
500	De Novo CD5-Positive Primary Gastric Diffuse Large B-Cell Lymphoma Coexpressing MYC and BCL6: Towards a Proper Subset of Double-Hit, Triple-Hit and, Maybe, Quadruple-Hit B-Cell Lymphomas?. 2018 , 54, 80-82	1
499	MEF2B Instructs Germinal Center Development and Acts as an Oncogene in B Cell Lymphomagenesis. 2018 , 34, 453-465.e9	35
498	Outcome and Prospective Factor Analysis of High-dose Therapy Combined with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Peripheral T-cell Lymphomas. 2018 , 15, 867-874	7
497	Uptake of [F]fluorodeoxyglucose in initial positron-emission tomography predicts survival in MALT lymphoma. 2018 , 2, 649-655	15
496	A prognostic model, including the EBV status of tumor cells, for primary gastric diffuse large B-cell lymphoma in the rituximab era. 2018 , 7, 3510	19
495	Historical Landmarks in an Understanding of the Lymphomas. 2018 , 675-721	1
494	Primary Diffuse Large B Cell Lymphoma Mimicking Hyperplastic Reactive Lesion (Lymphoma of the Oral Cavity). 2018 , 2018, 2981689	1
493	3D in vitro microvascular model-based lymphoma model. 2018 , 146, 149-158	2
492	Breast Implant-Associated Anaplastic Large Cell Lymphoma: Case Report and Review of the Literature. 2018 , 2018, 2414278	18
491	Diagnosis and Treatment of Non-Hodgkin Lymphoma of Adults. 2018 , 951-973	
490	Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib. 2018 , 10, 615-624	13
489	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?. 2018 , 11, 749-756	6
488	Oral lymphoma: a case series. 2018 , 45, 641-644	

487	Marginal Zone Lymphomas (Extranodal/Malt, Splenic, and Nodal). 2018 , 1277-1287.e6	
486	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. 2018 , 11, 87	8
485	Migratory polyarthrititis as a paraneoplastic syndrome in a patient with diffuse large B cell lymphoma: a case report. 2018 , 12, 189	2
484	Primary extra-nodal diffuse large B-cell lymphoma: A prognostic analysis of 141 patients. 2018 , 16, 1602-1614	16
483	Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. 2018 , 108, 499-509	6
482	Diagnosis of Superficial Gastric Lesions Together with Six Gastric Lymphoma Cases via Probe-Based Confocal Laser Endomicroscopy: A Retrospective Observational Study. 2018 , 2018, 5073182	3
481	Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. 2018 , 183, 385-399	11
480	Long non-coding RNAs expression levels in diffuse large B-cell lymphoma: An in silico analysis. 2018 , 214, 1462-1466	11
479	Comprehensive histopathological diagnostics of aggressive B-cell lymphomas based on the updated criteria of the World Health Organisation's 2017 classification. 2018 , 69, 1-19	5
478	Clinical characteristics and prognostic significance of EBER positivity in diffuse large B-cell lymphoma: A meta-analysis. 2018 , 13, e0199398	14
477	Pathogenesis of Enteropathy-Associated T Cell Lymphoma. 2018 , 13, 308-317	33
476	Novel prognostic index based on hemoglobin level and platelet count for diffuse large B-cell lymphoma, not otherwise specified in the R-CHOP era. 2019 , 30, 637-645	6
475	Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. 2019 , 60, 133-141	8
474	Orbital lymphoma. 2019 , 64, 45-66	81
473	HIV-triggered lymphoma. 2019 , 12, 230-234	0
472	Primary Mediastinal Large B-Cell Lymphoma: A Review for Radiologists. 2019 , 213, W194-W210	4
471	Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. 2019 , 12, 833-843	9
470	A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02). 2019 , 60, 677-684	3

469	Pixantrone beyond monotherapy: a review. 2019 , 98, 2025-2033	4
468	Quantitative proteomic analysis of cerebrospinal fluid from patients with diffuse large B-cell lymphoma with central nervous system involvement: A novel approach to diagnosis. 2019 , 11, 70-78	1
467	Mantle cell lymphoma pathology update in the 2016 WHO classification. 2019 , 3, 3-3	6
466	Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study. 2019 , 37, 2815-2824	93
465	Are Higher Doses of Consolidation Radiation Therapy Necessary in Diffuse Large B-cell Lymphoma Involving Osseous Sites?. 2019 , 4, 507-512	0
464	The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores. 2019 , 110, 438-446	4
463	Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. 2019 , 41, 2357-2379.e1	10
462	Novel Aurora Kinase Inhibitor-Based Combination Therapies for PTCL. 2019 ,	
461	Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. 2019 , 37, 578-585	10
460	Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. 2019 , 39, 58	6
459	Gastric MALT lymphoma refractory to antibiotic therapy. 2019 , 7, 2050313X19869473	
458	Classification of malignant lymphoma subtypes in Korean patients: a report of the 4th nationwide study. 2019 , 12, 173-181	5
457	Resistance to Targeted Therapies in Lymphomas. 2019 ,	
456	Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. 2019 , 19, e616-e623	1
455	Prognostic significance of DAPK promoter methylation in lymphoma: A meta-analysis. 2019 , 14, e0210943	1
454	[Clinical Efficacy of Radiotherapy in Negative or Unresponsive to Eradication Therapy Primary Gastric Mucosa-Associated Lymphoid Tissue Lymphoma]. 2019 , 73, 19-25	1
453	Utility of a Simple and Robust Flow Cytometry Assay for Rapid Clonality Testing in Mature Peripheral T-Cell Lymphomas. 2019 , 151, 494-503	15
452	JSH practical guidelines for hematological malignancies, 2018: 7. Peripheral T-cell lymphoma (PTCL). 2019 , 109, 137-140	6

451	Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study. 2019 , 19, e172-e183	7
450	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. 2019 , 17, 12-20	28
449	Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate. 2019 , 60, 2927-2930	5
448	C-X-C Chemokine Receptor 4 in Diffuse Large B Cell Lymphoma: Achievements and Challenges. 2019 , 142, 64-70	6
447	Treatment-associated outcomes of patients with primary ocular adnexal MALT lymphoma after accurate diagnosis. 2019 , 24, 1620-1628	1
446	CD30 large B cell lymphoma with anaplastic features and complete loss of B cell marker expression arising from follicular lymphoma. 2019 , 75, 602-605	2
445	Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. 2019 , 39, 2591-2598	
444	Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma. 2019 , 167-183	0
443	Diffuse large B cell lymphoma primarily presenting as acute liver failure in a surviving patient. 2019 , 9, 135-139	5
442	Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B-cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3. 2019 , 17, 3719-3726	8
441	Intracranial Cell Lymphomas That Mimic Meningiomas: Case Report To Understand Complex Genetic, Radiologic, and Histopathologic Entities. 2019 , 125, 339-342	1
440	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. 2019 , 94, 658-666	9
439	Stratification of Follicular Lymphoma: Time for a Paradigm Shift?. 2019 , 151, 539-541	2
438	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. 2019 , 37, 1188-1199	165
437	Turning Point in the Treatment of Mantle Cell Lymphoma. 2019 , 62, 1-7	1
436	Lenalidomide plus rituximab (R) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial. 2019 , 185, 874-882	24
435	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. 2019 , 60, 2432-2440	2
434	Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma. 2019 , 19, 322	6

433	The Utility of Phosphohistone H3 (PHH3) in Follicular Lymphoma Grading: A Comparative Study With Ki-67 and H&E Mitotic Count. 2019 , 151, 542-550	6
432	New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination. 2019 , 12, 137-146	7
431	Enfermedades linfoproliferativas pulmonares. 2019 , 23, 1-11	
430	COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study. 2019 , 3, 2013-2021	19
429	Primary extranodal jejunal diffuse large B cell lymphoma as a diagnostic challenge for intractable emesis: a case report and review of literature. 2019 , 9, 518-523	1
428	Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. 2019 , 12, 141	37
427	18F-FDG PET/CT for staging and response assessment of primary parotid MALT lymphoma with multiple sites involvement: A case report. 2019 , 98, e14270	1
426	Mantle cell lymphoma in patients not eligible for autologous stem cell transplantation. 2019 , 31, 374-379	2
425	Primary hepatic mucosa-associated lymphoid tissue lymphoma: A case report and literature review. 2019 , 98, e15034	8
424	Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016: An observational study. 2019 , 98, e17641	3
423	Mucosa-associated lymphoid tissue lymphoma with metachronous involvement of the palpebral conjunctiva and bronchus: A case report. 2019 , 26, 101-104	
422	Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995-2013: Findings from Texas and national SEER areas. 2019 , 58, 89-97	4
421	Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release. 2019 , 295, 21-30	31
420	Diagnostic and Therapeutic Implications of Pulmonary Lymphoma Associated With Nodular Amyloidosis. 2019 , 107, e325-e327	
419	Lymph Nodes. 2019 , 287-361	
418	Clinical presentation and characteristics of lymphoma in the head and neck region. 2019 , 15, 1	33
417	Moving to a higher echelon in CD30-positive T-cell lymphoma. 2019 , 393, 201-202	0
416	Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study. 2019 , 60, 1656-1667	11

415	Prognostic analysis of interim F-FDG PET/CT in patients with diffuse large B cell lymphoma after one cycle versus two cycles of chemotherapy. 2019 , 46, 478-488	11
414	Validation of the Marginal Zone Lymphoma International Prognostic Index. 2019 , 98, 457-464	7
413	Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. 2019 , 25, 69-74	18
412	Outcomes of myeloablative peripheral blood stem cell transplantation for non-complete remission patients with relapsed/refractory peripheral T cell lymphomas. 2019 , 98, 1237-1247	5
411	Automatic method for assessment of proliferation index in digital images of DLBCL tissue section. 2019 , 39, 30-37	5
410	The effect of high-dose cytarabine followed by autologous hematopoietic stem cell transplantation on the outcome of patients with mantle cell lymphoma. 2020 , 26, 273-278	1
409	Clinical significance of 'double-hit' and 'double-expression' lymphomas. 2020 , 73, 126-138	8
408	Breast implant-associated anaplastic large cell lymphoma: A rare case report of lymphoma in the form of a pericapsular solid formation. 2020 , 26, 247-251	1
407	A novel proximity graph: Circular neighborhood cell graph for histopathological tissue image analyzing. 2020 , 30, 311-326	
406	Double or triple-expressor lymphomas: prognostic impact of immunohistochemistry in patients with diffuse large B-cell lymphoma. 2020 , 42, 192-193	3
405	Costs associated with follicular lymphoma among individuals diagnosed with non-Hodgkin lymphoma: a longitudinal analysis using SEER-Medicare data. 2020 , 61, 75-83	1
404	Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis. 2020 , 36, 71-77	3
403	Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT. 2020 , 55, 796-803	5
402	CD20-positive primary nasal peripheral T-cell lymphoma: An analysis of one case and review of the literature. 2020 , 98, 348-354	0
401	Atlas of Cytopathology and Radiology. 2020 ,	
400	Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma. 2020 , 14, e1900091	7
399	Novel Therapeutics for Rare Lymphomas. 2020 ,	0
398	OSdlbcl: An online consensus survival analysis web server based on gene expression profiles of diffuse large B-cell lymphoma. 2020 , 9, 1790-1797	7

397	Prognostic Value of Bone Marrow F-18 FDG Uptake in Patients with Advanced-Stage Diffuse Large B-Cell Lymphoma. 2020 , 54, 28-34	2
396	PET/CT in Disease Detection and Follow-up of Subcutaneous Involvement in Marginal Zone Lymphoma. 2020 , 20, 252-259	
395	Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue in the oromaxillofacial head and neck region: A retrospective analysis of 105 patients. 2020 , 9, 194-203	8
394	High-dose therapy and autologous stem cell transplantation for relapsed or high-risk diffuse large B-cell lymphoma: a nationwide survey. 2020 , 111, 256-266	5
393	Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. 2020 , 295, 1165-1180	12
392	Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. 2020 , 88, 106286	0
391	The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management. 2020 , 70, 47-70	22
390	High pretreatment plasma Epstein-Barr virus (EBV) DNA level is a poor prognostic marker in HIV-associated, EBV-negative diffuse large B-cell lymphoma in Malawi. 2020 , 9, 552-561	7
389	Using the primary site as a prognostic tool for nodal mantle cell lymphoma: a SEER-based study. 2020 , 9, 861-876	0
388	Chemotherapy combined with radiotherapy for successful treatment of angioimmunoblastic T-cell lymphoma: a case report. 2020 , 14, 185	1
387	A case of "double hit" mantle cell lymphoma carrying CCND1 and MYC translocations relapsed/refractory to rituximab bendamustine cytarabine (R-BAC) and ibrutinib. 2020 , 99, 2715-2717	1
386	Primary bladder mucosa-associated lymphoid tissue lymphoma: A case report and literature review. 2020 , 99, e20825	5
385	Educational Case: Mantle Cell Lymphoma. 2020 , 7, 2374289520932286	
384	The Expression of IgG and IgG4 in Orbital MALT Lymphoma: The Similarities and Differences of IgG4-Related Diseases. 2020 , 13, 5755-5761	0
383	Genetic and epigenetic determinants of diffuse large B-cell lymphoma. 2020 , 10, 123	22
382	Dramatic radiotherapy response in a necrotic lymphoma mass: a case report. 2020 , 14, 118	
381	Follicular Lymphoma and Mantle Cell Lymphoma. 2020 ,	
380	Unusual Case of Anaplastic Large Cell Lymphoma Presenting as a Breast Mass in a Patient with no History of Breast Implants. 2020 , 2020, 7543836	2

379	Increased Serum Level of Interleukin-10 Predicts Poor Survival and Early Recurrence in Patients With Peripheral T-Cell Lymphomas. 2020 , 10, 584261	4
378	The spectrum of pathological diagnoses in non-sentinel axillary lymph node biopsy: A single institution's experience. 2020 , 49, 151646	
377	Time to Next Treatment, Health Care Resource Utilization, and Costs Associated with Ibrutinib Use Among U.S. Veterans with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Analysis. 2020 , 26, 1266-1275	1
376	Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma. 2020 , 24, 392-398	6
375	Reply to M. Hertzberg et al. 2020 , 38, 3723-3724	
374	DA-EPOCH-R in Burkitt Lymphoma: Is It Enough for High-Risk Disease?. 2020 , 38, 3722-3723	1
373	Linking Immuno-evasion and Metabolic Reprogramming in B-Cell-Derived Lymphomas. 2020 , 10, 594782	3
372	Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life. 2020 , 99, 1595-1604	8
371	Chimeric antigen receptor therapy in hematological malignancies: antigenic targets and their clinical research progress. 2020 , 99, 1681-1699	4
370	Differential B-Cell Receptor Signaling Requirement for Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells. 2020 , 12,	2
369	t(3;14)(p14.1;q32)/FOXP1-IGH translocation in thyroid extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). 2020 , 95, 106399	1
368	Rare non-Hodgkin lymphoma of childhood and adolescence: A consensus diagnostic and therapeutic approach to pediatric-type follicular lymphoma, marginal zone lymphoma, and nonanaplastic peripheral T-cell lymphoma. 2020 , 67, e28416	9
367	Dural-Based Primary Central Nervous System Lymphoma with Bone Invasion. 2020 , 139, 415-418	1
366	Contemporary strategies to improve outcomes for peripheral T-cell lymphoma patients following the failure of first-line therapy. 2020 , 13, 745-753	
365	Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma. 2020 , 38, 439-445	3
364	Mutation Is Associated with STAT3 Activation in CD30 ALK ALCL. 2020 , 12,	9
363	A Clinico-Genotypic Prognostic Index for De Novo Composite Diffuse Large B-Cell Lymphoma Arising from Follicular Lymphoma in Asian patients treated in the Rituximab Era. 2020 , 10, 4373	5
362	Systematic literature review of the global burden of illness of mantle cell lymphoma. 2020 , 36, 843-852	1

361	Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. 2020 , 10, 31	12
360	Lymphoma Classification. 2020 , 26, 176-185	14
359	Long non-coding RNA DBH-AS1 promotes cancer progression in diffuse large B-cell lymphoma by targeting FN1 via RNA-binding protein BUD13. 2020 , 44, 1331-1340	13
358	RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group. 2020 , 99, 799-808	10
357	Management of Mantle Cell Lymphoma in the Era of Novel Oral Agents. 2020 , 54, 879-898	2
356	Insignificance of surveillance imaging in patients with diffuse large B-cell lymphoma who achieved first complete remission: a retrospective cohort study. 2020 , 111, 567-573	
355	A Practical Approach to Diagnosis of B-Cell Lymphomas With Diffuse Large Cell Morphology. 2020 , 144, 160-167	6
354	Lymphocyte-monocyte ratio (LMR) can predict bendamustine therapeutic efficacy in low-grade B-cell lymphoma. 2020 , 42, 431-438	5
353	Gingival Mucosa-Associated Lymphoid Tissue (MALT) lymphoma developed around a mandibular extraosseous dental root canal overfilling: A case report. 2020 , 121, 743-745	0
352	The clinical significance of the prognostic nutritional index in very elderly patients over 80 years of age with diffuse large B-cell lymphoma. 2020 , 99, 1153-1155	4
351	The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy. 2020 , 61, 1601-1609	3
350	Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma. 2020 , 12, 2839-2851	3
349	Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma. 2020 , 10, 6721	3
348	BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas. 2020 , 12,	26
347	Health-related quality of life in the phase III GALLIUM study of obinutuzumab- or rituximab-based chemotherapy in patients with previously untreated advanced follicular lymphoma. 2020 , 99, 2837-2846	5
346	Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. <i>Blood</i> , 2020 , 135, 1214-1218	2.2 18
345	An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy. 2020 , 18, 144	5
344	Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas. 2021 , 106, 1705-1713	15

- 343 Anaplastic large cell lymphoma in human immunodeficiency virus-infected people and solid organ transplant recipients. **2021**, 192, 514-521 1
- 342 Clinical course of duodenal mucosa-associated lymphoid tissue lymphoma: Comparison with gastric mucosa-associated lymphoid tissue lymphoma. **2021**, 36, 406-412 3
- 341 Epigenetic targeting in lymphoma. **2021**, 192, 50-61 1
- 340 A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β_2 -microglobulin levels. **2021**, 193, 307-315 1
- 339 From the archives of MD Anderson Cancer Center: Untreated leukemic non-nodal mantle cell lymphoma with relapse as pleomorphic variant mantle cell lymphoma 21 years later. **2021**, 50, 151649 1
- 338 Clinical Characteristics of Hemophagocytic Lymphohistiocytosis Associated with Non-Hodgkin B-Cell Lymphoma: A Multicenter Retrospective Study. **2021**, 21, e198-e205 3
- 337 Fungating anterior chest wall mass in an adult: Cytologic diagnosis of a rare presentation. **2021**, 49, 436-438
- 336 Expression of germinal center cell markers by extranodal marginal zone lymphomas of MALT type within colonized follicles, a diagnostic pitfall with follicular lymphoma. **2021**, 62, 1116-1122 3
- 335 BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. **2021**, 21, 267-278.e10 1
- 334 Sequential Complications of Hypercalcemia, Necrotizing Granulomatous Vasculitis, and Aplastic Anemia Occurring in One Patient with Angioimmunoblastic T-cell Lymphoma. **2021**, 361, 375-382 1
- 333 Palatine Tonsils Primary Presentation of Blastoid Variant of Mantle Cell Lymphoma: Case Report. **2021**, 15, 588-592 1
- 332 Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures. **2021**, 32, 281-291 3
- 331 Simultaneous Discordant B-Lymphoblastic Lymphoma and Follicular Lymphoma. **2021**, 155, 308-317 2
- 330 Cost-effectiveness for KTE-X19 CAR T therapy for adult patients with relapsed/refractory mantle cell lymphoma in the United States. **2021**, 24, 421-431 5
- 329 Clinical characteristics of patients with B-cell lymphoma enrolled in clinical trials for aggressive lymphoma in Japan: Japan Clinical Oncology Group - Lymphoma Study Group study - JCOG0108A. **2021**, 61, 35-41
- 328 Function of Deptor and its roles in hematological malignancies. **2021**, 13, 1528-1564 1
- 327 Indolent and Aggressive B-Cell Lymphoma. **2021**, 217-250
- 326 PET Imaging. **2021**, 41-49

325 PET imaging of lymphomas. **2021**,

324 Natural Killer/T-cell Lymphomas. **2021**, 159-173

323 Geographic Distribution of the Peripheral T-cell Lymphomas. **2021**, 57-68

322 MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology. **2021**, 13, 49-62 2

321 Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas. **2021**, 10, 9 4

320 Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma. **2021**, 10, 15 6

319 Emerging Role of Consolidative Radiotherapy After Complete Remission Following R-CHOP Immunochemotherapy in Stage III-IV Diffuse Large B-Cell Lymphoma: A Single Institutional and Case-Matched Control Study. **2021**, 11, 578865

318 A rare cause of right ventricle out flow tract obstruction: Anterior mediastinal teratoma. **2021**, 62, 258-260

317 Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. **2021**, 23, 323-340 1

316 Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature. **2021**, 57, 2

315 Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. **2021**, 5, 1695-1705 5

314 Progression-free survival at 24 months as a predictor of survival outcomes after CHOP treatment in patients with peripheral T-cell lymphoma: a single-center validation study in a Japanese population. **2021**, 62, 1869-1876 1

313 The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. **2021**, 195, 15-24 3

312 References. **2021**, 301-427

311 Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin. **2021**, 58, 85-94 2

310 Follicular Lymphoma in Young Adults: Study from a Regional Cancer Center in South India. **2021**, 10, 115-119

309 Phase III Clinical Trials in First-Line Follicular Lymphoma: A Review of Their Design and Interpretation. **2021**, 38, 3489-3505 0

308 DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set. **2021**, 8, 135 3

307	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. 2021 , 10, 100126	4
306	Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials. 2021 , 62, 2169-2176	1
305	A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. 2021 , 112, 2845-2854	5
304	Past, present and future of prognostic scores in follicular lymphoma. 2021 , 50, 100865	6
303	Computational study on novel natural inhibitors targeting BCL2. 2021 , 38, 94	0
302	Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance. 2021 , 21, 879	1
301	Multiple primary tumor of hematopoietic tissue: myeloid sarcoma in combination with mantle cell lymphoma. Case report. 2021 , 93, 793-799	
300	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. 2021 , 13,	1
299	Prognostic impact of nutritional and inflammation-based risk scores in follicular lymphoma in the era of anti-CD20 targeted treatment strategies. 2021 , 1	0
298	One-Two Punch Therapy for the Treatment of T-Cell Malignancies Involving p53-Dependent Cellular Senescence. 2021 , 2021, 5529518	3
297	Defining and Treating High-grade B-cell lymphoma, NOS. <i>Blood</i> , 2021 ,	2.2 3
296	In-situ follicular neoplasia: a clinicopathological spectrum. 2021 , 79, 1072-1086	0
295	Molecular Heterogeneity in Localized Diffuse Large B-Cell Lymphoma. 2021 , 11, 638757	2
294	Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma. 2021 , 111, 106705	0
293	The mutation of BCOR is highly recurrent and oncogenic in mature T-cell lymphoma. 2021 , 21, 82	4
292	Maintenance therapy for untreated diffuse large B-cell lymphoma: a systematic review and network meta-analysis. 2021 , 12, 20406207211018894	
291	Biopsy remains indispensable for evaluating bone marrow involvement in DLBCL patients despite the use of positron emission tomography. 2021 , 113, 675-681	1
290	Pathology of Non-Hodgkin Lymphomas. 2021 , 15-26	

289	New classifications for non-Hodgkin's lymphoma. 1999 , 99, 1-26	3
288	Therapy of diffuse aggressive lymphomas. 1999 , 99, 47-73	1
287	Morphologic, immunologic and genetic features of peripheral T cell lymphomas (unspecified category). 1999 , 159-166	2
286	Non-Hodgkin Indolent B-Cell Lymphoma. 2013 , 241-250	1
285	Non-Hodgkin Aggressive B-Cell Lymphoma. 2013 , 251-262	1
284	Lymphoid Neoplasms. 2002 , 393-406	9
283	Extranodal NK/T Cell Lymphoma, Nasal Type. 2015 , 199-212	2
282	Identifying Cells in Histopathological Images. 2010 , 244-252	4
281	Extranodal Lymphoma. 2004 , 186-363	2
280	Cytopathology in the diagnosis of lymphoma. 2014 , 160, 211-40	5
279	Which lessons can be drawn from the study of Helicobacter pylori related MALT lymphoma?. 2003 , 231-239	1
278	Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma. 2021 , 5, 175-186	1
277	Retroperitoneum. 2009 , 1953-2040	2
276	Immunohistology of Non-Hodgkin Lymphoma. 2006 , 137-161	4
275	Non-Hodgkin's Lymphoma. 2008 , 2371-2404	3
274	Extranodal Marginal Zone Lymphoma. 2011 , 291-305	1
273	Diffuse Large B-Cell Lymphoma. 2011 , 349-381	4
272	Burkitt's Lymphoma. 2011 , 391-409	2

271	Bone Marrow Evaluation for Lymphoma. 2011 , 887-917	2
270	Lymphoplasmacytic Lymphoma/Waldenström's Macroglobulinemia. 2006 , 374-380	2
269	Nasal T/NK-Cell Lymphoma. 2006 , 451-455	1
268	Lymphomas and Hemopoietic Neoplasms. 2005 , 301-309	1
267	Leukocytic Disorders. 2011 , 601-655	2
266	Diffuse Aggressive B-Cell Lymphomas. 2012 , 261-292	1
265	Lymphoma/Myeloma. 2008 , 351-359	1
264	Lymph Nodes: Cytomorphology and Flow Cytometry. 2008 , 671-711	5
263	Protein arginine methyltransferase 5 represses tumor suppressor miRNAs that down-regulate CYCLIN D1 and c-MYC expression in aggressive B-cell lymphoma. 2020 , 295, 1165-1180	9
262	High Dose Cyclophosphamide Plus Recombinant Human Granulocyte-colony Stimulating Factor (rhG-CSF) in the Treatment of Follicular, Low Grade Non-Hodgkin's Lymphoma: CALGB 9150. 2001 , 42, 1255-1264	2
261	Classification of cutaneous lymphoma: a critical appraisal of recent proposals. 1999 , 21, 279-87	30
260	Primary nodal marginal zone lymphomas of splenic and MALT type. 1999 , 23, 59-68	131
259	Hodgkin's disease and non-Hodgkin's lymphoma. 1999 , 6, 205-15	4
258	Clinical, Immunophenotypic, and Genetic Analysis of Adult Lymphomas With Morphologic Features of Burkitt Lymphoma. 2005 , 29, 1086-1094	114
257	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. 2020 , 10,	1
256	Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. 2007 , 117, 823-34	228
255	Managing Indolent Lymphomas in Relapse. 2000 , 2000, 166-179	1
254	Prognostic Significance of Anaplastic Lymphoma Kinase (ALK) Protein Expression in Adults With Anaplastic Large Cell Lymphoma. <i>Blood</i> , 1999 , 93, 3913-3921	2.2 15

253	CD30+ anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. <i>Blood</i> , 2000 , 96, 3681-3695	2.2	198
252	The gastric marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , 2000 , 96, 410-419	2.2	35
251	ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. 2020 , 9, 941		2
250	Positron Emission Tomography in the Diagnosis and Monitoring of Lymphomas. 2018 , 63, 41-50		8
249	Synchronous colonic mucosa-associated lymphoid tissue lymphoma found after surgery for adenocarcinoma: A case report and review of literature. 2020 , 8, 6456-6464		1
248	Semi-supervised methods to predict patient survival from gene expression data. 2004 , 2, E108		457
247	Histological Transformation and Progression in Follicular Lymphoma: A Clonal Evolution Study. 2016 , 13, e1002197		110
246	A unified 35-gene signature for both subtype classification and survival prediction in diffuse large B-cell lymphomas. 2010 , 5, e12726		26
245	Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma. 2012 , 7, e39449		27
244	Variation in dicer gene is associated with increased survival in T-cell lymphoma. 2012 , 7, e51640		17
243	Proteomics Based Identification of Proteins with Deregulated Expression in B Cell Lymphomas. 2016 , 11, e0146624		5
242	Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry. 2017 , 12, e0177204		17
241	Primary colon mantle lymphoma: a misleading macroscopic appearance!. 2019 , 111, 965-967		2
240	The potential relevance of the endocannabinoid, 2-arachidonoylglycerol, in diffuse large B-cell lymphoma. 2016 , 3, 31-41		12
239	NK cell function is markedly impaired in patients with chronic lymphocytic leukaemia but is preserved in patients with small lymphocytic lymphoma. 2016 , 7, 68513-68526		32
238	Interim PET-CT may predict PFS and OS in T-ALL/LBL adult patients. 2017 , 8, 99104-99111		4
237	Pretreatment Epstein-Barr virus DNA in whole blood is a prognostic marker in peripheral T-cell lymphoma. 2017 , 8, 92312-92323		6
236	Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study. 2016 , 7, 33331-9		4

235	THE FIRST EXPERIENCE OF USING 99MTC-1-THIO-D-GLUCOSE FOR SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY IMAGING OF LYMPHOMAS. 2018 , 17, 81-87	5
234	A Novel Probabilistic Nuclei Segmentation Algorithm for H&E Stained Histopathological Tissue Images.	1
233	Primary bone lymphoma: report of a case with multifocal skeletal involvement. 2007 , 3, e52	11
232	The role of "watch and wait" in intestinal follicular lymphoma in rituximab era. 2016 , 51, 321-8	9
231	Clinicopathologic characteristics of T-cell non-Hodgkin's lymphoma: a single institution experience. 2009 , 24, 128-34	14
230	Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors. 2010 , 25, 227-36	8
229	Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. 2017 , 57, 120-142	48
228	Primary Splenic and Nodal Marginal Zone Lymphoma:. 2005 , 45, 1-14	4
227	Different histopathological types of orbital lymphoma 16 years after systemic follicular lymphoma: immunohistochemical and immunogenetic analyses of two cases. 2008 , 48, 17-24	10
226	Prognostic Implication of Programmed Death-1-Positive Tumor-infiltrating Lymphocytes in Diffuse Large B-Cell Lymphoma. 2011 , 45, 573	2
225	Primary mucosa-associated lymphoid tissue lymphoma of the liver: A report of two cases and review of the literature. 2017 , 9, 155-160	12
224	Prevalence and Implications of Bone Marrow Involvement in Patients with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma. 2018 , 12, 278-287	5
223	VPDL Chemotherapy for T-cell Lymphoblastic Lymphoma (T-LBL) in Adults: Comparison with Upfront Autologous Stem Cell Transplantation in a Single Center. 2008 , 43, 138	2
222	Grading of follicular lymphoma using flow cytometry. 2006 , 26, 205-10	5
221	Flow cytometric immunophenotyping of anaplastic large cell lymphoma. 2009 , 133, 49-56	41
220	Best practices in contemporary diagnostic immunohistochemistry: panel approach to hematolymphoid proliferations. 2009 , 133, 756-65	30
219	Extranodal lymphoplasmacytoid lymphoma (immunocytoma) presenting as small intestinal obstruction. 2001 , 125, 677-9	13
218	Detection of bcl-2/J(H) translocation by polymerase chain reaction: a summary of the experience of the Molecular Oncology Survey of the College of American Pathologist. 2002 , 126, 902-8	13

217	Peliosis hepatis associated with lymphoplasmacytic lymphoma: an autopsy case report. 2004 , 128, 1283-5	16
216	A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. 2004 , 128, 863-8	24
215	Hematologic malignancies with primary retroperitoneal presentation: clinicopathologic study of 32 cases. 2005 , 129, 655-60	13
214	Mantle cell lymphoma disguised as marginal zone lymphoma. 2005 , 129, 929-32	6
213	Lymphomas involving the pleura: a clinicopathologic study of 34 cases diagnosed by pleural biopsy. 2006 , 130, 1497-502	52
212	Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. 2007 , 131, 1084-8	23
211	Site-specific morphologic differences in extranodal marginal zone B-cell lymphomas. 2007 , 131, 1673-8	27
210	Clinicopathologic analysis of cutaneous lymphoma in taiwan: a high frequency of extranodal natural killer/t-cell lymphoma, nasal type, with an extremely poor prognosis. 2010 , 134, 996-1002	29
209	Time-to-treatment of diffuse large B-cell lymphoma in S Paulo. 2014 , 69, 367-71	2
208	Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data. 2021 ,	0
207	Primary sinonasal large B cell lymphoma is as histopathologically heterogeneous as systemic large B cell lymphoma but may show subtype-specific tropism for specific sinonasal anatomic sites. 2021 , 14, 269	
206	A single-center analysis of patients with extranodal marginal zone lymphoma of the breast. 2021 , 1-8	
205	Managing Indolent Lymphomas in Relapse. 2000 , 2000, 166-179	
204	Is Autologous Transplantation for Non-Hodgkin Lymphoma Underutilized?. 2000 , 161-174	
203	Incorporating pathology/biology data into prognostic models in diffuse large B-cell lymphoma. 2002 , 9, 268-269	1
202	Non-Hodgkin Lymphoma. 2003 , 295-318	
201	Tumors and Tumor-like Lesions of the Colon, Rectum, Anus, and Perianal Region. 2003 , 223-294	
200	Tumoren und tumorartige Lsionen des Dickdarms, Anorektums und Perianalbereichs. 2003 , 231-305	

199 Niedrigmaligne B-Zell-Lymphome. **2003**, 411-455

198 Primary Follicular Lymphoma in the Submandibular Lymph Node accompanied by a Chronic Sialadenitis of the Submandibular gland: A case report. **2004**, 9, 155-161

197 Current Status of Lymphoma Classification. **2004**, 8-13

196 Nodal and Leukemic NK/T-Cell Lymphoma. **2004**, 121-185

1

195 Data Mining Approaches to Diffuse Large B-Cell Lymphoma Gene Expression Data Interpretation. **2004**, 279-288

2

194 Stem Cell Transplantation for Hodgkin- and Non-Hodgkin- Lymphomas. **2004**, 47-84

193 Nodal B-Cell Lymphoma. **2004**, 19-120

3

192 Mycosis fungoides associated with intestinal mucosa-associated lymphoid tissue lymphoma. **2006**, 060720080827153

191 Large-Cell Lymphoma. **2006**, 295-324

190 Peripheral T-Cell Lymphoma. **2006**, 437-450

189 Non-Hodgkin's (Breticulum Cell-) Lymphoma. **2006**, 867-872

188 Lymph Node. **2006**, 423-465

187 Mantelzell-Lymphom (zentrozytisches Lymphom). **2006**, 2953-2986

186 Primary Extranodal Non-Hodgkin's Lymphomas. **2006**, 325-347

2

185 Klassifikation der Non-Hodgkin-Lymphome. **2006**, 2829-2844

1

184 Leukemias.

183 MALT lymphomas--a closer look in the genomics era. **2006**, 99, 1322-4

1

182 A Case of Helicobacter pylori Infection and Rectal MALT Lymphoma Following Erythema Nodosum. **2007**, 69, 126-130

181 Lymphomas including Hodgkin lymphoma. **2008**, 1151-1165

180 Anterior Mediastinal Masses. **2008**, 1473-1525

3

179 World Health Organization Classification of Hematologic Malignancies. **2008**, 2131-2137

178 MALT lymphoma pathology, initial diagnosis, and post-treatment evaluation. **2008**, 114-123

0

177 Ovarian lymphoid and hematopoietic neoplasms. **2009**, 779-793

176 Lymphomas. **2009**, 830-843

175 A resected case of pulmonary metastases from malignant lymphoma of the stomach. **2009**, 23, 630-635

174 Treatment Strategies for Follicular Center Cell Non-Hodgkin's Lymphoma. **2010**, 159-175

173 Mantle Cell Lymphoma. **2010**, 257-265

172 Hodgkin Disease and Non-Hodgkin Lymphomas. **2010**, 571-639

171 Malignant Lymphomas in the Ear, Nose and Throat Area. **2010**, 623-628

170 Formes pédiatriques rares. **2010**, 107-115

169 Lacrimal Gland Tumors. **2010**, 89-101

168 Lymphoplasmacytic Lymphoma. **2010**, 233-239

167 Gastrointestinal Lymphomas. **2010**, 445-460.e5

166 Mechanisms of Cancer Growth and Progression in Lymphoma. **2010**, 115-128

1

165 Marginal Zone B-Cell Lymphoma. **2010**, 221-231

164 Techniques to Detect Defining Chromosomal Translocations/Abnormalities. **2010**, 129-152

163 Burkitt Lymphoma and Leukemia. **2011**, 175-210

162 Rare Variants of Primary CNS Lymphoma. **2012**, 243-263

161 Pulmonary MALT Lymphoma: Clinical, Molecular and Therapeutic Aspects. **2011**, 521-531

160 Follicular Lymphoma. **2011**, 267-290

2

159 Principles of Classification of Lymphoid Neoplasms. **2011**, 211-220

158 Angioimmunoblastic T-Cell Lymphoma. **2011**, 554-563

157 Idiotypic vaccination for Non-Hodgkin lymphoma.

156 A Case of Follicular Lymphoma of the Ileum in Which Complete Response to Chemotherapy was Confirmed by Surgical Resection of the Remaining Cicatricial Stenosis. **2011**, 44, 890-897

155 A CASE REPORT OF ENTEROPATHY-TYPE T-CELL LYMPHOMA WITH JEJUNUM PERFORATION IN A JAPANESE PATIENT WITH HTLV-1 INFECTION. **2011**, 72, 97-102

2

154 Encyclopedia of Cancer. **2011**, 2142-2149

153 CD44s and CD44v6 Are Predominantly Expressed in the Non-germinal Center B-Cell-like Type of Diffuse Large B-Cell Lymphomas. **2011**, 45, 589

152 A case of small lymphocytic lymphoma arising in the palate. **2011**, 57, 501-505

1

151 Diseases. 160-300

150 Mantle Cell Lymphoma. 121-133

149 Follicular Lymphoma. 108-120

148 An Introduction to Lymphoma Diagnosis. 59-62

147 Cutaneous lymphoproliferative diseases and related disorders. **2012**, 1311-1420

146 Small B-Cell Lymphomas. **2012**, 205-260

145 Non-Hodgkin's Lymphoma. **2012**, 1545-1572

144 Towards Personalized Medicine in Pediatric Cancer: Genome-Wide Strategies to Investigate Cancer Risk and Response to Therapy. **2012**, 1-19

143 Molecular Biology of Mantle Cell Lymphoma. **2012**, 113-135

142 Two Cases of Gastric MALT Lymphoma Diagnosed at Long Last after Successful Eradication of *Helicobacter pylori*. **2012**, 12, 265

1

141 Genetic polymorphism study of the BCL-6 gene, in diffuse large B-cell lymphoma. **2012**, 1, 74

140 Molecular Profiling and Prognosis in T-Cell Lymphomas. **2013**, 41-56

139 T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science. **2013**, 179-216

138 The Role of Hematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphomas. **2013**, 279-293

1

137 Antigen-Driven Lymphomagenesis. **2013**, 63-80

136 Current Therapies for T-cell Lymphomas. **2013**, 213-237

135 Prognostic Factors in B-Cell Lymphomas. **2013**, 101-139

134 Angioimmunoblastic T-cell lymphoma-associated pure red cell aplasia with abdominal pain. **2013**, 4, 75-80

1

133 MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma). **2013**, 111-126

132 T-Cell Lymphomas. **2013**, 211-229

131 Molecular Profiling of Peripheral T-Cell Lymphomas. **2013**, 53-63

130 Nodal Marginal Zone Lymphoma. **2013**, 137-142

129 Lymphoid Neoplasms: Classification Systems. **2014**, 1-10

128 Ocular and Adnexal T-Cell Lymphoma. **2014**, 103-115

127 Lymph Nodes. **2014**, 213-276

126 [Case of primary lymphoplasmacytic lymphoma limited to the paratracheal mediastinum]. **2013**, 35, 213-8 o

125 MicroRNAs in Hematologic Malignancies. **2014**, 67-95

124 WHO Classification of Hematologic Malignancies. **2014**, 219-225.e2

123 Principles of the Pathology and Biology of Malignant Lymphomas. **2014**, 3-16

122 Mucosal-Associated Lymphoid Tissue (MALT) Lymphoma. **2014**, 253-276

121 Mantle Cell Lymphoma. **2014**, 277-302

120 Hochmaligne Non-Hodgkin-Lymphome. **1998**, 333-372

119 Classification of Malignant Lymphomas. **1999**, 181-189

118 Non-Hodgkin's Lymphoma. **1999**, 453-488

117 New TNM Classifications Recommended for Testing. 171-191

116 Non-Hodgkin's Malignant Lymphoma.

115 Encyclopedia of Cancer. **2015**, 2627-2635

114 Hematolymphoid Lesions. **2015**, 323-388

113 Encyclopedia of Cancer. **2015**, 1-9

112 Transplantation in Burkitt and lymphoblastic lymphoma. 201-208

111 Diffuse large B-cell lymphoma. 145-159 1

110 HIV and Indolent Lymphoma. **2016**, 107-117

109 T-Cell Lymphomas. **2016**, 603-614

108 Mantle cell lymphoma. **2017**, 113-122

107 Molecular Etiopathogenesis of Extranodal Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue. **2017**, 147-169

106 Hepatosplenic T-cell Lymphoma: Case Report & Literature Review. **2017**, 5,

105 Diffuse Large B cell Lymphoma: Case Report. **2017**, 8,

104 Follicular Lymphoma in Blood and Bone Marrow. **2018**, 828-831

103 Lymph Node Cytology. **2018**, 259-288

102 First-Line Treatment of Mantle-Cell Lymphoma: Analysis of Effectiveness and Cost-Effectiveness. **2018**, 11, 150-159

1

101 Why Watch and wait is still a valuable option for low grade lymphomas. **2018**, 17, 20-24

100 Estimating a common covariance matrix for network meta-analysis of gene expression datasets in diffuse large B-cell lymphoma. **2018**, 12,

O

99 Diagnostische Strategien, Immunhistochemie und molekulare Diagnostik lymphatischer Gewebe. **2019**, 227-234

98 Indolente und kleinzellige B-Zell Lymphome. **2019**, 523-600

97 Classification of Lymphomas. **2019**, 355-370

96 Aggressive Lymphoma. **2019**, 387-399

95 Aggressive Lymphoma in Children and Adolescents. **2019**, 245-282

94 Pattern of T-cell non-Hodgkin's lymphoma in a tertiary care center in North East India. **2019**, 40, 391

93 Peripheral T-Cell Lymphoma. **2019**, 263-269

92 Pattern of non-hodgkin lymphoma in a tertiary care center in Northeast India using morphology and immunohistochemistry. **2019**, 40, 595

- 91 Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma. **2019**, 71-86 1
- 90 Lymph Nodes and Spleen. **2020**, 65-100
- 89 Large B-Cell Lymphoma. **2020**, 123-155
- 88 Blastoid Mantle Cell Lymphoma of the Palate: Report of a Rare Aggressive Entity and Review of the Literature. **2021**, 1
- 87 The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma. **2021**, 21, 573
- 86 Breast implant associated anaplastic large cell lymphoma detected by 18F-FDG PET/CT case report. **2021**,
- 85 Uncommon Tumors and Uncommon Presentations of Cancer in the Breast. **2021**, 13, 331 o
- 84 Intestinal T-cell lymphoma, NOS, presenting with sole peritoneal and mucosal lymphomatosis throughout abdominal cavity. **2020**, 60, 117-120 o
- 83 Current and Emerging Treatment Strategies for Primary Mediastinal B-Cell Lymphoma. **2020**, 83-100
- 82 Is TP53 mutation screening in Mantle Cell Lymphoma (MCL) ready for prime time?. **2019**, 1-4
- 81 A case of B-cell type lymphoma coexisted in mandible and central nervous system. **2020**, 32, 45-55
- 80 PET in Lymphoma. **2020**, 685-729
- 79 Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma. **2019**, 19, 2047-2059 o
- 78 Radiotherapy alone for stage IE ocular adnexal mucosa-associated lymphoid tissue lymphomas: long-term results. **2020**, 15, 25 1
- 77 Mantle Cell Lymphoma: Definition, Epidemiology, Pathobiology Lymphomagenesis, Morphology, Variants, Immunophenotype, Prognostic Factors. **2020**, 49-93
- 76 Non-Hodgkin lymphoma. **2020**, 5288-5302
- 75 Clinical presentations and morphological verification of mediastinal tumors. **2020**, 9, 60
- 74 Differential B-cell receptor signaling requirement for adhesion of mantle cell lymphoma cells to stromal cells.

73	Treatment of Lymphoblastic Lymphoma in Adults. 2008 , 203-214		
72	On the delayed approach to mediastinal lymphomas in the SARS-CoV2 era. 2020 , 59,		0
71	Lymph nodes and spleen. 688-812		1
70	Successful treatment of paraneoplastic pemphigus and bronchiolitis obliterans associated with follicular lymphoma with obinutuzumab and bendamustine. 2021 , 100813		1
69	Impact of the microenvironment on the pathogenesis of mucosa-associated lymphoid tissue lymphomas.. 2022 , 14, 153-162		0
68	Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study.. 2021 , 11, 770988		
67	DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway. 2021 , 24, 50-61		
66	The Role of Epstein-Barr Virus in Modulating Key Tumor Suppressor Genes in Associated Malignancies: Epigenetics, Transcriptional, and Post-Translational Modifications.. 2022 , 12,		3
65	Artificial Intelligence Analysis of Gene Expression Predicted the Overall Survival of Mantle Cell Lymphoma and a Large Pan-Cancer Series.. 2022 , 10,		3
64	High ETV6 Levels Support Aggressive B Lymphoma Cell Survival and Predict Poor Outcome in Diffuse Large B-Cell Lymphoma Patients.. 2022 , 14,		
63	Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.. 2022 , 13, 835103		0
62	RECENT ADVANCES IN T-CELL LYMPHOID NEOPLASMS. 2021 ,		0
61	A case of primary mucosa-associated lymphoid tissue lymphoma of the prostate. 2009 , 1, 169-170		7
60	Limited-stage Diffuse Large B-cell Lymphoma.. <i>Blood</i> , 2021 ,	2.2	1
59	Diagnostic Interval in Extranodal Non-Hodgkin Head and Neck Lymphomas.. 2022 , 11,		0
58	Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.. 2021 , 65, 402-409		
57	Related Research Progress of Epstein-Barr Virus Associated Diseases with Primary Infection in Children. 2022 , 12, 2211-2217		
56	Analysis of the Clinicopathologic Characteristics and Prognosis of Head and Neck Lymphoma.. 2022 , 2022, 4936099		0

55	Diffuse Large B Cell Lymphoma with Cutaneous and Gastrointestinal Involvement.. 2022 , 2022, 2687291		
54	Current Status of the Spectrum and Therapeutics of -Negative Mucosa-Associated Lymphoid Tissue Lymphoma.. 2022 , 14,		o
53	Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma, results of a phase 2 study.. 2022 , ,		
52	Use of bronchoalveolar lavage in diagnosing angioimmunoblastic T-cell lymphoma: A case report.. 2022 , 10, e0924		1
51	Epstein-Barr virus copy number in peripheral blood mononuclear cells predicts prognosis in diffuse large B cell lymphoma.. 2022 , 1-9		
50	A cascaded deep network for automated tumor detection and segmentation in clinical PET imaging of diffuse large B-cell lymphoma. 2022 ,		1
49	Follicular Lymphoma.		o
48	Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis. 2021 , 1-10		o
47	Epstein-Barr Virus-Positive Diffuse Large B Cell Lymphoma. 27-46		o
46	WHO classification of lymphomas. 228-256		
45	Lymphoblastic lymphoma. 487-493		
44	Lymph nodes. 11-77		
43	Novel prognostic predictor of haemoglobin-platelet index in diffuse large B-cell lymphoma, not otherwise specified: Anaemia and thrombocytopenia are associated with IL-6 production in lymphoma cells.. 2022 ,		
42	Peripheral Blood Involvement at Staging in Patients With Aggressive Peripheral T-Cell Lymphoma.. 2022 ,		
41	The role of surveillance computed tomography in patients with follicular lymphoma.. 2022 , 13, 20406207221095963		
40	Immunotherapy in indolent Non-Hodgkin's Lymphoma. 2022 , 17, 100325		
39	The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. <i>Blood</i> ,	2.2	18
38	Management of Extranodal Marginal Zone Lymphoma: Present and Upcoming Perspectives. 2022 , 14, 3019		o

- 37 Primary extranodal diffuse large B-cell lymphoma in the rituximab era: a single center, retrospective analysis. **2022**, 27, 757-764
- 36 Mantle-Cell Lymphoma. **2022**, 386, 2495-2506 1
- 35 Causes of Death in Low Grade B-Cell Lymphomas in the Rituximab Era: A Prospective Cohort Study.
- 34 The clinical features, treatment, and prognostic factors for peripheral T-cell lymphomas: A single-institution analysis of 240 Chinese patients. 0
- 33 Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint).
- 32 Developing a Classification of Hematologic Neoplasms in the Era of Precision Medicine. *Blood*, 2.2 0
- 31 From Microarray to Bedside: Targeting NF- κ B for Therapy of Lymphomas. **2005**, 11, 2-6 5
- 30 Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study.
- 29 Metachronous lesions in the orbit, retroperitoneum, and pleura of mucosa-associated lymphoid tissue lymphoma: A case report.
- 28 The Clinical Impact of Precisely Defining Mantle Cell Lymphoma: Contributions of Elaine Jaffe. **2022**, 3, 508-517
- 27 Physical activity program for the survival of elderly patients with lymphoma (PHARAOM): a study protocol for a randomized phase III trial (Preprint). 0
- 26 T cell rich B cell lymphoma of CNS in a young female- An unusual presentation. **2022**, 8, 191-193 0
- 25 Clonal relationship of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT lymphoma) involving multiple organ systems with review of the literature. 0
- 24 Treatment of aggressive T-cell lymphoma/leukemia with anti-CD4 CAR T cells. 13, 0
- 23 Ocular adnexal lymphoma: Subtype-specific clinical and genetic features. **2022**, 100, 3-37 0
- 22 Revealing the clinical impact of MTOR and ARID2 gene mutations on MALT lymphoma of the alimentary canal using targeted sequencing. 0
- 21 Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. 0
- 20 Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. 115-122 0

19	Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018). 2022 ,	o
18	Neoplasms in People Living with Human Immunodeficiency Virus. 1-18	o
17	Ascites as First Atypical and Only Clinical Manifestation of De Novo Follicular Lymphoma. 2022 , 58, 1381	o
16	Prognostic biomarkers for HIV-infected Diffuse Large B-cell lymphoma. 2022 ,	o
15	Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System. 2022 ,	o
14	Activated B-cell signet ring lymphoma: A case report and a comparative review of the literature. 2022 , 30, 300682	o
13	B-cell Lymphoblastic Lymphoma of the Paranasal Sinuses: A Case Study of a Rare Clinical Entity. 2022 ,	o
12	Improving Treatment Strategies for Patients with Follicular Lymphoma: How to Translate Novel Study Data into Clinical Practice. 2-10	o
11	Malignant Lymphoma [A Changing Spectrum. 2009 , 38, 837-839	o
10	Nasal natural killer/T-cell lymphoma mimicking orbital cellulitis: A diagnostic dilemma. 2022 ,	o
9	Primary extranodal diffuse large B-cell lymphoma: Molecular features, treatment, and prognosis.	o
8	Natural killer T-cell primary CNS lymphoma presenting as lymphomatosis cerebri. 2022 , Publish Ahead of Print,	o
7	Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy. 2023 ,	1
6	Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma. 12,	o
5	An aberrant presentation of non-hodgkin lymphoma as pus: A curious journey. 2023 , 7, 173-175	o
4	Large B-Cell Lymphomas in the 5th Edition of the WHO-Classification of Haematolymphoid Neoplasms Updated Classification and New Concepts. 2023 , 15, 2285	o
3	Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK-cell counts in rituximab chemotherapy responsive elderly DLBCL patients: A LYSA group study. 2023 , 201, 256-266	o
2	Comparison of Primary B/NKT Non-Hodgkin Lymphomas in Nasopharynx, Nasal Cavity, and Paranasal Sinuses. 2023 , 168, 1107-1118	o

- 1 Helicobacter Pylori-Negative MALT Lymphoma: A Series of Two Cases Presenting with Life-Threatening Upper Gastrointestinal Bleeding. **2023**, 2023, 1-4

o